diff --git a/Extractors/Gender/GenderRegExtractor.py b/Extractors/Gender/GenderRegExtractor.py index 1ef0dce..eab1382 100755 --- a/Extractors/Gender/GenderRegExtractor.py +++ b/Extractors/Gender/GenderRegExtractor.py @@ -11,8 +11,12 @@ def __init__(self, rawTextFileName, intermediateXMLFileName): def findEntity(self): extract_gender_m = [] extract_gender_f = [] - extract_gender_m = re.search(r'.(\bmale\b)',self.Text,re.IGNORECASE) - extract_gender_f = re.search(r'.(\bfemale\b)',self.Text,re.IGNORECASE) + gender = "" + gender_offset = "" + + extract_gender_m = re.search(r'.(\bmale\b|\bman\b|he|his|him)',self.Text,re.IGNORECASE) + extract_gender_f = re.search(r'.(\bfemale\b|\bwoman\b|she|her|hers)',self.Text,re.IGNORECASE) + if not extract_gender_f: if not extract_gender_m: gender = "UNK" diff --git a/Extractors/Weight/WeightNltkExtractor.py b/Extractors/Weight/WeightNltkExtractor.py index 96f9cde..2588660 100644 --- a/Extractors/Weight/WeightNltkExtractor.py +++ b/Extractors/Weight/WeightNltkExtractor.py @@ -58,6 +58,7 @@ def findEntity(self): for tags in final_tags: if any(word in tags for word in weight_keyword_list): extract_weight_weightCode = tags #format: '71;50:52 year;53:57' + break #assuming that the demographics (weight) of the patient is always at the beginning of the narrative if not extract_weight_weightCode: weight = "UNK" diff --git a/Postprocessing/Intermediate4/fda008_Intermediate.xml b/Postprocessing/Intermediate4/fda008_Intermediate.xml index b84f8da..7323f4f 100755 --- a/Postprocessing/Intermediate4/fda008_Intermediate.xml +++ b/Postprocessing/Intermediate4/fda008_Intermediate.xml @@ -1 +1 @@ -16-Apr-2015, Spontaneous, Health authority, Patient/Consumer Serious report.16-Apr-2015,Spontaneous,Healthauthority,Patient/ConsumerSeriousreport.(S1 (S (S (NP (NP (NN 16-Apr-2015)) (, ,) (NP (ADJP (JJ Spontaneous))) (, ,) (NP (NN Health) (NN authority)) (, ,)) (NP (NN Patient/Consumer) (JJ Serious) (NN report))) (. .)))(Report duplicates - 01001307081: GB-JNJFOC-20150407438; MHRAUK: GB-MHRA-ADR 22956126)(Reportduplicates-01001307081:GB-JNJFOC-20150407438;MHRAUK:GB-MHRA-ADR22956126)(S1 (S (PRN (-LRB- -LRB-) (NP (NP (NN Report) (VBZ duplicates)) (: -) (NP (CD 01001307081)) (: :) (NP (CD GB-JNJFOC-20150407438)) (: ;) (NP (NN MHRAUK)) (: :) (NP (NN GB-MHRA-ADR) (CD 22956126))) (-RRB- -RRB-))))A Consumer/other non health professional reported the case of a Female patient (age unknown) who received ERYTHROMYCIN (Product be excluded as a Teva product), DOMPERIDONE (not Teva's product). AConsumer/othernonhealthprofessionalreportedthecaseofaFemalepatient(ageunknown)whoreceivedERYTHROMYCIN(ProductbeexcludedasaTevaproduct),DOMPERIDONE[orch,phsu][orch,phsu][orch,phsu][orch,phsu](notTeva'sproduct).(S1 (S (S (NP (DT A) (NN Consumer/other) (JJ non) (NN health) (NN professional)) (VP (VBD reported) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (NP (DT a) (JJ Female) (NN patient)) (PRN (-LRB- -LRB-) (ADJP (NN age) (JJ unknown)) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (NP (NN ERYTHROMYCIN)) (PRN (-LRB- -LRB-) (S (NP (NN Product)) (VP (VB be) (VP (VBN excluded) (PP (IN as) (NP (DT a) (NN Teva) (NN product)))))) (-RRB- -RRB-))) (, ,) (NP (NP (NN DOMPERIDONE)) (PRN (-LRB- -LRB-) (NP (QP (RB not) (CD Teva's)) (NN product)) (-RRB- -RRB-)))))))))))) (. .)))The patient took ERYTHROMYCIN for GASTROPARESIS (Unknown, Dosage Form: Unspecified) batch: Unknown, DOMPERIDONE for GASTROPARESIS (Unknown, Dosage Form: Unspecified) batch: Unknown.ThepatienttookERYTHROMYCINforGASTROPARESIS(Unknown,DosageForm:Unspecified)batch:Unknown,DOMPERIDONEforGASTROPARESIS(Unknown,DosageForm:Unspecified)batch:Unknown.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD took) (NP (NP (NN ERYTHROMYCIN)) (PP (IN for) (NP (NN GASTROPARESIS)))) (PRN (-LRB- -LRB-) (NP (NP (JJ Unknown)) (, ,) (NP (NN Dosage) (NN Form)) (: :) (NP (ADJP (NN Unspecified) (-RRB- -RRB-) (JJ batch))) (: :) (NP (JJ Unknown)) (, ,) (NP (ADJP (NP (NP (NN DOMPERIDONE)) (PP (IN for) (NP (NN GASTROPARESIS)))) (-LRB- -LRB-) (NP (NP (JJ Unknown)) (, ,) (NP (NN Dosage) (NN Form)) (: :) (NP (ADJP (JJ Unspecified)))) (-RRB- -RRB-) (JJ batch))) (: :) (NP (JJ Unknown)))))) (. .)))While on the suspect medication(s), the patient experienced ARRHYTHMIA(Serious); POSSIBLE DRUG INTERACTION(Serious); UNWELL(Not Serious); SEVERE FATIGUE(Not Serious); DRY EYES(Not Serious); DRY MOUTH(Not Serious); PERIOD STOPPED(Not Serious).Whileonthesuspectmedication(s),thepatientexperiencedARRHYTHMIA(Serious);POSSIBLEDRUGINTERACTION(Serious);UNWELL(NotSerious);SEVEREFATIGUE(NotSerious);DRYEYES(NotSerious);DRYMOUTH(NotSerious);PERIODSTOPPED(NotSerious).(S1 (S (S (PP (IN While) (PP (IN on) (NP (NP (DT the) (NN suspect) (NN medication)) (PRN (-LRB- -LRB-) (NP (NN s)) (-RRB- -RRB-))))) (, ,) (NP (DT the) (NN patient) (NP (NP (NP (VBN experienced) (NP (NP (NP (NP (NP (NN ARRHYTHMIA)) (PRN (-LRB- -LRB-) (ADJP (JJ Serious)) (-RRB- -RRB-))) (: ;) (NP (NP (JJ POSSIBLE) (NN DRUG) (NN INTERACTION)) (PRN (-LRB- -LRB-) (ADJP (JJ Serious)) (-RRB- -RRB-))) (: ;) (NP (NNP UNWELL))) (PRN (-LRB- -LRB-) (NP (RB Not) (JJ Serious)) (-RRB- -RRB-))) (: ;) (NP (NP (JJ SEVERE) (NN FATIGUE)) (PRN (-LRB- -LRB-) (ADJP (RB Not) (JJ Serious)) (-RRB- -RRB-))) (: ;)) (JJ DRY) (NNS EYES)) (PRN (-LRB- -LRB-) (NP (RB Not) (JJ Serious)) (-RRB- -RRB-))) (: ;) (NP (NP (NP (JJ DRY) (NN MOUTH)) (PRN (-LRB- -LRB-) (NP (RB Not) (JJ Serious)) (-RRB- -RRB-))) (: ;) (NP (NN PERIOD))))) (VP (VBD STOPPED) (PRN (-LRB- -LRB-) (NP (RB Not) (JJ Serious)) (-RRB- -RRB-)))) (. .)))MHRA verbatim: This spontaneous report was received from a consumer (patient's mother) and concerns a female patient of unspecified age from the United Kingdom. MHRAverbatim:Thisspontaneousreportwasreceivedfromaconsumer(patient'smother)andconcernsafemalepatientofunspecifiedagefromtheUnitedKingdom.(S1 (S (NP (NP (NN MHRA) (NN verbatim)) (: :) (S (NP (DT This) (JJ spontaneous) (NN report)) (VP (VBD was) (VP (VP (VBN received) (PP (IN from) (NP (NP (DT a) (NN consumer)) (PRN (-LRB- -LRB-) (NP (CD patient's) (NN mother)) (-RRB- -RRB-))))) (CC and) (VP (VBZ concerns) (NP (NP (DT a) (JJ female) (NN patient)) (PP (IN of) (NP (JJ unspecified) (NN age))) (PP (IN from) (NP (DT the) (JJ United) (NN Kingdom)))))))) (. .))))The patient's height and weight were not reported.Thepatient'sheightandweightwerenotreported.(S1 (S (S (NP (DT The) (NNS patient's) (NP (NP (NN height)) (CC and) (NP (NN weight)))) (VP (VBD were) (RB not) (VP (VBN reported)))) (. .)))The patient's medical history and concurrent conditions included: Crohn's disease and gastroparesis.Thepatient'smedicalhistoryandconcurrentconditionsincluded:Crohn'sdiseaseandgastroparesis.(S1 (S (NP (NP (NP (DT The) (UCP (NP (JJ patient's) (JJ medical) (NN history)) (CC and) (ADJP (JJ concurrent))) (NNS conditions)) (VP (VBN included))) (: :) (NP (NP (NN Crohn's) (NN disease)) (CC and) (NP (NN gastroparesis))) (. .))))The reporter stated that the patient was treated with domperidone (route and formulation unspecified, batch unknown) dosage and frequency unspecified initiated on an unspecified date for gastroparesis and non-company suspect drug erythromycin (route and formulation unspecified) dosage and frequency unspecified initiated on an unspecified date for gastroparesis (possible drug interaction).Thereporterstatedthatthepatientwastreatedwithdomperidone(routeandformulationunspecified,batchunknown)dosageandfrequencyunspecifiedinitiatedonanunspecifieddateforgastroparesisandnon-companysuspectdrugerythromycin[phsu][phsu][phsu][phsu][phsu][phsu][phsu][phsu](routeandformulationunspecified)dosageandfrequencyunspecifiedinitiatedonanunspecifieddateforgastroparesis(possibledruginteraction).(S1 (S (S (NP (DT The) (NN reporter)) (VP (VBN stated) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NP (NN domperidone)) (PRN (-LRB- -LRB-) (NP (NP (NN route)) (CC and) (NP (NN formulation) (JJ unspecified))) (, ,) (NP (JJ batch) (JJ unknown)) (-RRB- -RRB-)) (NP (NP (NP (NN dosage)) (CC and) (NP (NN frequency))) (VP (VBN unspecified) (PP (VBN initiated) (PP (IN on) (NP (NP (NP (NP (DT an) (JJ unspecified) (NN date)) (PP (IN for) (NP (NP (NN gastroparesis)) (CC and) (NP (NP (JJ non-company) (NN suspect) (NN drug) (NN erythromycin)) (PRN (-LRB- -LRB-) (NP (NP (NN route)) (CC and) (NP (NN formulation) (JJ unspecified))) (-RRB- -RRB-))) (NP (NN dosage))))) (CC and) (NP (NN frequency) (NN unspecified))) (VP (VBN initiated) (PP (IN on) (NP (NP (DT an) (JJ unspecified) (NN date)) (PP (IN for) (NP (NP (NN gastroparesis)) (PRN (-LRB- -LRB-) (NP (JJ possible) (NN drug) (NN interaction)) (-RRB- -RRB-)))))))))))))))))))) (. .)))Concomitant medications included mesalazine for Crohn's disease.ConcomitantmedicationsincludedmesalazineforCrohn'sdisease.(S1 (S (S (NP (JJ Concomitant) (NNS medications)) (VP (VBD included) (NP (NP (NN mesalazine)) (PP (IN for) (NP (NN Crohn's) (NN disease)))))) (. .)))On an unspecified date, the patient was unwell and experienced arrhythmia, severe fatigue, dry mouth and dry eyes.Onanunspecifieddate,thepatientwasunwellandexperiencedarrhythmia,severefatigue,drymouthanddryeyes.(S1 (S (S (PP (IN On) (NP (DT an) (JJ unspecified) (NN date))) (, ,) (NP (DT the) (NN patient)) (VP (VBD was) (NP (NP (NP (NN unwell)) (CC and) (NP (VBN experienced) (NN arrhythmia))) (, ,) (NP (JJ severe) (NN fatigue)) (, ,) (NP (JJ dry) (NN mouth)) (CC and) (NP (NN dry) (NN eyes))))) (. .)))The reporter stated that the patient's periods stopped after starting domperidone on an unspecified date and have started again on an unspecified date.Thereporterstatedthatthepatient'speriodsstoppedafterstartingdomperidoneonanunspecifieddateandhavestartedagainonanunspecifieddate.(S1 (S (S (NP (NP (DT The) (NN reporter)) (VP (VBN stated) (PP (IN that) (NP (DT the) (CD patient's) (NNS periods))))) (VP (VBD stopped) (PP (IN after) (S (VP (VP (VBG starting) (NP (NP (NN domperidone)) (PP (IN on) (NP (DT an) (JJ unspecified) (NN date))))) (CC and) (VP (VBP have) (VP (VBN started) (ADVP (RB again)) (PP (IN on) (NP (DT an) (JJ unspecified) (NN date)))))))))) (. .)))Action taken with domperidone and erythromycin was not reported.Actiontakenwithdomperidoneanderythromycinwasnotreported.(S1 (S (S (NP (NP (NN Action)) (VP (VBN taken) (PP (IN with) (NP (NP (NN domperidone)) (CC and) (NP (NN erythromycin)))))) (VP (VBD was) (RB not) (VP (VBN reported)))) (. .)))The patient's outcome was not reported for the events arrhythmia, possible drug interaction, unwell, severe fatigue, dry eyes and dry mouth.Thepatient'soutcomewasnotreportedfortheeventsarrhythmia,possibledruginteraction,unwell,severefatigue,dryeyesanddrymouth.(S1 (S (S (NP (DT The) (JJ patient's) (NN outcome)) (VP (VBD was) (RB not) (VP (VBN reported) (PP (IN for) (NP (DT the) (NNS events) (NP (NP (NN arrhythmia)) (, ,) (NP (JJ possible) (NN drug) (NN interaction)) (, ,) (NP (NN unwell)) (, ,) (NP (JJ severe) (NN fatigue)) (, ,) (NP (JJ dry) (NN eyes)) (CC and) (NP (JJ dry) (NN mouth)))))))) (. .)))The consent for follow up was not reported.Theconsentforfollowupwasnotreported.(S1 (S (S (NP (NP (DT The) (NN consent)) (PP (IN for) (NP (VBP follow) (NN up)))) (VP (VBD was) (RB not) (VP (VBN reported)))) (. .)))This report was serious (medically significant).Thisreportwasserious(medicallysignificant).(S1 (S (S (NP (DT This) (NN report)) (VP (VBD was) (ADJP (JJ serious)) (PRN (-LRB- -LRB-) (NP (RB medically) (JJ significant)) (-RRB- -RRB-)))) (. .)))At the time of the report the outcome of the AEs were: ARRHYTHMIA: Unknown, POSSIBLE DRUG INTERACTION: Unknown, UNWELL: Unknown, SEVERE FATIGUE: Unknown, DRY EYES: Unknown, DRY MOUTH: Unknown, PERIOD STOPPED: recovered/resolved.AtthetimeofthereporttheoutcomeoftheAEswere:ARRHYTHMIA:Unknown,POSSIBLEDRUGINTERACTION:Unknown,UNWELL:Unknown,SEVEREFATIGUE:Unknown,DRYEYES:[sosy][sosy][sosy][sosy]Unknown[sosy][sosy][sosy][sosy],DRYMOUTH:Unknown,PERIODSTOPPED:recovered/resolved.(S1 (S (S (PP (IN At) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (DT the) (NN report))))) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (DT the) (NN AEs)))) (VP (VBD were))) (: :) (S (NP (NP (NN ARRHYTHMIA)) (: :) (NP (ADJP (ADJP (JJ Unknown)) (, ,) (ADJP (JJ POSSIBLE))) (NN DRUG) (NN INTERACTION)) (: :) (NP (JJ Unknown)) (, ,) (NP (NN UNWELL)) (: :) (NP (ADJP (ADJP (JJ Unknown)) (, ,) (ADJP (JJ SEVERE))) (NN FATIGUE)) (: :) (NP (NP (ADJP (ADJP (JJ Unknown)) (, ,) (ADJP (JJ DRY))) (NNS EYES)) (: :) (NP (JJ Unknown) (, ,) (JJ DRY) (NN MOUTH))) (: :) (NP (JJ Unknown)) (, ,) (NP (NN PERIOD))) (VP (VBN STOPPED))) (: :) (NP (JJ recovered/resolved)) (. .)))Action taken with suspect drugs: ERYTHROMYCIN - Unknown; DOMPERIDONE - Unknown.Actiontakenwithsuspectdrugs:ERYTHROMYCIN-Unknown;DOMPERIDONE-Unknown.(S1 (S (NP (NP (NP (NN Action)) (VP (VBN taken) (PP (IN with) (NP (NN suspect) (NNS drugs))))) (: :) (NP (NN ERYTHROMYCIN)) (: -) (NP (JJ Unknown)) (: ;) (NP (NP (NN DOMPERIDONE)) (CC -) (NP (JJ Unknown))) (. .))))The patient had medical history of CROHN'S DISEASE(Not Continuing), GASTROPARESIS(Not Continuing).ThepatienthadmedicalhistoryofCROHN'SDISEASE[dsyn][dsyn][dsyn][dsyn]([dsyn][dsyn][dsyn][dsyn]NotContinuing),GASTROPARESIS(NotContinuing).(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (NP (NP (JJ medical) (NN history)) (PP (IN of) (NP (NP (NP (JJ CROHN'S) (NN DISEASE)) (PRN (-LRB- -LRB-) (ADVP (RB Not)) (VP (VBG Continuing)) (-RRB- -RRB-))) (, ,) (NP (NP (NN GASTROPARESIS)) (PRN (-LRB- -LRB-) (ADVP (RB Not)) (VP (VBG Continuing)) (-RRB- -RRB-)))))))) (. .))) The patient's concomitant medication included MESALAZINE( Unknown, Dosage Form: Unspecified, for CROHN'S DISEASE). Thepatient'sconcomitantmedicationincludedMESALAZINE([orch,phsu][orch,phsu][orch,phsu][orch,phsu]Unknown,DosageForm:Unspecified,forCROHN'SDISEASE).(S1 (S (NP (DT The) (JJ patient's) (JJ concomitant) (NN medication)) (VP (VBD included) (NP (NP (NN MESALAZINE)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (ADJP (JJ Unknown)) (, ,) (ADJP (JJ Dosage))) (NN Form)) (: :) (NP (NN Unspecified)) (, ,) (PP (IN for) (NP (JJ CROHN'S) (NN DISEASE)))) (-RRB- -RRB-)))) (. .)))The patient's past medication were unspecified. Thepatient'spastmedicationwereunspecified.(S1 (S (S (NP (DT The) (JJ patient's) (JJ past) (NN medication)) (VP (VBD were) (VP (VBN unspecified)))) (. .)))Lab tests were not reported.Labtestswerenotreported.(S1 (S (S (NP (NN Lab) (NNS tests)) (VP (VBD were) (RB not) (VP (VBN reported)))) (. .)))This case was considered serious based on the following criteria: (Other Serious (Important Medical Events))Thiscasewasconsideredseriousbasedonthefollowingcriteria:(OtherSerious(ImportantMedicalEvents))(S1 (S (S (NP (DT This) (NN case)) (VP (VBD was) (VP (VBN considered) (S (ADJP (JJ serious) (PP (VBN based) (PP (IN on) (NP (DT the) (JJ following) (NNS criteria)))))))) (: :)) (PRN (-LRB- -LRB-) (NP (NP (JJ Other) (JJ Serious)) (PRN (-LRB- -LRB-) (NP (JJ Important) (JJ Medical) (NNS Events)) (-RRB- -RRB-))) (-RRB- -RRB-))))Teva Comment: ERYTHROMYCIN- Events ARRHYTHMIA and POSSIBLE DRUG INTERACTION Un-assessable due to insufficient information.TevaComment:ERYTHROMYCIN-EventsARRHYTHMIAandPOSSIBLEDRUGINTERACTIONUn-assessableduetoinsufficientinformation.(S1 (S (NP (NP (NN Teva) (NN Comment)) (: :) (NP (NP (NP (JJ ERYTHROMYCIN-) (NNS Events) (NN ARRHYTHMIA)) (CC and) (NP (JJ POSSIBLE) (NN DRUG) (NN INTERACTION))) (ADJP (JJ Un-assessable) (PP (JJ due) (TO to) (NP (JJ insufficient) (NN information))))) (. .))))Because this is a spontaneous case, regulatory distribution will be handled as though it is a related case.Becausethisisaspontaneouscase,regulatorydistributionwillbehandledasthoughitisarelatedcase.(S1 (S (S (SBAR (IN Because) (S (NP (DT this)) (VP (VBZ is) (NP (DT a) (JJ spontaneous) (NN case))))) (, ,) (NP (JJ regulatory) (NN distribution)) (VP (MD will) (VP (VB be) (VP (VBN handled) (SBAR (RB as) (IN though) (S (NP (PRP it)) (VP (VBZ is) (NP (DT a) (JJ related) (NN case))))))))) (. .)))23-Apr-2015:23-Apr-2015:(S1 (S (NP (NP (NN 23-Apr-2015)) (: :))))Additional information received from MHRA.AdditionalinformationreceivedfromMHRA.(S1 (S (S (NP (JJ Additional) (NN information)) (VP (VBD received) (PP (IN from) (NP (NN MHRA))))) (. .)))Additional information was received from a consumer (patient's mother) on 13-APR-2015.Additionalinformationwasreceivedfromaconsumer(patient'smother)on13-APR-2015.(S1 (S (S (NP (JJ Additional) (NN information)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (NP (NP (DT a) (NN consumer)) (PRN (-LRB- -LRB-) (NP (CD patient's) (NN mother)) (-RRB- -RRB-))) (PP (IN on) (NP (NN 13-APR-2015)))))))) (. .)))A phone call attempt was made at 13:21, 13:59 and 15:15 on 10-APR-2015 however phone call was not answered.Aphonecallattemptwasmadeat13:21,13:59and15:15on10-APR-2015howeverphonecallwasnotanswered.(S1 (S (S (NP (DT A) (NN phone) (NN call) (NN attempt)) (VP (VBD was) (VP (VBN made) (PP (IN at) (NP (NP (CD 13:21)) (, ,) (NP (CD 13:59)) (CC and) (NP (CD 15:15)))) (PP (IN on) (NP (NN 10-APR-2015)))) (SBAR (WHADVP (WRB however)) (S (NP (NN phone) (NN call)) (VP (VBD was) (RB not) (VP (VBN answered))))))) (. .)))On 13-APR-2015 company representative spoke to the patient's mother.On13-APR-2015companyrepresentativespoketothepatient'smother.(S1 (S (PP (IN On) (NP (NN 13-APR-2015) (NN company) (NN representative))) (VP (VBP spoke) (PP (TO to) (NP (DT the) (NN patient's) (NN mother)))) (. .)))The patient mother stated that the patient had been taking both domperidone and erythromycin for at least 5 years.Thepatientmotherstatedthatthepatienthadbeentakingbothdomperidoneanderythromycinforatleast5years.(S1 (S (S (NP (NP (DT The) (NN patient) (NN mother)) (VP (VBN stated) (PP (IN that) (NP (DT the) (NN patient))))) (VP (VBD had) (VP (VBN been) (S (VP (VBG taking) (NP (CC both) (NP (NN domperidone)) (CC and) (NP (NN erythromycin))) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 5)) (NNS years)))))))) (. .)))The onset of symptoms was 2 months prior.Theonsetofsymptomswas2monthsprior.(S1 (S (S (NP (NP (DT The) (NN onset)) (PP (IN of) (NP (NNS symptoms)))) (VP (VBD was) (NP (CD 2) (NNS months) (JJ prior)))) (. .)))The patient had other auto immune problems.Thepatienthadotherautoimmuneproblems.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (NP (JJ other) (JJ auto) (JJ immune) (NNS problems)))) (. .)))The patient's mother was unsure of exact dose and brand of domperidone and erythromycin but stated that the patient was on a low dose of erythromycin 3 times a day.Thepatient'smotherwasunsureofexactdoseandbrandofdomperidoneanderythromycinbutstatedthatthepatientwasonalowdoseoferythromycin3timesaday.(S1 (S (S (S (NP (DT The) (NN patient's) (NN mother)) (VP (VBD was) (NP (NP (NN unsure)) (PP (IN of) (NP (NP (NP (JJ exact) (NN dose)) (CC and) (NP (NN brand))) (PP (IN of) (NP (NP (NN domperidone)) (CC and) (NP (NN erythromycin))))))))) (CC but) (S (VP (VBN stated) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (VBD was) (PP (IN on) (NP (NP (DT a) (JJ low) (NN dose)) (PP (IN of) (NP (NN erythromycin))))) (NP (NP (CD 3) (NNS times)) (NP (DT a) (NN day))))))))) (. .)))The patient had stopped taking erythromycin 10 days prior.Thepatienthadstoppedtakingerythromycin10daysprior.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (VP (VBN stopped) (S (VP (VBG taking) (NP (NN erythromycin) (CD 10) (NNS days)) (ADVP (RB prior))))))) (. .)))Treatment with erythromycin was withdrawn on an unspecified date.Treatmentwitherythromycinwaswithdrawnonanunspecifieddate.(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN erythromycin)))) (VP (VBD was) (VP (VBN withdrawn) (PP (IN on) (NP (DT an) (JJ unspecified) (NN date)))))) (. .)))The symptoms have not yet improved.Thesymptomshavenotyetimproved.(S1 (S (S (NP (DT The) (NNS symptoms)) (VP (VBP have) (RB not) (ADVP (RB yet)) (VP (VBN improved)))) (. .)))The patient had not recovered from arrhythmia, unwell, severe fatigue, dry eyes and dry mouth.Thepatienthadnotrecoveredfromarrhythmia,unwell,severefatigue,dryeyesanddrymouth.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (RB not) (VP (VBN recovered) (PP (IN from) (NP (NP (NN arrhythmia)) (, ,) (NP (NN unwell)) (, ,) (NP (JJ severe) (NN fatigue)) (, ,) (NP (JJ dry) (NN eyes)) (CC and) (NP (JJ dry) (NN mouth))))))) (. .)))The reporter stated that the patient would be seeing a specialist on 24-Apr-2015.Thereporter[sosy][sosy][sosy][sosy]stated[sosy][sosy][sosy][sosy]thatthepatientwouldbeseeingaspecialiston24-Apr-2015.(S1 (S (S (NP (DT The) (NN reporter)) (VP (VBN stated) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (MD would) (VP (VB be) (VP (VBG seeing) (NP (NP (DT a) (NN specialist)) (PP (IN on) (NP (NN 24-Apr-2015))))))))))) (. .)))No further information was available at the time of this report.Nofurtherinformationwasavailableatthetimeofthisreport.(S1 (S (S (NP (DT No) (JJ further) (NN information)) (VP (VBD was) (ADJP (JJ available)) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (DT this) (NN report))))))) (. .)))The new information added in this FU included:ThenewinformationaddedinthisFUincluded:(S1 (S (S (NP (NP (DT The) (JJ new) (NN information)) (VP (VBN added) (PP (IN in) (NP (DT this) (NN FU))))) (VP (VBD included))) (: :)))Patient past medical history includes: Autoimmune disorder.Patientpastmedicalhistoryincludes:Autoimmunedisorder.(S1 (S (S (NP (NN Patient) (JJ past) (JJ medical) (NN history)) (VP (VBZ includes)) (: :) (NP (JJ Autoimmune) (NN disorder))) (. .)))Therapy start date of Domperidone was provided as: --2010.TherapystartdateofDomperidonewasprovidedas:--2010.(S1 (S (S (NP (NP (NN Therapy) (NN start) (NN date)) (PP (IN of) (NP (NN Domperidone)))) (VP (VBD was) (VP (VBN provided) (PP (IN as) (: :)) (: --) (NP (NN 2010))))) (. .)))Reporter causality for the events "Arrhythmia", "Drug interaction", "Unwell", "Fatigue", "Dry eyes", "Dry mouth", and "Menses lack of" with regard to "Domperidone" were provided as "Possible" respectively.Reportercausalityfortheevents"Arrhythmia","Druginteraction","Unwell","Fatigue","Dryeyes[sosy][sosy][sosy][sosy]","Drymouth",and"Menseslackof"withregardto"Domperidone"wereprovidedas"Possible"respectively.(S1 (S (NP (NP (NN Reporter) (NN causality)) (PP (IN for) (NP (NP (DT the) (NNS events)) (PP (VBG ") (NP (NP (NN Arrhythmia) (NN ")) (, ,) (NP (NN ") (NN Drug) (NN interaction) (NN ")) (, ,) (NP (NNP ") (NNP Unwell) (NNP ") (, ,) (NNP ") (NNP Fatigue) (NNP ")) (, ,) (NP (NN ") (NN Dry) (NN eyes) (NN ")) (, ,) (NP (NN ") (NN Dry) (NN mouth) (NN ")) (, ,) (CC and) (NP (NP (CD ") (NNS Menses) (NN lack)) (PP (IN of) (NP (NP (NNS ")) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NN ") (NN Domperidone) (NN "))))))))))))) (VP (VBD were) (VP (VBN provided) (PP (IN as) (NP (NP (JJ ") (JJ Possible) (NN ")) (ADVP (RB respectively)))))) (. .)))Therapy start date of Erythromycin was provided as: 2010.TherapystartdateofErythromycinwasprovidedas:2010.(S1 (S (S (NP (NP (NN Therapy) (NN start) (NN date)) (PP (IN of) (NP (NN Erythromycin)))) (VP (VBD was) (VP (VBN provided) (PP (IN as) (: :) (NP (NN 2010)))))) (. .)))Therapy stop date of Erythromycin was provided as: -Apr-2015.TherapystopdateofErythromycinwasprovidedas:-Apr-2015.(S1 (S (S (NP (NP (NN Therapy) (NN stop) (NN date)) (PP (IN of) (NP (NN Erythromycin)))) (VP (VBD was) (VP (VBN provided) (PP (IN as) (: :) (NP (NN -Apr-2015)))))) (. .)))Last action taken with drug "Erythromycin" was provided as: Drug Discontinued.Lastactiontakenwithdrug"Erythromycin"wasprovidedas:DrugDiscontinued.(S1 (S (S (NP (NP (JJ Last) (NN action)) (VP (VBN taken) (PP (IN with) (NP (NN drug) (NN ") (NN Erythromycin) (NN "))))) (VP (VBD was) (VP (VBN provided) (PP (IN as) (: :) (NP (NP (NN Drug)) (VP (VBN Discontinued))))))) (. .)))TEva Comment: Erythromycin - Considering the long-term uneventful therapy with suspect drug, its role in the reported events was considered unrelated.TEvaComment:Erythromycin-Consideringthelong-termuneventfultherapywithsuspectdrug,itsroleinthereportedeventswasconsideredunrelated.(S1 (S (NP (NP (NN TEva) (NN Comment)) (: :) (NP (NN Erythromycin)) (: -) (S (S (VP (VBG Considering) (NP (NP (DT the) (JJ long-term) (NN uneventful) (NN therapy)) (PP (IN with) (NP (NN suspect) (NN drug)))))) (, ,) (NP (NP (PRP$ its) (NN role)) (PP (IN in) (NP (DT the) (VBN reported) (NNS events)))) (VP (VBD was) (VP (VBN considered) (ADJP (JJ unrelated))))) (. .))))27-Apr-2015:27-Apr-2015:(S1 (S (NP (NP (NN 27-Apr-2015)) (: :))))Additional information was received from the Health Authority.AdditionalinformationwasreceivedfromtheHealthAuthority.(S1 (S (S (NP (JJ Additional) (NN information)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (DT the) (NN Health) (NN Authority)))))) (. .)))Dosage text for the suspect drug "Erythromycin" was provided as "Dosage form: Unspecified, Low dose".Dosagetextforthesuspectdrug"Erythromycin"wasprovidedas"Dosageform:Unspecified,Lowdose".(S1 (S (S (NP (NP (NN Dosage) (NN text)) (PP (IN for) (NP (DT the) (NN suspect) (NN drug) (NN ") (NN Erythromycin) (NN ")))) (VP (VBD was) (VP (VBN provided) (PP (IN as) (NP (NP (NP (NN ") (NN Dosage) (NN form)) (: :) (NP (NN Unspecified))) (, ,) (NP (JJ Low) (NN dose) (NN "))))))) (. .)))"No Medical Assessment"."NoMedicalAssessment".(S1 (S (S (VP (VBG ") (NP (DT No) (JJ Medical) (NN Assessment) (NN ")))) (. .)))13-May-2015:13-May-2015:(S1 (S (NP (NP (NN 13-May-2015)) (: :))))Additional information was received from a consumer via regulatory authority (MHRA) (GB-MHRA-ADR 22956126) on 16-APR-2015.Additionalinformationwasreceivedfromaconsumerviaregulatoryauthority(MHRA)(GB-MHRA-ADR22956126)on16-APR-2015.(S1 (S (S (NP (JJ Additional) (NN information)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (NP (DT a) (NN consumer)) (PP (IN via) (NP (NP (NP (NP (JJ regulatory) (NN authority)) (PRN (-LRB- -LRB-) (NP (NN MHRA)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN GB-MHRA-ADR) (CD 22956126)) (-RRB- -RRB-))) (PP (IN on) (NP (NN 16-APR-2015)))))))))) (. .)))Health authority numbers were updated in the case ID screen.HealthauthoritynumberswereupdatedinthecaseIDscreen.(S1 (S (S (NP (NN Health) (NN authority) (NNS numbers)) (VP (VBD were) (VP (VBN updated) (PP (IN in) (NP (DT the) (NN case) (NN ID) (NN screen)))))) (. .)))Follow-up report was received on 23-APR-2015.Follow-upreportwasreceivedon23-APR-2015.(S1 (S (S (NP (JJ Follow-up) (NN report)) (VP (VBD was) (VP (VBN received) (PP (IN on) (NP (NN 23-APR-2015)))))) (. .)))This report contains no new information and no changes were made to the report.Thisreportcontainsnonewinformationandnochangesweremadetothereport.(S1 (S (S (S (NP (DT This) (NN report)) (VP (VBZ contains) (NP (DT no) (JJ new) (NN information)))) (CC and) (S (NP (DT no) (NNS changes)) (VP (VBD were) (VP (VBN made) (PP (TO to) (NP (DT the) (NN report))))))) (. .)))Follow-up report was received on 27-APR-2015.Follow-upreportwasreceivedon27-APR-2015.(S1 (S (S (NP (JJ Follow-up) (NN report)) (VP (VBD was) (VP (VBN received) (PP (IN on) (NP (NN 27-APR-2015)))))) (. .)))Other company manufacturer's reference number was updated.Othercompanymanufacturer'sreferencenumberwasupdated.(S1 (S (S (NP (JJ Other) (NN company) (NN manufacturer's) (NN reference) (NN number)) (VP (VBD was) (VP (VBN updated)))) (. .)))This report contains no new information and no changes were made to the report.Thisreportcontainsnonewinformationandnochangesweremadetothereport.(S1 (S (S (S (NP (DT This) (NN report)) (VP (VBZ contains) (NP (DT no) (JJ new) (NN information)))) (CC and) (S (NP (DT no) (NNS changes)) (VP (VBD were) (VP (VBN made) (PP (TO to) (NP (DT the) (NN report))))))) (. .)))Additional information was received from the patient's mother on 04-MAY-2015.Additionalinformationwasreceivedfromthepatient'smotheron04-MAY-2015.(S1 (S (S (NP (JJ Additional) (NN information)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (NP (DT the) (NN patient's) (NN mother)) (PP (IN on) (NP (NN 04-MAY-2015)))))))) (. .)))The patient stated that her general practitioner (GP) and specialist did not think that the problems were the side effects of domperidone.Thepatientstatedthathergeneralpractitioner(GP)andspecialistdidnotthinkthattheproblemswerethesideeffectsofdomperidone.(S1 (S (S (NP (NP (DT The) (NN patient)) (VP (VBN stated) (PP (IN that) (NP (NP (NP (PRP$ her) (JJ general) (NN practitioner)) (PRN (-LRB- -LRB-) (NP (NN GP)) (-RRB- -RRB-))) (CC and) (NP (NN specialist)))))) (VP (VBD did) (RB not) (VP (VBP think) (SBAR (IN that) (S (NP (DT the) (NNS problems)) (VP (VBD were) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NN domperidone)))))))))) (. .)))No further information was reported at the time of the report.Nofurtherinformationwasreportedatthetimeofthereport.(S1 (S (S (NP (DT No) (JJ further) (NN information)) (VP (VBD was) (VP (VBN reported) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (DT the) (NN report)))))))) (. .)))Other reference number include - MHRA: 01001307081; 01001307081: GB-JNJFOC-20150407438.Otherreferencenumberinclude-MHRA:01001307081;01001307081:GB-JNJFOC-20150407438.(S1 (S (S (NP (JJ Other) (NN reference) (NN number)) (VP (VBP include) (: -) (NP (NP (NNP MHRA)) (: :) (NP (NP (CD 01001307081)) (: ;) (NP (CD 01001307081)) (: :) (NP (CD GB-JNJFOC-20150407438)))))) (. .)))Duration of suspect drug "Domperidone" was reported as 5 years.Durationofsuspectdrug"Domperidone"[phsu][phsu][phsu][phsu][phsu][phsu][phsu][phsu]wasreported[orch,phsu][orch,phsu][orch,phsu][orch,phsu]as5years.(S1 (S (S (NP (NP (NN Duration)) (PP (IN of) (NP (NN suspect) (NN drug) (NN ") (NN Domperidone) (NN ")))) (VP (VBD was) (VP (VBN reported) (PP (IN as) (NP (CD 5) (NNS years)))))) (. .)))"No medical assessment"."Nomedicalassessment".(S1 (S (S (VP (VBG ") (NP (DT No) (JJ medical) (NN assessment) (NN ")))) (. .))) \ No newline at end of file +16 Apr 2015, Spontaneous, Health authority, Patient/Consumer Serious report.16Apr2015,Spontaneous,Healthauthority,Patient/ConsumerSeriousreport.(S1 (S (S (NP (NP (NP (NP (CD 16) (NNP Apr) (CD 2015)) (, ,) (ADJP (JJ Spontaneous))) (, ,) (NP (NN Health) (NN authority)) (, ,)) (NNP Patient/Consumer)) (NP (JJ Serious) (NN report))) (. .)))(Report duplicates 01001307081: GB JNJFOC 20150407438; MHRAUK: GB MHRA ADR 22956126)(Reportduplicates01001307081:GBJNJFOC20150407438;MHRAUK:GBMHRAADR22956126)(S1 (S (PRN (-LRB- -LRB-) (NP (NN Report) (NNS duplicates) (CD 01001307081)) (: :) (NP (NP (NN GB) (NN JNJFOC) (NN 20150407438)) (: ;) (NP (NN MHRAUK)) (: :) (NP (NN GB) (NN MHRA) (NN ADR) (CD 22956126))) (-RRB- -RRB-))))A Consumer/other non health professional reported the case of a Female patient (age unknown) who received ERYTHROMYCIN (Product be excluded as a Teva product), DOMPERIDONE (not Teva's product). AConsumer/othernonhealthprofessionalreportedthecaseofaFemalepatient(ageunknown)whoreceivedERYTHROMYCIN(ProductbeexcludedasaTevaproduct),DOMPERIDONE[orch,phsu](notTeva'sproduct).(S1 (S (S (NP (DT A) (NN Consumer/other) (JJ non) (NN health) (NN professional)) (VP (VBD reported) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (NP (DT a) (JJ Female) (NN patient)) (PRN (-LRB- -LRB-) (NP (NP (NN age)) (ADJP (JJ unknown))) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (NP (NN ERYTHROMYCIN)) (PRN (-LRB- -LRB-) (S (NP (NN Product)) (VP (VB be) (VP (VBN excluded) (PP (IN as) (NP (DT a) (NN Teva) (NN product)))))) (-RRB- -RRB-))) (, ,) (NP (NP (NN DOMPERIDONE)) (PRN (-LRB- -LRB-) (RB not) (NP (NNP Teva) (POS 's) (NN product)) (-RRB- -RRB-)))))))))))) (. .)))The patient took ERYTHROMYCIN for GASTROPARESIS (Unknown, Dosage Form: Unspecified) batch: Unknown, DOMPERIDONE for GASTROPARESIS (Unknown, Dosage Form: Unspecified) batch: Unknown.ThepatienttookERYTHROMYCINforGASTROPARESIS(Unknown,DosageForm:Unspecified)batch:Unknown,DOMPERIDONEforGASTROPARESIS(Unknown,DosageForm:Unspecified)batch:Unknown.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD took) (NP (NP (NN ERYTHROMYCIN)) (PP (IN for) (NP (NN GASTROPARESIS)))) (PRN (-LRB- -LRB-) (NP (NP (JJ Unknown)) (, ,) (NP (NN Dosage) (NN Form)) (: :) (NP (ADJP (NN Unspecified) (-RRB- -RRB-) (JJ batch))) (: :) (NP (JJ Unknown)) (, ,) (NP (ADJP (NP (NP (NN DOMPERIDONE)) (PP (IN for) (NP (NN GASTROPARESIS)))) (-LRB- -LRB-) (NP (NP (JJ Unknown)) (, ,) (NP (NN Dosage) (NN Form)) (: :) (NP (ADJP (JJ Unspecified)))) (-RRB- -RRB-) (JJ batch))) (: :) (NP (JJ Unknown)))))) (. .)))While on the suspect medication(s), the patient experienced ARRHYTHMIA(Serious); POSSIBLE DRUG INTERACTION(Serious); UNWELL(Not Serious); SEVERE FATIGUE(Not Serious); DRY EYES(Not Serious); DRY MOUTH(Not Serious); PERIOD STOPPED(Not Serious).Whileonthesuspectmedication(s),thepatientexperiencedARRHYTHMIA(Serious);POSSIBLEDRUGINTERACTION(Serious);UNWELL(NotSerious);SEVEREFATIGUE(NotSerious);DRYEYES(NotSerious);DRYMOUTH(NotSerious);PERIODSTOPPED(NotSerious).(S1 (S (S (PP (IN While) (PP (IN on) (NP (NP (DT the) (NN suspect) (NN medication)) (PRN (-LRB- -LRB-) (NP (NN s)) (-RRB- -RRB-))))) (, ,) (NP (DT the) (NN patient) (NP (NP (NP (VBN experienced) (NP (NP (NP (NP (NP (NN ARRHYTHMIA)) (PRN (-LRB- -LRB-) (ADJP (JJ Serious)) (-RRB- -RRB-))) (: ;) (NP (NP (JJ POSSIBLE) (NN DRUG) (NN INTERACTION)) (PRN (-LRB- -LRB-) (ADJP (JJ Serious)) (-RRB- -RRB-))) (: ;) (NP (NNP UNWELL))) (PRN (-LRB- -LRB-) (NP (RB Not) (JJ Serious)) (-RRB- -RRB-))) (: ;) (NP (NP (JJ SEVERE) (NN FATIGUE)) (PRN (-LRB- -LRB-) (ADJP (RB Not) (JJ Serious)) (-RRB- -RRB-))) (: ;)) (JJ DRY) (NNS EYES)) (PRN (-LRB- -LRB-) (NP (RB Not) (JJ Serious)) (-RRB- -RRB-))) (: ;) (NP (NP (NP (JJ DRY) (NN MOUTH)) (PRN (-LRB- -LRB-) (NP (RB Not) (JJ Serious)) (-RRB- -RRB-))) (: ;) (NP (NN PERIOD))))) (VP (VBD STOPPED) (PRN (-LRB- -LRB-) (NP (RB Not) (JJ Serious)) (-RRB- -RRB-)))) (. .)))MHRA verbatim: This spontaneous report was received from a consumer (patient's mother) and concerns a female patient of unspecified age from the United Kingdom. MHRAverbatim:Thisspontaneousreportwasreceivedfromaconsumer(patient'smother)andconcernsafemalepatientofunspecifiedagefromtheUnitedKingdom.(S1 (S (NP (NP (NN MHRA) (NN verbatim)) (: :) (S (NP (DT This) (JJ spontaneous) (NN report)) (VP (VBD was) (VP (VP (VBN received) (PP (IN from) (NP (NP (DT a) (NN consumer)) (PRN (-LRB- -LRB-) (NP (NP (NN patient) (POS 's)) (NN mother)) (-RRB- -RRB-))))) (CC and) (VP (VBZ concerns) (NP (NP (DT a) (JJ female) (NN patient)) (PP (IN of) (NP (JJ unspecified) (NN age))) (PP (IN from) (NP (DT the) (JJ United) (NN Kingdom)))))))) (. .))))The patient's height and weight were not reported.Thepatient'sheightandweightwerenotreported.(S1 (S (S (NP (NP (NP (DT The) (NN patient) (POS 's)) (NN height)) (CC and) (NP (NN weight))) (VP (VBD were) (RB not) (VP (VBN reported)))) (. .)))The patient's medical history and concurrent conditions included: Crohn's disease and gastroparesis.Thepatient'smedicalhistoryandconcurrentconditionsincluded:Crohn'sdiseaseandgastroparesis.(S1 (S (S (NP (NP (NP (DT The) (NN patient) (POS 's)) (JJ medical) (NN history)) (CC and) (NP (JJ concurrent) (NNS conditions))) (VP (VBD included) (: :) (NP (NP (NP (NN Crohn) (POS 's)) (NN disease)) (CC and) (NP (NN gastroparesis))))) (. .)))The reporter stated that the patient was treated with domperidone (route and formulation unspecified, batch unknown) dosage and frequency unspecified initiated on an unspecified date for gastroparesis and non company suspect drug erythromycin (route and formulation unspecified) dosage and frequency unspecified initiated on an unspecified date for gastroparesis (possible drug interaction).Thereporterstatedthatthepatientwastreatedwithdomperidone(routeandformulationunspecified,batchunknown)dosageandfrequencyunspecifiedinitiatedonanunspecifieddateforgastroparesisandnoncompanysuspectdrugerythromycin[phsu][phsu](routeandformulationunspecified)dosageandfrequencyunspecifiedinitiatedonanunspecifieddateforgastroparesis(possibledruginteraction).(S1 (S (S (NP (DT The) (NN reporter)) (VP (VBN stated) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NP (NN domperidone)) (PRN (-LRB- -LRB-) (NP (NP (NN route)) (CC and) (NP (NN formulation) (JJ unspecified))) (, ,) (NP (NP (JJ batch) (JJ unknown) (-RRB- -RRB-) (NN dosage)) (CC and) (NP (NP (NN frequency) (NN unspecified)) (VP (VBN initiated) (PP (IN on) (NP (NP (NP (NP (DT an) (JJ unspecified) (NN date)) (PP (IN for) (NP (NP (NN gastroparesis)) (CC and) (NP (NP (JJ non) (NN company) (NN suspect) (NN drug) (NN erythromycin)) (PRN (-LRB- -LRB-) (NP (NP (NN route)) (CC and) (NP (NN formulation) (JJ unspecified))) (-RRB- -RRB-))) (NP (NN dosage))))) (CC and) (NP (NN frequency) (NN unspecified))) (VP (VBN initiated) (PP (IN on) (NP (NP (DT an) (JJ unspecified) (NN date)) (PP (IN for) (NP (NP (NN gastroparesis)) (PRN (-LRB- -LRB-) (NP (JJ possible) (NN drug) (NN interaction)) (-RRB- -RRB-))))))))))))))))))))) (. .)))Concomitant medications included mesalazine for Crohn's disease.ConcomitantmedicationsincludedmesalazineforCrohn's[dsyn]disease[dsyn].(S1 (S (S (NP (JJ Concomitant) (NNS medications)) (VP (VBD included) (NP (NP (NN mesalazine)) (PP (IN for) (NP (NP (NN Crohn) (POS 's)) (NN disease)))))) (. .)))On an unspecified date, the patient was unwell and experienced arrhythmia, severe fatigue, dry mouth and dry eyes.Onanunspecifieddate,thepatientwasunwellandexperiencedarrhythmia,severefatigue,drymouthanddryeyes.(S1 (S (S (PP (IN On) (NP (DT an) (JJ unspecified) (NN date))) (, ,) (NP (DT the) (NN patient)) (VP (VBD was) (NP (NP (NP (NN unwell)) (CC and) (NP (VBN experienced) (NN arrhythmia))) (, ,) (NP (JJ severe) (NN fatigue)) (, ,) (NP (JJ dry) (NN mouth)) (CC and) (NP (NN dry) (NN eyes))))) (. .)))The reporter stated that the patient's periods stopped after starting domperidone on an unspecified date and have started again on an unspecified date.Thereporterstatedthatthepatient'speriodsstoppedafterstartingdomperidoneonanunspecifieddateandhavestartedagainonanunspecifieddate.(S1 (S (S (NP (NP (DT The) (NN reporter)) (VP (VBN stated) (PP (IN that) (NP (NP (DT the) (NN patient) (POS 's)) (NNS periods))))) (VP (VBD stopped) (PP (IN after) (S (VP (VP (VBG starting) (NP (NP (NN domperidone)) (PP (IN on) (NP (DT an) (JJ unspecified) (NN date))))) (CC and) (VP (VBP have) (VP (VBN started) (ADVP (RB again)) (PP (IN on) (NP (DT an) (JJ unspecified) (NN date)))))))))) (. .)))Action taken with domperidone and erythromycin was not reported.Actiontakenwithdomperidoneanderythromycinwasnotreported.(S1 (S (S (NP (NP (NN Action)) (VP (VBN taken) (PP (IN with) (NP (NP (NN domperidone)) (CC and) (NP (NN erythromycin)))))) (VP (VBD was) (RB not) (VP (VBN reported)))) (. .)))The patient's outcome was not reported for the events arrhythmia, possible drug interaction, unwell, severe fatigue, dry eyes and dry mouth.Thepatient'soutcomewasnotreportedfortheeventsarrhythmia,possibledruginteraction,unwell,severefatigue,dryeyesanddrymouth.(S1 (S (S (NP (NP (DT The) (NN patient) (POS 's)) (NN outcome)) (VP (VBD was) (RB not) (VP (VBN reported) (PP (IN for) (NP (DT the) (NNS events) (NP (NP (NN arrhythmia)) (, ,) (NP (JJ possible) (NN drug) (NN interaction)) (, ,) (NP (NN unwell)) (, ,) (NP (JJ severe) (NN fatigue)) (, ,) (NP (JJ dry) (NN eyes)) (CC and) (NP (JJ dry) (NN mouth)))))))) (. .)))The consent for follow up was not reported.Theconsentforfollowupwasnotreported.(S1 (S (S (NP (NP (DT The) (NN consent)) (PP (IN for) (NP (VBP follow) (NN up)))) (VP (VBD was) (RB not) (VP (VBN reported)))) (. .)))This report was serious (medically significant).Thisreportwasserious(medicallysignificant).(S1 (S (S (NP (DT This) (NN report)) (VP (VBD was) (ADJP (JJ serious)) (PRN (-LRB- -LRB-) (NP (RB medically) (JJ significant)) (-RRB- -RRB-)))) (. .)))At the time of the report the outcome of the AEs were: ARRHYTHMIA: Unknown, POSSIBLE DRUG INTERACTION: Unknown, UNWELL: Unknown, SEVERE FATIGUE: Unknown, DRY EYES: Unknown, DRY MOUTH: Unknown, PERIOD STOPPED: recovered/resolved.AtthetimeofthereporttheoutcomeoftheAEswere:ARRHYTHMIA:Unknown,POSSIBLEDRUGINTERACTION:Unknown,UNWELL:Unknown,SEVEREFATIGUE:Unknown,DRYEYES:[sosy]Unknown[sosy],DRYMOUTH:Unknown,PERIODSTOPPED:recovered/resolved.(S1 (S (S (PP (IN At) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (DT the) (NN report))))) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (DT the) (NN AEs)))) (VP (VBD were))) (: :) (S (NP (NP (NN ARRHYTHMIA)) (: :) (NP (ADJP (ADJP (JJ Unknown)) (, ,) (ADJP (JJ POSSIBLE))) (NN DRUG) (NN INTERACTION)) (: :) (NP (JJ Unknown)) (, ,) (NP (NN UNWELL)) (: :) (NP (ADJP (ADJP (JJ Unknown)) (, ,) (ADJP (JJ SEVERE))) (NN FATIGUE)) (: :) (NP (NP (ADJP (ADJP (JJ Unknown)) (, ,) (ADJP (JJ DRY))) (NNS EYES)) (: :) (NP (JJ Unknown) (, ,) (JJ DRY) (NN MOUTH))) (: :) (NP (JJ Unknown)) (, ,) (NP (NN PERIOD))) (VP (VBN STOPPED))) (: :) (NP (JJ recovered/resolved)) (. .)))Action taken with suspect drugs: ERYTHROMYCIN Unknown; DOMPERIDONE Unknown.Actiontakenwithsuspectdrugs:ERYTHROMYCINUnknown;DOMPERIDONEUnknown.(S1 (S (S (NP (NP (NN Action)) (VP (VBN taken) (PP (IN with) (NP (NN suspect) (NNS drugs))))) (: :) (NP (NN ERYTHROMYCIN) (JJ Unknown)) (: ;) (NP (NN DOMPERIDONE) (JJ Unknown))) (. .)))The patient had medical history of CROHN'S DISEASE(Not Continuing), GASTROPARESIS(Not Continuing).ThepatienthadmedicalhistoryofCROHN'SDISEASE[dsyn]([dsyn]NotContinuing),GASTROPARESIS(NotContinuing).(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (NP (NP (JJ medical) (NN history)) (PP (IN of) (NP (NP (NP (NP (NN CROHN) (POS 'S)) (NN DISEASE)) (PRN (-LRB- -LRB-) (ADVP (RB Not)) (VP (VBG Continuing)) (-RRB- -RRB-))) (, ,) (NP (NP (NN GASTROPARESIS)) (PRN (-LRB- -LRB-) (ADVP (RB Not)) (VP (VBG Continuing)) (-RRB- -RRB-)))))))) (. .))) The patient's concomitant medication included MESALAZINE( Unknown, Dosage Form: Unspecified, for CROHN'S DISEASE). Thepatient'sconcomitantmedicationincludedMESALAZINE([orch,phsu]Unknown,DosageForm:Unspecified,forCROHN'SDISEASE).(S1 (S (S (NP (NP (DT The) (NN patient) (POS 's)) (JJ concomitant) (NN medication)) (VP (VBD included) (NP (NP (NN MESALAZINE)) (PRN (-LRB- -LRB-) (NP (NP (JJ Unknown)) (, ,) (NP (NN Dosage) (NN Form)) (: :) (NP (ADJP (JJ Unspecified))) (, ,) (PP (IN for) (NP (NP (NN CROHN) (POS 'S)) (NN DISEASE)))) (-RRB- -RRB-))))) (. .)))The patient's past medication were unspecified. Thepatient'spastmedicationwereunspecified.(S1 (S (S (NP (NP (DT The) (NN patient) (POS 's)) (JJ past) (NN medication)) (VP (VBD were) (VP (VBN unspecified)))) (. .)))Lab tests were not reported.Labtestswerenotreported.(S1 (S (S (NP (NN Lab) (NNS tests)) (VP (VBD were) (RB not) (VP (VBN reported)))) (. .)))This case was considered serious based on the following criteria: (Other Serious (Important Medical Events))Thiscasewasconsideredseriousbasedonthefollowingcriteria:(OtherSerious(ImportantMedicalEvents))(S1 (S (S (NP (DT This) (NN case)) (VP (VBD was) (VP (VBN considered) (S (ADJP (JJ serious) (PP (VBN based) (PP (IN on) (NP (DT the) (JJ following) (NNS criteria)))))))) (: :)) (PRN (-LRB- -LRB-) (NP (NP (JJ Other) (JJ Serious)) (PRN (-LRB- -LRB-) (NP (JJ Important) (JJ Medical) (NNS Events)) (-RRB- -RRB-))) (-RRB- -RRB-))))Teva Comment: ERYTHROMYCIN Events ARRHYTHMIA and POSSIBLE DRUG INTERACTION Un assessable due to insufficient information.TevaComment:ERYTHROMYCINEventsARRHYTHMIAandPOSSIBLEDRUGINTERACTIONUnassessableduetoinsufficientinformation.(S1 (S (NP (NP (NN Teva) (NN Comment)) (: :) (NP (NP (NP (NN ERYTHROMYCIN) (NNS Events) (NN ARRHYTHMIA)) (CC and) (NP (JJ POSSIBLE) (NN DRUG) (NN INTERACTION) (NN Un))) (ADJP (JJ assessable) (PP (JJ due) (TO to) (NP (JJ insufficient) (NN information))))) (. .))))Because this is a spontaneous case, regulatory distribution will be handled as though it is a related case.Becausethisisaspontaneouscase,regulatorydistributionwillbehandledasthoughitisarelatedcase.(S1 (S (S (SBAR (IN Because) (S (NP (DT this)) (VP (VBZ is) (NP (DT a) (JJ spontaneous) (NN case))))) (, ,) (NP (JJ regulatory) (NN distribution)) (VP (MD will) (VP (VB be) (VP (VBN handled) (SBAR (RB as) (IN though) (S (NP (PRP it)) (VP (VBZ is) (NP (DT a) (JJ related) (NN case))))))))) (. .)))23 Apr 2015:23Apr2015:(S1 (S (NP (NP (CD 23) (NNP Apr) (CD 2015)) (: :))))Additional information received from MHRA.AdditionalinformationreceivedfromMHRA.(S1 (S (S (NP (JJ Additional) (NN information)) (VP (VBD received) (PP (IN from) (NP (NN MHRA))))) (. .)))Additional information was received from a consumer (patient's mother) on 13 APR 2015.Additionalinformationwasreceivedfromaconsumer(patient'smother)on13APR2015.(S1 (S (S (NP (JJ Additional) (NN information)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (NP (NP (DT a) (NN consumer)) (PRN (-LRB- -LRB-) (NP (NP (NN patient) (POS 's)) (NN mother)) (-RRB- -RRB-))) (PP (IN on) (NP (CD 13) (NN APR) (CD 2015)))))))) (. .)))A phone call attempt was made at 13:21, 13:59 and 15:15 on 10 APR 2015 however phone call was not answered.Aphonecallattemptwasmadeat13:21,13:59and15:15on10APR2015howeverphonecallwasnotanswered.(S1 (S (S (S (NP (DT A) (NN phone) (NN call) (NN attempt)) (VP (VBD was) (VP (VBN made) (PP (IN at) (NP (NP (CD 13:21)) (, ,) (NP (CD 13:59)) (CC and) (NP (CD 15:15)))) (PP (IN on) (NP (CD 10) (NN APR) (CD 2015)))))) (S (ADVP (RB however)) (NP (NN phone) (NN call)) (VP (VBD was) (RB not) (VP (VBN answered))))) (. .)))On 13 APR 2015 company representative spoke to the patient's mother.On13APR2015companyrepresentativespoketothepatient'smother.(S1 (S (S (PP (IN On) (NP (NP (CD 13) (NNP APR) (CD 2015)) (NN company) (NN representative))) (VP (VBP spoke) (PP (TO to) (NP (NP (DT the) (NN patient) (POS 's)) (NN mother))))) (. .)))The patient mother stated that the patient had been taking both domperidone and erythromycin for at least 5 years.Thepatientmotherstatedthatthepatienthadbeentakingbothdomperidoneanderythromycinforatleast5years.(S1 (S (S (NP (NP (DT The) (NN patient) (NN mother)) (VP (VBN stated) (PP (IN that) (NP (DT the) (NN patient))))) (VP (VBD had) (VP (VBN been) (S (VP (VBG taking) (NP (CC both) (NP (NN domperidone)) (CC and) (NP (NN erythromycin))) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 5)) (NNS years)))))))) (. .)))The onset of symptoms was 2 months prior.Theonsetofsymptomswas2monthsprior.(S1 (S (S (NP (NP (DT The) (NN onset)) (PP (IN of) (NP (NNS symptoms)))) (VP (VBD was) (NP (CD 2) (NNS months) (JJ prior)))) (. .)))The patient had other auto immune problems.Thepatienthadotherautoimmuneproblems.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (NP (JJ other) (JJ auto) (JJ immune) (NNS problems)))) (. .)))The patient's mother was unsure of exact dose and brand of domperidone and erythromycin but stated that the patient was on a low dose of erythromycin 3 times a day.Thepatient'smotherwasunsureofexactdoseandbrandofdomperidoneanderythromycinbutstatedthatthepatientwasonalowdoseoferythromycin3timesaday.(S1 (S (S (S (NP (NP (DT The) (NN patient) (POS 's)) (NN mother)) (VP (VBD was) (NP (NP (NN unsure)) (PP (IN of) (NP (NP (NP (JJ exact) (NN dose)) (CC and) (NP (NN brand))) (PP (IN of) (NP (NP (NN domperidone)) (CC and) (NP (NN erythromycin))))))))) (CC but) (S (VP (VBN stated) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (VBD was) (PP (IN on) (NP (NP (DT a) (JJ low) (NN dose)) (PP (IN of) (NP (NN erythromycin))))) (NP (NP (CD 3) (NNS times)) (NP (DT a) (NN day))))))))) (. .)))The patient had stopped taking erythromycin 10 days prior.Thepatienthadstoppedtakingerythromycin10daysprior.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (VP (VBN stopped) (S (VP (VBG taking) (NP (NN erythromycin) (CD 10) (NNS days)) (ADVP (RB prior))))))) (. .)))Treatment with erythromycin was withdrawn on an unspecified date.Treatmentwitherythromycinwaswithdrawnonanunspecifieddate.(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN erythromycin)))) (VP (VBD was) (VP (VBN withdrawn) (PP (IN on) (NP (DT an) (JJ unspecified) (NN date)))))) (. .)))The symptoms have not yet improved.Thesymptomshavenotyetimproved.(S1 (S (S (NP (DT The) (NNS symptoms)) (VP (VBP have) (RB not) (ADVP (RB yet)) (VP (VBN improved)))) (. .)))The patient had not recovered from arrhythmia, unwell, severe fatigue, dry eyes and dry mouth.Thepatienthadnotrecoveredfromarrhythmia,unwell,severefatigue,dryeyesanddrymouth.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (RB not) (VP (VBN recovered) (PP (IN from) (NP (NP (NN arrhythmia)) (, ,) (NP (NN unwell)) (, ,) (NP (JJ severe) (NN fatigue)) (, ,) (NP (JJ dry) (NN eyes)) (CC and) (NP (JJ dry) (NN mouth))))))) (. .)))The reporter stated that the patient would be seeing a specialist on 24 Apr 2015.Thereporter[sosy]stated[sosy]thatthepatientwouldbeseeingaspecialiston24Apr2015.(S1 (S (S (NP (DT The) (NN reporter)) (VP (VBN stated) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (MD would) (VP (VB be) (VP (VBG seeing) (NP (NP (DT a) (NN specialist)) (PP (IN on) (NP (CD 24) (NNP Apr) (CD 2015))))))))))) (. .)))No further information was available at the time of this report.Nofurtherinformationwasavailableatthetimeofthisreport.(S1 (S (S (NP (DT No) (JJ further) (NN information)) (VP (VBD was) (ADJP (JJ available)) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (DT this) (NN report))))))) (. .)))The new information added in this FU included:ThenewinformationaddedinthisFUincluded:(S1 (S (S (NP (NP (DT The) (JJ new) (NN information)) (VP (VBN added) (PP (IN in) (NP (DT this) (NN FU))))) (VP (VBD included))) (: :)))Patient past medical history includes: Autoimmune disorder.Patientpastmedicalhistoryincludes:Autoimmunedisorder.(S1 (S (S (NP (NN Patient) (JJ past) (JJ medical) (NN history)) (VP (VBZ includes)) (: :) (NP (JJ Autoimmune) (NN disorder))) (. .)))Therapy start date of Domperidone was provided as: 2010.TherapystartdateofDomperidonewasprovidedas:2010.(S1 (S (S (NP (NP (NN Therapy) (NN start) (NN date)) (PP (IN of) (NP (NN Domperidone)))) (VP (VBD was) (VP (VBN provided) (PP (IN as) (: :) (NP (NN 2010)))))) (. .)))Reporter causality for the events "Arrhythmia", "Drug interaction", "Unwell", "Fatigue", "Dry eyes", "Dry mouth", and "Menses lack of" with regard to "Domperidone" were provided as "Possible" respectively.Reportercausalityfortheevents``Arrhythmia'',``Druginteraction'',``Unwell'',``Fatigue'',``Dryeyes'',``Drymouth'',and``Menseslackof''withregardto``Domperidone''wereprovidedas``Possible''respectively.(S1 (S (S (NP (NP (NN Reporter) (NN causality)) (PP (IN for) (NP (DT the) (NNS events) (NP (NP (`` ``) (NN Arrhythmia) (NN '')) (, ,) (NP (`` ``) (NN Drug) (NN interaction) (NN '')) (, ,) (NP (`` ``) (NN Unwell) (NN '')) (, ,) (NP (`` ``) (NN Fatigue) (NN '')) (, ,) (NP (`` ``) (JJ Dry) (NN eyes) (NN '')) (, ,) (NP (`` ``) (JJ Dry) (NN mouth) (NN '')) (, ,) (CC and) (NP (`` ``) (NNS Menses) (NN lack))))) (PP (IN of) (NP (NP (NNS '')) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (`` ``) (NN Domperidone) (NN '')))))))) (VP (VBD were) (VP (VBN provided) (PP (IN as) (NP (NP (`` ``) (JJ Possible) (NNS '')) (ADVP (RB respectively))))))) (. .)))Therapy start date of Erythromycin was provided as: 2010.TherapystartdateofErythromycinwasprovidedas:2010.(S1 (S (S (NP (NP (NN Therapy) (NN start) (NN date)) (PP (IN of) (NP (NN Erythromycin)))) (VP (VBD was) (VP (VBN provided) (PP (IN as) (: :) (NP (NN 2010)))))) (. .)))Therapy stop date of Erythromycin was provided as: Apr 2015.TherapystopdateofErythromycinwasprovidedas:Apr2015.(S1 (S (S (NP (NP (NN Therapy) (NN stop) (NN date)) (PP (IN of) (NP (NN Erythromycin)))) (VP (VBD was) (VP (VBN provided) (PP (IN as) (: :) (NP (NN Apr) (CD 2015)))))) (. .)))Last action taken with drug "Erythromycin" was provided as: Drug Discontinued.Lastactiontakenwithdrug``Erythromycin''wasprovidedas:DrugDiscontinued.(S1 (S (S (NP (NP (JJ Last) (NN action)) (VP (VBN taken) (PP (IN with) (NP (NN drug) (`` ``) (NN Erythromycin) (NN ''))))) (VP (VBD was) (VP (VBN provided) (PP (IN as) (: :) (NP (NP (NN Drug)) (VP (VBN Discontinued))))))) (. .)))TEva Comment: Erythromycin Considering the long term uneventful therapy with suspect drug, its role in the reported events was considered unrelated.TEvaComment:ErythromycinConsideringthelongtermuneventfultherapywithsuspectdrug,itsroleinthereportedeventswasconsideredunrelated.(S1 (S (NP (NP (NN TEva) (NN Comment)) (: :) (S (S (NP (NN Erythromycin)) (VP (VBG Considering) (NP (NP (DT the) (JJ long) (NN term) (NN uneventful) (NN therapy)) (PP (IN with) (NP (NN suspect) (NN drug)))))) (, ,) (NP (NP (PRP$ its) (NN role)) (PP (IN in) (NP (DT the) (VBN reported) (NNS events)))) (VP (VBD was) (VP (VBN considered) (ADJP (JJ unrelated))))) (. .))))27 Apr 2015:27Apr2015:(S1 (S (NP (NP (CD 27) (NNP Apr) (CD 2015)) (: :))))Additional information was received from the Health Authority.AdditionalinformationwasreceivedfromtheHealthAuthority.(S1 (S (S (NP (JJ Additional) (NN information)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (DT the) (NN Health) (NN Authority)))))) (. .)))Dosage text for the suspect drug "Erythromycin" was provided as "Dosage form: Unspecified, Low dose".Dosagetextforthesuspectdrug``Erythromycin''wasprovidedas``Dosageform:Unspecified,Lowdose''.(S1 (S (S (NP (NP (NN Dosage) (NNS text)) (PP (IN for) (NP (DT the) (NN suspect) (NN drug) (`` ``) (NN Erythromycin) (NN '')))) (VP (VBD was) (VP (VBN provided) (PP (IN as) (NP (NP (NP (`` ``) (NN Dosage) (NN form)) (: :) (NP (NN Unspecified))) (, ,) (NP (JJ Low) (NN dose) (CD ''))))))) (. .)))"No Medical Assessment".``NoMedicalAssessment''.(S1 (S (S (`` ``) (NP (DT No) (JJ Medical) (NN Assessment) (NNS ''))) (. .)))13 May 2015:13May2015:(S1 (S (NP (CD 13) (NN May) (CD 2015) (: :))))Additional information was received from a consumer via regulatory authority (MHRA) (GB MHRA ADR 22956126) on 16 APR 2015.Additionalinformationwasreceivedfromaconsumerviaregulatoryauthority(MHRA)(GBMHRAADR22956126)on16APR2015.(S1 (S (S (NP (JJ Additional) (NN information)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (NP (DT a) (NN consumer)) (PP (IN via) (NP (NP (NP (NP (JJ regulatory) (NN authority)) (PRN (-LRB- -LRB-) (NP (NN MHRA)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN GB) (NN MHRA) (NN ADR) (CD 22956126)) (-RRB- -RRB-))) (PP (IN on) (NP (CD 16) (NN APR) (CD 2015)))))))))) (. .)))Health authority numbers were updated in the case ID screen.HealthauthoritynumberswereupdatedinthecaseIDscreen.(S1 (S (S (NP (NN Health) (NN authority) (NNS numbers)) (VP (VBD were) (VP (VBN updated) (PP (IN in) (NP (DT the) (NN case) (NN ID) (NN screen)))))) (. .)))Follow up report was received on 23 APR 2015.Followupreportwasreceivedon23APR2015.(S1 (S (S (VP (VBP Follow) (SBAR (IN up) (S (NP (NN report)) (VP (VBD was) (VP (VBN received) (PP (IN on) (NP (CD 23) (NN APR) (CD 2015))))))))) (. .)))This report contains no new information and no changes were made to the report.Thisreportcontainsnonewinformationandnochangesweremadetothereport.(S1 (S (S (S (NP (DT This) (NN report)) (VP (VBZ contains) (NP (DT no) (JJ new) (NN information)))) (CC and) (S (NP (DT no) (NNS changes)) (VP (VBD were) (VP (VBN made) (PP (TO to) (NP (DT the) (NN report))))))) (. .)))Follow up report was received on 27 APR 2015.Followupreportwasreceivedon27APR2015.(S1 (S (S (VP (VBP Follow) (SBAR (IN up) (S (NP (NN report)) (VP (VBD was) (VP (VBN received) (PP (IN on) (NP (CD 27) (NN APR) (CD 2015))))))))) (. .)))Other company manufacturer's reference number was updated.Othercompanymanufacturer'sreferencenumberwasupdated.(S1 (S (S (NP (NP (JJ Other) (NN company) (NN manufacturer) (POS 's)) (NN reference) (NN number)) (VP (VBD was) (VP (VBN updated)))) (. .)))This report contains no new information and no changes were made to the report.Thisreportcontainsnonewinformationandnochangesweremadetothereport.(S1 (S (S (S (NP (DT This) (NN report)) (VP (VBZ contains) (NP (DT no) (JJ new) (NN information)))) (CC and) (S (NP (DT no) (NNS changes)) (VP (VBD were) (VP (VBN made) (PP (TO to) (NP (DT the) (NN report))))))) (. .)))Additional information was received from the patient's mother on 04 MAY 2015.Additionalinformationwasreceivedfromthepatient'smotheron04MAY2015.(S1 (S (S (NP (JJ Additional) (NN information)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (NP (NP (DT the) (NN patient) (POS 's)) (NN mother)) (PP (IN on) (NP (NN 04) (NN MAY) (CD 2015)))))))) (. .)))The patient stated that her general practitioner (GP) and specialist did not think that the problems were the side effects of domperidone.Thepatientstatedthathergeneralpractitioner(GP)andspecialistdidnotthinkthattheproblemswerethesideeffectsofdomperidone.(S1 (S (S (NP (NP (DT The) (NN patient)) (VP (VBN stated) (PP (IN that) (NP (NP (NP (PRP$ her) (JJ general) (NN practitioner)) (PRN (-LRB- -LRB-) (NP (NN GP)) (-RRB- -RRB-))) (CC and) (NP (NN specialist)))))) (VP (VBD did) (RB not) (VP (VBP think) (SBAR (IN that) (S (NP (DT the) (NNS problems)) (VP (VBD were) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NN domperidone)))))))))) (. .)))No further information was reported at the time of the report.Nofurtherinformationwasreportedatthetimeofthereport.(S1 (S (S (NP (DT No) (JJ further) (NN information)) (VP (VBD was) (VP (VBN reported) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (DT the) (NN report)))))))) (. .)))Other reference number include MHRA: 01001307081; 01001307081: GB JNJFOC 20150407438.OtherreferencenumberincludeMHRA:01001307081;01001307081:GBJNJFOC20150407438.(S1 (S (S (NP (JJ Other) (NN reference) (NN number)) (VP (VBP include) (NP (NP (NN MHRA)) (: :) (NP (CD 01001307081)) (: ;) (NP (CD 01001307081)) (: :) (NP (NN GB) (NN JNJFOC) (NN 20150407438))))) (. .)))Duration of suspect drug "Domperidone" was reported as 5 years.Durationofsuspectdrug``Domperidone''wasreportedas5years.(S1 (S (S (NP (NP (NN Duration)) (PP (IN of) (NP (NN suspect) (NN drug) (`` ``) (NN Domperidone) (NN '')))) (VP (VBD was) (VP (VBN reported) (PP (IN as) (NP (CD 5) (NNS years)))))) (. .)))"No medical assessment".``Nomedicalassessment''.(S1 (S (S (`` ``) (NP (DT No) (JJ medical) (NN assessment) (NNS ''))) (. .))) \ No newline at end of file diff --git a/Postprocessing/Intermediate4/fda009_Intermediate.xml b/Postprocessing/Intermediate4/fda009_Intermediate.xml index a53d94b..f15ac65 100755 --- a/Postprocessing/Intermediate4/fda009_Intermediate.xml +++ b/Postprocessing/Intermediate4/fda009_Intermediate.xml @@ -1 +1 @@ -A spontaneous report was received from a Health canada via Health professional concerning a Female patient.AspontaneousreportwasreceivedfromaHealthcanadaviaHealthprofessionalconcerningaFemalepatient.(S1 (S (S (NP (DT A) (JJ spontaneous) (NN report)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (NP (DT a) (NN Health) (NN canada) (IN via) (NN Health) (NN professional)) (VP (VBG concerning) (NP (DT a) (JJ Female) (NN patient)))))))) (. .)))Concomitant medications included paracetamol, ramipril, amlodipine besilate, hydrochlorothiazide, candesartan cilexetil, levothyroxine sodium, ergocalciferol, ezetimibe, lisinopril, methylprednisolone, prednisone, sitagliptin phosphate, rosuvastatin calcium and levothyroxine sodium.Patients relevant history and concurrent disease were not available.The patient had been receiving oral Nexium (Esomeprazole magnesium), started on an unknown date, intra-articular Depo-medrol (Methylprednisolone acetate) for product used for unknown indication, started on an unknown date, unknown Diamicron (Gliclazide) for product used for unknown indication, started on an unknown date, unknown Domperidone (Domperidone) for product used for unknown indication, started on an unknown date, subcutaneous Lantus (Insulin glargine) for product used for unknown indication, started on an unknown date, unknown Lyrica (Pregabalin) for product used for unknown indication, started on an unknown date and intravenous (not otherwise specified) Rituxan (Rituximab), 1000.0 milligrams, unknown for product used for unknown indication, started on an unknown date.It was reported that a patient had arthritis (preferred term: arthritis) and her condition aggravated (preferred term: condition aggravated).Concomitantmedications[phsu][phsu][phsu][phsu]includedparacetamol[orch,phsu][orch,phsu][orch,phsu][orch,phsu],ramipril[orch,phsu][orch,phsu][orch,phsu][orch,phsu],amlodipine[orch,phsu][orch,phsu][orch,phsu][orch,phsu]besilate[orch,phsu][orch,phsu][orch,phsu][orch,phsu],hydrochlorothiazide[orch,phsu][orch,phsu][orch,phsu][orch,phsu],candesartan[orch,phsu][orch,phsu][orch,phsu][orch,phsu]cilexetil[orch,phsu][orch,phsu][orch,phsu][orch,phsu],levothyroxinesodium,ergocalciferol,ezetimibe[orch,phsu][orch,phsu][orch,phsu][orch,phsu],lisinopril,methylprednisolone,prednisone,sitagliptin[orch,phsu][orch,phsu][orch,phsu][orch,phsu]phosphate[orch,phsu][orch,phsu][orch,phsu][orch,phsu],rosuvastatincalciumandlevothyroxinesodium.Patientsrelevanthistoryandconcurrentdisease[dsyn][dsyn][dsyn][dsyn]werenotavailable.ThepatienthadbeenreceivingoralNexium[orch,phsu][orch,phsu][orch,phsu][orch,phsu](Esomeprazole[orch,phsu][orch,phsu][orch,phsu][orch,phsu]magnesium[orch,phsu][orch,phsu][orch,phsu][orch,phsu]),startedonanunknowndate,intra-articularDepo-medrol(Methylprednisoloneacetate)forproductusedforunknownindication,startedonanunknowndate,unknownDiamicron[orch,phsu][orch,phsu][orch,phsu][orch,phsu](Gliclazide[orch,phsu][orch,phsu][orch,phsu][orch,phsu])forproductusedforunknownindication,startedonanunknowndate,unknownDomperidone[orch,phsu][orch,phsu][orch,phsu][orch,phsu](Domperidone[orch,phsu][orch,phsu][orch,phsu][orch,phsu])forproductusedforunknownindication,startedonanunknowndate,subcutaneousLantus(Insulinglargine)forproductusedforunknownindication,startedonanunknowndate,unknownLyrica[orch,phsu][orch,phsu][orch,phsu][orch,phsu](Pregabalin)forproductusedforunknownindication,startedonanunknowndateandintravenous(nototherwisespecified)Rituxan(Rituximab),1000.0milligrams,unknownforproductusedforunknownindication,startedonanunknowndate.Itwasreportedthatapatienthadarthritis[dsyn][dsyn][dsyn][dsyn](preferredterm:arthritis[dsyn][dsyn][dsyn][dsyn])andhercondition[dsyn][dsyn][dsyn][dsyn]aggravated(preferredterm:condition[dsyn][dsyn][dsyn][dsyn]aggravated).(S1 (S (NP (JJ Concomitant) (NNS medications)) (VP (VBD included) (NP (NP (NP (NN paracetamol)) (, ,) (NP (NN ramipril)) (, ,) (NP (NN amlodipine) (NN besilate)) (, ,) (NP (NN hydrochlorothiazide)) (, ,) (NP (NN candesartan) (NN cilexetil)) (, ,) (NP (NN levothyroxine) (NN sodium)) (, ,) (NP (NN ergocalciferol)) (, ,) (NP (NNS ezetimibe)) (, ,) (NP (NN lisinopril)) (, ,) (NP (NN methylprednisolone)) (, ,) (NP (NN prednisone)) (, ,) (NP (NN sitagliptin) (NN phosphate)) (, ,) (NP (NN rosuvastatin) (NN calcium)) (CC and) (NP (NN levothyroxine) (NNS sodium.Patients))) (S (NP (NP (JJ relevant) (NN history)) (CC and) (NP (JJ concurrent) (NN disease))) (VP (VBD were) (SBAR (ADVP (RB not)) (S (NP (NN available.The) (NN patient)) (VP (VBD had) (VP (VBN been) (VP (VBG receiving) (NP (NP (NP (JJ oral) (NN Nexium)) (PRN (-LRB- -LRB-) (NP (NN Esomeprazole) (NN magnesium)) (-RRB- -RRB-))) (, ,) (VP (VBN started) (PP (IN on) (NP (NP (DT an) (JJ unknown) (NN date)) (, ,) (NP (NP (NP (NP (NP (JJ intra-articular) (NN Depo-medrol)) (PRN (-LRB- -LRB-) (NP (NN Methylprednisolone) (NN acetate)) (-RRB- -RRB-))) (PP (IN for) (NP (NP (NN product)) (VP (VP (VP (VBD used) (SBAR (IN for) (S (NP (JJ unknown) (NN indication)) (, ,) (VP (VP (VBD started) (PP (IN on) (NP (NP (NP (DT an) (JJ unknown) (NN date)) (, ,) (NP (NP (JJ unknown) (NN Diamicron)) (PRN (-LRB- -LRB-) (NP (NN Gliclazide)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NN product)) (VP (VBN used) (PP (IN for) (NP (JJ unknown) (NN indication))))))))) (, ,) (VP (VBD started) (PP (IN on) (NP (DT an) (JJ unknown) (NN date))) (, ,) (S (NP (NP (NP (JJ unknown) (NN Domperidone)) (PRN (-LRB- -LRB-) (NP (NN Domperidone)) (-RRB- -RRB-))) (PP (IN for) (NP (NN product)))) (VP (VBN used) (PP (IN for) (NP (JJ unknown) (NN indication)))))) (, ,) (VP (VBD started) (PP (IN on) (NP (DT an) (JJ unknown) (NN date)))) (, ,) (S (NP (NP (NP (JJ subcutaneous) (NN Lantus)) (PRN (-LRB- -LRB-) (NP (NN Insulin) (NN glargine)) (-RRB- -RRB-))) (PP (IN for) (NP (NN product)))) (VP (VBN used) (PP (IN for) (NP (JJ unknown) (NN indication))))))))) (, ,) (VP (VBD started) (PP (IN on) (NP (DT an) (JJ unknown) (NN date))) (, ,) (S (NP (NP (NP (JJ unknown) (NN Lyrica)) (PRN (-LRB- -LRB-) (NP (NNP Pregabalin)) (-RRB- -RRB-))) (PP (IN for) (NP (NN product)))) (VP (VBN used) (PP (IN for) (NP (JJ unknown) (NN indication)))))) (, ,) (VP (VBD started) (PP (IN on) (NP (DT an) (JJ unknown) (NN date))))) (CC and) (ADJP (JJ intravenous)))))) (PRN (-LRB- -LRB-) (ADVP (RB not)) (VP (ADVP (RB otherwise)) (VBN specified)) (-RRB- -RRB-)) (NP (NNP Rituxan)) (PRN (-LRB- -LRB-) (NP (NN Rituximab)) (-RRB- -RRB-))) (, ,) (NP (CD 1000.0) (NNS milligrams)) (, ,) (ADJP (JJ unknown) (PP (IN for) (NP (NP (NN product)) (VP (VBN used) (PP (IN for) (NP (JJ unknown) (NN indication))))))) (, ,) (VP (VBN started) (SBAR (IN on) (S (NP (DT an) (JJ unknown) (NN date.It)) (VP (VBD was) (VP (VBN reported) (PP (IN that) (S (NP (DT a) (NN patient)) (VP (VBD had) (NP (NP (NP (NN arthritis)) (PRN (-LRB- -LRB-) (NP (NP (JJ preferred) (NN term)) (: :) (NP (NN arthritis))) (-RRB- -RRB-))) (CC and) (NP (PRP$ her) (NN condition))) (VP (VBD aggravated) (PRN (-LRB- -LRB-) (NP (JJ preferred) (NN term)) (: :) (S (NP (NN condition)) (VP (VBD aggravated))) (-RRB- -RRB-))))))))))))))))))))))))) (. .)))Patient also had coronary artery occlusion (preferred term: coronary artery occlusion).Action taken with all suspect drugs were unknown.The outcome of the event of arthritis, condition aggravated and coronary artery occlusion were unknown.The reporter has assessed the events of arthritis, condition aggravated and coronary artery occlusion to be serious with seriousness criteria of important medical event.Patientalsohadcoronary[dsyn][dsyn][dsyn][dsyn]artery[dsyn][dsyn][dsyn][dsyn]occlusion[dsyn][dsyn][dsyn][dsyn](preferredterm:coronary[dsyn][dsyn][dsyn][dsyn]artery[dsyn][dsyn][dsyn][dsyn]occlusion[dsyn][dsyn][dsyn][dsyn]).Actiontakenwithallsuspectdrugs[phsu][phsu][phsu][phsu]wereunknown.Theoutcomeoftheeventofarthritis[dsyn][dsyn][dsyn][dsyn],condition[dsyn][dsyn][dsyn][dsyn]aggravatedandcoronary[dsyn][dsyn][dsyn][dsyn]artery[dsyn][dsyn][dsyn][dsyn]occlusion[dsyn][dsyn][dsyn][dsyn]wereunknown.Thereporterhasassessedtheeventsofarthritis[dsyn][dsyn][dsyn][dsyn],condition[dsyn][dsyn][dsyn][dsyn]aggravatedandcoronary[dsyn][dsyn][dsyn][dsyn]artery[dsyn][dsyn][dsyn][dsyn]occlusion[dsyn][dsyn][dsyn][dsyn]tobeseriouswithseriousnesscriteriaofimportantmedicalevent.(S1 (S (S (NP (NN Patient)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJ coronary) (NN artery) (NN occlusion)) (PRN (-LRB- -LRB-) (NP (NP (JJ preferred) (NN term)) (: :) (NP (JJ coronary) (NN artery) (NN occlusion))) (-RRB- -RRB-))))) (S (NP (NP (NN .Action)) (VP (VBN taken) (PP (IN with) (NP (DT all) (NN suspect) (NNS drugs))))) (VP (VBD were) (NP (NP (NN unknown.The) (NN outcome)) (PP (IN of) (NP (NP (DT the) (NN event)) (PP (IN of) (NP (NP (NN arthritis)) (, ,) (NP (NP (NN condition)) (VP (VBN aggravated)))))))))) (CC and) (S (NP (JJ coronary) (NN artery) (NN occlusion)) (VP (VBD were) (VP (VBG unknown.The) (S (NP (NN reporter)) (VP (VBZ has) (VP (VBN assessed) (NP (NP (DT the) (NNS events)) (PP (IN of) (NP (NP (NP (NN arthritis)) (, ,) (NP (NP (NN condition)) (VP (VBN aggravated)))) (CC and) (NP (JJ coronary) (NN artery) (NN occlusion))))) (S (VP (TO to) (VP (VB be) (ADJP (JJ serious) (PP (IN with) (NP (NP (NNS seriousness) (NNS criteria)) (PP (IN of) (NP (JJ important) (JJ medical) (NN event))))))))))))))) (. .))) \ No newline at end of file +A spontaneous report was received from a Health canada via Health professional concerning a Female patient.AspontaneousreportwasreceivedfromaHealthcanadaviaHealthprofessionalconcerningaFemalepatient.(S1 (S (S (NP (DT A) (JJ spontaneous) (NN report)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (NP (DT a) (NN Health) (NN canada) (IN via) (NN Health) (NN professional)) (VP (VBG concerning) (NP (DT a) (JJ Female) (NN patient)))))))) (. .)))Concomitant medications included paracetamol, ramipril, amlodipine besilate, hydrochlorothiazide, candesartan cilexetil, levothyroxine sodium, ergocalciferol, ezetimibe, lisinopril, methylprednisolone, prednisone, sitagliptin phosphate, rosuvastatin calcium and levothyroxine sodium.Patients relevant history and concurrent disease were not available.The patient had been receiving oral Nexium (Esomeprazole magnesium), started on an unknown date, intra articular Depo medrol (Methylprednisolone acetate) for product used for unknown indication, started on an unknown date, unknown Diamicron (Gliclazide) for product used for unknown indication, started on an unknown date, unknown Domperidone (Domperidone) for product used for unknown indication, started on an unknown date, subcutaneous Lantus (Insulin glargine) for product used for unknown indication, started on an unknown date, unknown Lyrica (Pregabalin) for product used for unknown indication, started on an unknown date and intravenous (not otherwise specified) Rituxan (Rituximab), 1000.0 milligrams, unknown for product used for unknown indication, started on an unknown date.It was reported that a patient had arthritis (preferred term: arthritis) and her condition aggravated (preferred term: condition aggravated).Concomitantmedications[phsu]includedparacetamol[orch,phsu],ramipril[orch,phsu],amlodipine[orch,phsu]besilate[orch,phsu],hydrochlorothiazide[orch,phsu],candesartan[orch,phsu]cilexetil[orch,phsu],levothyroxinesodium,ergocalciferol,ezetimibe[orch,phsu],lisinopril,methylprednisolone,prednisone,sitagliptin[orch,phsu]phosphate[orch,phsu],rosuvastatincalciumandlevothyroxinesodium.Patientsrelevanthistoryandconcurrentdisease[dsyn]werenotavailable.ThepatienthadbeenreceivingoralNexium[orch,phsu](Esomeprazole[orch,phsu]magnesium[orch,phsu]),startedonanunknowndate,intraarticularDepomedrol(Methylprednisoloneacetate)forproductusedforunknownindication,startedonanunknowndate,unknownDiamicron[orch,phsu](Gliclazide[orch,phsu])forproductusedforunknownindication,startedonanunknowndate,unknownDomperidone[orch,phsu](Domperidone[orch,phsu])forproductusedforunknownindication,startedonanunknowndate,subcutaneousLantus(Insulinglargine)forproductusedforunknownindication,startedonanunknowndate,unknownLyrica[orch,phsu](Pregabalin)forproductusedforunknownindication,startedonanunknowndateandintravenous(nototherwisespecified)Rituxan(Rituximab),1000.0milligrams,unknownforproductusedforunknownindication,startedonanunknowndate.Itwasreportedthatapatienthadarthritis[dsyn](preferredterm:arthritis[dsyn])andhercondition[dsyn]aggravated(preferredterm:condition[dsyn]aggravated).(S1 (S (NP (JJ Concomitant) (NNS medications)) (VP (VBD included) (NP (NP (NP (NN paracetamol)) (, ,) (NP (NN ramipril)) (, ,) (NP (NN amlodipine) (NN besilate)) (, ,) (NP (NN hydrochlorothiazide)) (, ,) (NP (NN candesartan) (NN cilexetil)) (, ,) (NP (NN levothyroxine) (NN sodium)) (, ,) (NP (NN ergocalciferol)) (, ,) (NP (NNS ezetimibe)) (, ,) (NP (NN lisinopril)) (, ,) (NP (NN methylprednisolone)) (, ,) (NP (NN prednisone)) (, ,) (NP (NN sitagliptin) (NN phosphate)) (, ,) (NP (NN rosuvastatin) (NN calcium)) (CC and) (NP (NN levothyroxine) (NNS sodium.Patients))) (S (NP (NP (JJ relevant) (NN history)) (CC and) (NP (JJ concurrent) (NN disease))) (VP (VBD were) (SBAR (ADVP (RB not)) (S (NP (NN available.The) (NN patient)) (VP (VBD had) (VP (VBN been) (VP (VBG receiving) (NP (NP (NP (NP (NP (JJ oral) (NN Nexium)) (PRN (-LRB- -LRB-) (NP (NN Esomeprazole) (NN magnesium)) (-RRB- -RRB-))) (, ,) (VP (VP (VP (VBN started) (PP (IN on) (NP (NP (NP (DT an) (JJ unknown) (NN date)) (, ,) (NP (NP (NP (NN intra) (NN articular) (NN Depo) (NN medrol)) (PRN (-LRB- -LRB-) (NP (NN Methylprednisolone) (NN acetate)) (-RRB- -RRB-))) (PP (IN for) (NP (NP (NN product)) (VP (VBD used) (SBAR (IN for) (S (NP (JJ unknown) (NN indication)) (, ,) (VP (VP (VBD started) (PP (IN on) (NP (NP (NP (DT an) (JJ unknown) (NN date)) (, ,) (NP (NP (JJ unknown) (NN Diamicron)) (PRN (-LRB- -LRB-) (NP (NN Gliclazide)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NN product)) (VP (VBN used) (PP (IN for) (NP (JJ unknown) (NN indication))))))))) (, ,) (VP (VBD started) (PP (IN on) (NP (DT an) (JJ unknown) (NN date))) (, ,) (S (NP (NP (NP (JJ unknown) (NN Domperidone)) (PRN (-LRB- -LRB-) (NP (NN Domperidone)) (-RRB- -RRB-))) (PP (IN for) (NP (NN product)))) (VP (VBN used) (PP (IN for) (NP (JJ unknown) (NN indication)))))) (, ,) (VP (VBD started) (PP (IN on) (NP (NP (NP (DT an) (JJ unknown) (NN date)) (, ,) (NP (NP (JJ subcutaneous) (NN Lantus)) (PRN (-LRB- -LRB-) (NP (NN Insulin) (NN glargine)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NN product)) (VP (VBN used) (PP (IN for) (NP (JJ unknown) (NN indication))))))))) (, ,) (VP (VBD started) (PP (IN on) (NP (DT an) (JJ unknown) (NN date))))))))))) (, ,) (NP (NP (JJ unknown) (NN Lyrica)) (PRN (-LRB- -LRB-) (NP (NNP Pregabalin)) (-RRB- -RRB-)))) (PP (IN for) (NP (NN product))) (VP (VBN used) (PP (IN for) (NP (JJ unknown) (NN indication))))))) (, ,) (VP (VBD started) (PP (IN on) (NP (DT an) (JJ unknown) (NN date))))) (CC and) (ADJP (JJ intravenous)))) (PRN (-LRB- -LRB-) (ADVP (RB not)) (VP (ADVP (RB otherwise)) (VBN specified)) (-RRB- -RRB-)) (NP (NNP Rituxan)) (PRN (-LRB- -LRB-) (NP (NN Rituximab)) (-RRB- -RRB-))) (, ,) (NP (CD 1000.0) (NNS milligrams)) (, ,) (ADJP (JJ unknown) (PP (IN for) (NP (NP (NN product)) (VP (VBN used) (PP (IN for) (NP (JJ unknown) (NN indication))))))) (, ,) (VP (VBN started) (SBAR (IN on) (S (NP (DT an) (JJ unknown) (NN date.It)) (VP (VBD was) (VP (VBN reported) (PP (IN that) (S (NP (DT a) (NN patient)) (VP (VBD had) (NP (NP (NP (NN arthritis)) (PRN (-LRB- -LRB-) (NP (NP (JJ preferred) (NN term)) (: :) (NP (NN arthritis))) (-RRB- -RRB-))) (CC and) (NP (PRP$ her) (NN condition))) (VP (VBD aggravated) (PRN (-LRB- -LRB-) (NP (JJ preferred) (NN term)) (: :) (S (NP (NN condition)) (VP (VBD aggravated))) (-RRB- -RRB-))))))))))))))))))))) (. .)))Patient also had coronary artery occlusion (preferred term: coronary artery occlusion).Action taken with all suspect drugs were unknown.The outcome of the event of arthritis, condition aggravated and coronary artery occlusion were unknown.The reporter has assessed the events of arthritis, condition aggravated and coronary artery occlusion to be serious with seriousness criteria of important medical event.Patientalsohadcoronary[dsyn]artery[dsyn]occlusion[dsyn](preferredterm:coronary[dsyn]artery[dsyn]occlusion[dsyn]).Actiontakenwithallsuspectdrugs[phsu]wereunknown.Theoutcomeoftheeventofarthritis[dsyn],condition[dsyn]aggravatedandcoronary[dsyn]artery[dsyn]occlusion[dsyn]wereunknown.Thereporterhasassessedtheeventsofarthritis[dsyn],condition[dsyn]aggravatedandcoronary[dsyn]artery[dsyn]occlusion[dsyn]tobeseriouswithseriousnesscriteriaofimportantmedicalevent.(S1 (S (S (NP (NN Patient)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJ coronary) (NN artery) (NN occlusion)) (PRN (-LRB- -LRB-) (NP (NP (JJ preferred) (NN term)) (: :) (NP (JJ coronary) (NN artery) (NN occlusion))) (-RRB- -RRB-))))) (S (NP (NP (NN .Action)) (VP (VBN taken) (PP (IN with) (NP (DT all) (NN suspect) (NNS drugs))))) (VP (VBD were) (NP (NP (NN unknown.The) (NN outcome)) (PP (IN of) (NP (NP (DT the) (NN event)) (PP (IN of) (NP (NP (NN arthritis)) (, ,) (NP (NP (NN condition)) (VP (VBN aggravated)))))))))) (CC and) (S (NP (JJ coronary) (NN artery) (NN occlusion)) (VP (VBD were) (VP (VBG unknown.The) (S (NP (NN reporter)) (VP (VBZ has) (VP (VBN assessed) (NP (NP (DT the) (NNS events)) (PP (IN of) (NP (NP (NP (NN arthritis)) (, ,) (NP (NP (NN condition)) (VP (VBN aggravated)))) (CC and) (NP (JJ coronary) (NN artery) (NN occlusion))))) (S (VP (TO to) (VP (VB be) (ADJP (JJ serious) (PP (IN with) (NP (NP (NNS seriousness) (NNS criteria)) (PP (IN of) (NP (JJ important) (JJ medical) (NN event))))))))))))))) (. .))) \ No newline at end of file diff --git a/Postprocessing/Intermediate4/fda010_Intermediate.xml b/Postprocessing/Intermediate4/fda010_Intermediate.xml index e5e9b91..98b7b64 100755 --- a/Postprocessing/Intermediate4/fda010_Intermediate.xml +++ b/Postprocessing/Intermediate4/fda010_Intermediate.xml @@ -1 +1 @@ -This spontaneous report from a patient concerns a 71 year old Caucasian female from the United States: Local ID: 1 1878275180.Thisspontaneousreportfromapatientconcernsa71yearoldCaucasianfemalefromtheUnitedStates:LocalID:11878275180.(S1 (S (S (NP (NP (DT This) (JJ spontaneous) (NN report)) (PP (IN from) (NP (DT a) (NN patient)))) (VP (VBZ concerns) (NP (NP (DT a) (ADJP (CD 71) (NN year) (JJ old)) (NN Caucasian) (NN female)) (PP (IN from) (NP (NP (DT the) (JJ United) (NNS States)) (: :) (NP (JJ Local) (NN ID) (: :) (CD 1) (NN 1878275180))))))) (. .)))The patient's weight was 160 pounds and height was 67.5 inches.Thepatient'sweightwas160poundsandheightwas67.5inches.(S1 (S (S (S (NP (NP (DT The) (NN patient) (POS 's)) (NN weight)) (VP (VBD was) (NP (CD 160) (NNS pounds)))) (CC and) (S (NP (NN height)) (VP (VBD was) (NP (CD 67.5) (NNS inches))))) (. .)))Concurrent conditions included abdominal bloating, abdominal gas, abdominal pain, allergy to trees, belching (abdominal), diabetic paresis (coded as diabetic gastroparesis), no alcohol use, no smoking, and type 2 diabetes.Concurrentconditionsincludedabdominalbloating,abdominalgas,abdominalpain,allergytotrees,belching(abdominal),diabeticparesis(codedasdiabeticgastroparesis),noalcoholuse,nosmoking,andtype2diabetes.(S1 (S (S (NP (JJ Concurrent) (NNS conditions)) (VP (VBD included) (NP (NP (JJ abdominal) (NN bloating)) (, ,) (NP (JJ abdominal) (NN gas)) (, ,) (NP (JJ abdominal) (NN pain)) (, ,) (NP (NP (NN allergy)) (PP (TO to) (NP (NNS trees)))) (, ,) (NP (NP (NN belching)) (PRN (-LRB- -LRB-) (NP (JJ abdominal)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ diabetic) (NN paresis)) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (JJ diabetic) (NN gastroparesis)))) (-RRB- -RRB-))) (, ,) (NP (DT no) (NN alcohol) (NN use)) (, ,) (NP (NN no) (NN smoking)) (, ,) (CC and) (NP (NN type) (CD 2) (NNS diabetes))))) (. .)))Other medical history included no history of drug abuse/illicit drug use.Othermedicalhistoryincludednohistoryofdrugabuse/illicitdruguse.(S1 (S (S (NP (JJ Other) (JJ medical) (NN history)) (VP (VBD included) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (NN drug) (NN abuse/illicit) (NN drug) (NN use)))))) (. .)))The patient had previously experienced allergy when taking mycins (not otherwise specified or NOS) (antibacterials for systemic use) and sulfa (sulfacetamide sodium).Thepatienthadpreviouslyexperiencedallergywhentakingmycins(nototherwisespecifiedorNOS)(antibacterialsforsystemicuse)andsulfa(sulfacetamidesodium).(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (ADVP (RB previously)) (VP (VBN experienced) (NP (NN allergy))) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (NP (NP (NP (NNS mycins)) (PRN (-LRB- -LRB-) (NP (ADJP (ADVP (RB not) (RB otherwise)) (VBN specified)) (NN or) (NN NOS)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NNS antibacterials)) (PP (IN for) (NP (JJ systemic) (NN use)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN sulfa)) (PRN (-LRB- -LRB-) (NP (NN sulfacetamide) (NN sodium)) (-RRB- -RRB-))))))))) (. .)))The patient was treated with canagliflozin (tablet, oral, batch unknown) 300 mg once a day, initiated on 06 AUG 2014, for type 2 diabetes and domperidone (unspecified, batch unknown) dose and frequency unspecified, initiated on an unspecified date, for diabetic gastroparesis.Thepatientwastreatedwithcanagliflozin(tablet,oral,batchunknown)300mgonceaday,initiatedon06AUG2014,fortype2diabetesanddomperidone(unspecified,batchunknown)doseandfrequencyunspecified,initiatedonanunspecifieddate,fordiabeticgastroparesis.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NP (NN canagliflozin)) (PRN (-LRB- -LRB-) (NP (NN tablet)) (, ,) (NP (NP (JJ oral)) (, ,) (NP (JJ batch) (JJ unknown))) (-RRB- -RRB-))) (NP (NP (CD 300) (NN mg)) (PP (IN once) (NP (NP (DT a) (NN day)) (, ,) (VP (VBN initiated) (PP (IN on) (NP (NN 06) (NN AUG) (NN 2014)))) (, ,))) (PP (IN for) (NP (NN type) (CD 2) (NNS diabetes))))) (CC and) (NP (NP (NN domperidone)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ unspecified)) (, ,) (ADJP (NN batch) (JJ unknown))) (-RRB- -RRB-)) (NP (NN dose) (CC and) (NN frequency) (NN unspecified)) (, ,) (VP (VBN initiated) (PP (IN on) (NP (DT an) (JJ unspecified) (NN date)))) (, ,)))) (PP (IN for) (NP (JJ diabetic) (NN gastroparesis)))))) (. .)))Concomitant medications were not reported.Concomitantmedicationswerenotreported.(S1 (S (S (NP (JJ Concomitant) (NNS medications)) (VP (VBD were) (RB not) (VP (VBN reported)))) (. .)))The patient was not initially prescribed 100 mg dose of canagliflozin.Thepatientwasnotinitiallyprescribed100mgdoseofcanagliflozin.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD was) (RB not) (ADVP (RB initially)) (VP (VBN prescribed) (NP (NP (ADJP (CD 100) (NN mg)) (NN dose)) (PP (IN of) (NP (NN canagliflozin))))))) (. .)))On 06 AUG 2014, the patient experienced "worsening of pre existing abdominal belching" (coded as increased belching), "worsening of pre existing abdominal pain" (coded as worsening of abdominal pain), "worsening of pre existing abdominal gassiness" (coded as very gaseous), and "worsening of pre existing abdominal bloating" (coded as worsening of bloating).On06AUG2014,thepatientexperienced``worseningofpreexistingabdominalbelching''(codedasincreasedbelching),``worseningofpreexistingabdominalpain''(codedasworseningofabdominalpain),``worseningofpreexistingabdominalgassiness''(codedasverygaseous),and``worseningofpreexistingabdominalbloating''(codedasworseningofbloating).(S1 (S (S (PP (IN On) (NP (NN 06) (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VBN experienced) (NP (NP (NP (`` ``) (ADJP (ADJP (JJ worsening) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN belching) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (VBN increased) (NN belching)))) (-RRB- -RRB-))))) (, ,) (`` ``) (ADJP (JJ worsening) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN pain) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (NP (NN worsening)) (PP (IN of) (NP (JJ abdominal) (NN pain)))))) (-RRB- -RRB-))))) (, ,)) (`` ``) (NN worsening)) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN gassiness) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (ADJP (RB very) (JJ gaseous)))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (`` ``) (NN worsening)) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN bloating) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (NP (NN worsening)) (PP (IN of) (NP (NN bloating)))))) (-RRB- -RRB-)))))))) (. .)))In AUG 2014, the patient contacted her physician about the events and was prescribed an increased dosage of domperidone.InAUG2014,thepatientcontactedherphysicianabouttheeventsandwasprescribedanincreaseddosageofdomperidone.(S1 (S (S (PP (IN In) (NP (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBD contacted) (NP (PRP$ her) (NN physician)) (PP (IN about) (NP (DT the) (NNS events)))) (CC and) (VP (VBD was) (VP (VBN prescribed) (NP (NP (DT an) (VBN increased) (NN dosage)) (PP (IN of) (NP (NN domperidone)))))))) (. .)))The patient reported the increased dose of domperidone had not relieved her worsening symptoms.Thepatientreportedtheincreaseddoseofdomperidonehadnotrelievedherworseningsymptoms.(S1 (S (S (NP (NP (DT The) (NN patient)) (VP (VBD reported) (NP (NP (DT the) (VBN increased) (NN dose)) (PP (IN of) (NP (NN domperidone)))))) (VP (VBD had) (RB not) (VP (VBN relieved) (NP (PRP$ her) (JJ worsening) (NNS symptoms))))) (. .)))On 13 AUG 2014, the patient experienced not feeling well today.On13AUG2014,thepatientexperiencednotfeelingwelltoday.(S1 (S (S (PP (IN On) (NP (CD 13) (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VBN experienced) (NP (RB not) (NN feeling)) (PP (RB well) (ADVP (RB today))))) (. .)))No laboratory findings were provided.Nolaboratoryfindingswereprovided.(S1 (S (S (NP (NN No) (NN laboratory) (NNS findings)) (VP (VBD were) (VP (VBN provided)))) (. .)))The dose of domperidone was increased and the dose of canagliflozin was not changed.Thedoseofdomperidonewasincreasedandthedoseofcanagliflozinwasnotchanged.(S1 (S (S (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NN domperidone)))) (VP (VBD was) (VP (VBN increased)))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN canagliflozin)))) (VP (VBD was) (RB not) (VP (VBN changed))))) (. .)))The patient had not recovered from increased belching, worsening of abdominal pain, very gaseous, worsening of bloating, and not feeling well today. Thepatienthadnotrecoveredfromincreasedbelching,worseningofabdominalpain,verygaseous,worseningofbloating,andnotfeelingwelltoday.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (RB not) (VP (VBN recovered) (PP (IN from) (NP (VBN increased) (UCP (ADJP (JJ belching)) (, ,) (NP (NP (NN worsening)) (PP (IN of) (NP (JJ abdominal) (NN pain)))) (, ,) (ADJP (RB very) (JJ gaseous)) (, ,) (ADJP (JJ worsening) (PP (IN of) (NP (NN bloating)))) (, ,) (CC and) (ADJP (RB not) (JJ feeling))) (NN well) (NN today)))))) (. .)))This report was identified by the call center as a product quality complaint: PQMS reference number 10000228235.Thisreportwasidentifiedbythecallcenterasaproductqualitycomplaint:PQMSreferencenumber10000228235.(S1 (S (S (NP (DT This) (NN report)) (VP (VBD was) (VP (VBN identified) (PP (IN by) (NP (DT the) (NN call) (NN center))) (PP (IN as) (NP (NP (DT a) (NN product) (NN quality) (NN complaint)) (: :) (NP (NN PQMS) (NN reference) (NN number) (CD 10000228235))))))) (. .)))This report was not serious.Thisreportwasnotserious.(S1 (S (S (NP (DT This) (NN report)) (VP (VBD was) (RB not) (ADJP (JJ serious)))) (. .))) \ No newline at end of file +This spontaneous report from a patient concerns a 71 year old Caucasian Female from the United States: Local ID: 1 1878275180.Thisspontaneousreportfromapatientconcernsa71yearoldCaucasianFemalefromtheUnitedStates:LocalID:11878275180.(S1 (S (S (NP (NP (DT This) (JJ spontaneous) (NN report)) (PP (IN from) (NP (DT a) (NN patient)))) (VP (VBZ concerns) (NP (NP (DT a) (ADJP (CD 71) (NN year) (JJ old)) (NN Caucasian) (NN Female)) (PP (IN from) (NP (NP (DT the) (JJ United) (NNS States)) (: :) (NP (JJ Local) (NN ID) (: :) (CD 1) (NN 1878275180))))))) (. .)))The patient's weight was 160 pounds and height was 67.5 inches.Thepatient'sweightwas160poundsandheightwas67.5inches.(S1 (S (S (S (NP (NP (DT The) (NN patient) (POS 's)) (NN weight)) (VP (VBD was) (NP (CD 160) (NNS pounds)))) (CC and) (S (NP (NN height)) (VP (VBD was) (NP (CD 67.5) (NNS inches))))) (. .)))Concurrent conditions included abdominal bloating, abdominal gas, abdominal pain, allergy to trees, belching (abdominal), diabetic paresis (coded as diabetic gastroparesis), no alcohol use, no smoking, and type 2 diabetes.Concurrentconditionsincludedabdominalbloating,abdominalgas,abdominalpain,allergytotrees,belching(abdominal),diabeticparesis(codedasdiabeticgastroparesis),noalcoholuse,nosmoking,andtype2diabetes.(S1 (S (S (NP (JJ Concurrent) (NNS conditions)) (VP (VBD included) (NP (NP (JJ abdominal) (NN bloating)) (, ,) (NP (JJ abdominal) (NN gas)) (, ,) (NP (JJ abdominal) (NN pain)) (, ,) (NP (NP (NN allergy)) (PP (TO to) (NP (NNS trees)))) (, ,) (NP (NP (NN belching)) (PRN (-LRB- -LRB-) (NP (JJ abdominal)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ diabetic) (NN paresis)) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (JJ diabetic) (NN gastroparesis)))) (-RRB- -RRB-))) (, ,) (NP (DT no) (NN alcohol) (NN use)) (, ,) (NP (NN no) (NN smoking)) (, ,) (CC and) (NP (NN type) (CD 2) (NNS diabetes))))) (. .)))Other medical history included no history of drug abuse/illicit drug use.Othermedicalhistoryincludednohistoryofdrugabuse/illicitdruguse.(S1 (S (S (NP (JJ Other) (JJ medical) (NN history)) (VP (VBD included) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (NN drug) (NN abuse/illicit) (NN drug) (NN use)))))) (. .)))The patient had previously experienced allergy when taking mycins (not otherwise specified or NOS) (antibacterials for systemic use) and sulfa (sulfacetamide sodium).Thepatienthadpreviouslyexperiencedallergywhentakingmycins(nototherwisespecifiedorNOS)(antibacterialsforsystemicuse)andsulfa(sulfacetamidesodium).(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (ADVP (RB previously)) (VP (VBN experienced) (NP (NN allergy))) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (NP (NP (NP (NNS mycins)) (PRN (-LRB- -LRB-) (NP (ADJP (ADVP (RB not) (RB otherwise)) (VBN specified)) (NN or) (NN NOS)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NNS antibacterials)) (PP (IN for) (NP (JJ systemic) (NN use)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN sulfa)) (PRN (-LRB- -LRB-) (NP (NN sulfacetamide) (NN sodium)) (-RRB- -RRB-))))))))) (. .)))The patient was treated with canagliflozin (tablet, oral, batch unknown) 300 mg once a day, initiated on 06 AUG 2014, for type 2 diabetes and domperidone (unspecified, batch unknown) dose and frequency unspecified, initiated on an unspecified date, for diabetic gastroparesis.Thepatientwastreatedwithcanagliflozin(tablet,oral,batchunknown)300mgonceaday,initiatedon06AUG2014,fortype2diabetesanddomperidone(unspecified,batchunknown)doseandfrequencyunspecified,initiatedonanunspecifieddate,fordiabeticgastroparesis.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NP (NN canagliflozin)) (PRN (-LRB- -LRB-) (NP (NN tablet)) (, ,) (NP (NP (JJ oral)) (, ,) (NP (JJ batch) (JJ unknown))) (-RRB- -RRB-))) (NP (NP (CD 300) (NN mg)) (PP (IN once) (NP (NP (DT a) (NN day)) (, ,) (VP (VBN initiated) (PP (IN on) (NP (NN 06) (NN AUG) (NN 2014)))) (, ,))) (PP (IN for) (NP (NN type) (CD 2) (NNS diabetes))))) (CC and) (NP (NP (NN domperidone)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ unspecified)) (, ,) (ADJP (NN batch) (JJ unknown))) (-RRB- -RRB-)) (NP (NN dose) (CC and) (NN frequency) (NN unspecified)) (, ,) (VP (VBN initiated) (PP (IN on) (NP (DT an) (JJ unspecified) (NN date)))) (, ,)))) (PP (IN for) (NP (JJ diabetic) (NN gastroparesis)))))) (. .)))Concomitant medications were not reported.Concomitantmedicationswerenotreported.(S1 (S (S (NP (JJ Concomitant) (NNS medications)) (VP (VBD were) (RB not) (VP (VBN reported)))) (. .)))The patient was not initially prescribed 100 mg dose of canagliflozin.Thepatientwasnotinitiallyprescribed100mgdoseofcanagliflozin.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD was) (RB not) (ADVP (RB initially)) (VP (VBN prescribed) (NP (NP (ADJP (CD 100) (NN mg)) (NN dose)) (PP (IN of) (NP (NN canagliflozin))))))) (. .)))On 06 AUG 2014, the patient experienced "worsening of pre existing abdominal belching" (coded as increased belching), "worsening of pre existing abdominal pain" (coded as worsening of abdominal pain), "worsening of pre existing abdominal gassiness" (coded as very gaseous), and "worsening of pre existing abdominal bloating" (coded as worsening of bloating).On06AUG2014,thepatientexperienced``worseningofpreexistingabdominalbelching''(codedasincreasedbelching),``worseningofpreexistingabdominalpain''(codedasworseningofabdominalpain),``worseningofpreexistingabdominalgassiness''(codedasverygaseous),and``worseningofpreexistingabdominalbloating''(codedasworseningofbloating).(S1 (S (S (PP (IN On) (NP (NN 06) (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VBN experienced) (NP (NP (NP (`` ``) (ADJP (ADJP (JJ worsening) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN belching) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (VBN increased) (NN belching)))) (-RRB- -RRB-))))) (, ,) (`` ``) (ADJP (JJ worsening) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN pain) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (NP (NN worsening)) (PP (IN of) (NP (JJ abdominal) (NN pain)))))) (-RRB- -RRB-))))) (, ,)) (`` ``) (NN worsening)) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN gassiness) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (ADJP (RB very) (JJ gaseous)))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (`` ``) (NN worsening)) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN bloating) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (NP (NN worsening)) (PP (IN of) (NP (NN bloating)))))) (-RRB- -RRB-)))))))) (. .)))In AUG 2014, the patient contacted her physician about the events and was prescribed an increased dosage of domperidone.InAUG2014,thepatientcontactedherphysicianabouttheeventsandwasprescribedanincreaseddosageofdomperidone.(S1 (S (S (PP (IN In) (NP (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBD contacted) (NP (PRP$ her) (NN physician)) (PP (IN about) (NP (DT the) (NNS events)))) (CC and) (VP (VBD was) (VP (VBN prescribed) (NP (NP (DT an) (VBN increased) (NN dosage)) (PP (IN of) (NP (NN domperidone)))))))) (. .)))The patient reported the increased dose of domperidone had not relieved her worsening symptoms.Thepatientreportedtheincreaseddoseofdomperidonehadnotrelievedherworseningsymptoms.(S1 (S (S (NP (NP (DT The) (NN patient)) (VP (VBD reported) (NP (NP (DT the) (VBN increased) (NN dose)) (PP (IN of) (NP (NN domperidone)))))) (VP (VBD had) (RB not) (VP (VBN relieved) (NP (PRP$ her) (JJ worsening) (NNS symptoms))))) (. .)))On 13 AUG 2014, the patient experienced not feeling well today.On13AUG2014,thepatientexperiencednotfeelingwelltoday.(S1 (S (S (PP (IN On) (NP (CD 13) (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VBN experienced) (NP (RB not) (NN feeling)) (PP (RB well) (ADVP (RB today))))) (. .)))No laboratory findings were provided.Nolaboratoryfindingswereprovided.(S1 (S (S (NP (NN No) (NN laboratory) (NNS findings)) (VP (VBD were) (VP (VBN provided)))) (. .)))The dose of domperidone was increased and the dose of canagliflozin was not changed.Thedoseofdomperidonewasincreasedandthedoseofcanagliflozinwasnotchanged.(S1 (S (S (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NN domperidone)))) (VP (VBD was) (VP (VBN increased)))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN canagliflozin)))) (VP (VBD was) (RB not) (VP (VBN changed))))) (. .)))The patient had not recovered from increased belching, worsening of abdominal pain, very gaseous, worsening of bloating, and not feeling well today. Thepatienthadnotrecoveredfromincreasedbelching,worseningofabdominalpain,verygaseous,worseningofbloating,andnotfeelingwelltoday.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (RB not) (VP (VBN recovered) (PP (IN from) (NP (VBN increased) (UCP (ADJP (JJ belching)) (, ,) (NP (NP (NN worsening)) (PP (IN of) (NP (JJ abdominal) (NN pain)))) (, ,) (ADJP (RB very) (JJ gaseous)) (, ,) (ADJP (JJ worsening) (PP (IN of) (NP (NN bloating)))) (, ,) (CC and) (ADJP (RB not) (JJ feeling))) (NN well) (NN today)))))) (. .)))This report was identified by the call center as a product quality complaint: PQMS reference number 10000228235.Thisreportwasidentifiedbythecallcenterasaproductqualitycomplaint:PQMSreferencenumber10000228235.(S1 (S (S (NP (DT This) (NN report)) (VP (VBD was) (VP (VBN identified) (PP (IN by) (NP (DT the) (NN call) (NN center))) (PP (IN as) (NP (NP (DT a) (NN product) (NN quality) (NN complaint)) (: :) (NP (NN PQMS) (NN reference) (NN number) (CD 10000228235))))))) (. .)))This report was not serious.Thisreportwasnotserious.(S1 (S (S (NP (DT This) (NN report)) (VP (VBD was) (RB not) (ADJP (JJ serious)))) (. .))) \ No newline at end of file diff --git a/Postprocessing/Intermediate4/gen034_Intermediate.xml b/Postprocessing/Intermediate4/gen034_Intermediate.xml index 9fab4ce..82c436d 100755 --- a/Postprocessing/Intermediate4/gen034_Intermediate.xml +++ b/Postprocessing/Intermediate4/gen034_Intermediate.xml @@ -1 +1 @@ -HISTORY OF PRESENT ILLNESS: The patient is a 68-year-old woman whom I have been following, who has had angina.HISTORYOFPRESENTILLNESS:Thepatientisa68-year-oldwomanwhomIhavebeenfollowing,whohashadangina[sosy][sosy][sosy][sosy].(S1 (S (S (NP (NP (NN HISTORY)) (PP (IN OF) (NP (JJ PRESENT) (NN ILLNESS)))) (: :) (S (NP (DT The) (NN patient)) (VP (VBZ is) (NP (NP (DT a) (JJ 68-year-old) (NN woman)) (SBAR (WHNP (WP whom)) (S (NP (PRP I)) (VP (VBP have) (VP (VBN been) (NP (NP (NN following)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBZ has) (VP (VBD had) (NP (NN angina))))))))))))))) (. .)))In any case today, she called me because she had a recurrent left arm pain after her stent, three days ago, and this persisted after two sublingual nitroglycerin when I spoke to her.Inanycasetoday,shecalledmebecauseshehadarecurrentleft[sosy][sosy][sosy][sosy]arm[sosy][sosy][sosy][sosy]pain[sosy][sosy][sosy][sosy]afterherstent,threedaysago,andthispersistedaftertwosublingualnitroglycerin[orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu]whenIspoketoher.(S1 (S (PP (IN In) (NP (NP (DT any) (NN case)) (ADVP (RB today)))) (, ,) (NP (PRP she)) (VP (VBN called) (NP (NN me)) (SBAR (IN because) (S (S (NP (PRP she)) (VP (VBD had) (NP (DT a) (JJ recurrent) (JJ left) (NN arm) (NN pain)) (PP (IN after) (NP (PRP$ her) (NN stent))) (, ,) (ADVP (NP (CD three) (NNS days)) (RB ago)))) (, ,) (CC and) (S (NP (DT this)) (VP (VBD persisted) (PP (IN after) (NP (CD two) (JJ sublingual) (NN nitroglycerin))) (SBAR (WHADVP (WRB when)) (S (NP (PRP I)) (VP (VBP spoke) (PP (TO to) (NP (PRP$ her))))))))))) (. .)))I advised her to call 911, which she did.Iadvisedhertocall911,whichshedid.(S1 (S (S (NP (PRP I)) (VP (VBN advised) (NP (PRP$ her) (PP (TO to) (NP (NN call) (CD 911))) (, ,) (SBAR (WHNP (WDT which)) (S (NP (PRP she)) (VP (VBD did))))))) (. .)))While waiting for 911, she was attended to by a physician who is her neighbor and he advised her to take the third nitroglycerin and that apparently relieved her pain.Whilewaitingfor911,shewasattendedtobyaphysicianwhoisherneighborandheadvisedhertotakethethirdnitroglycerin[orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu]andthatapparentlyrelievedherpain[sosy][sosy][sosy][sosy].[sosy][sosy][sosy][sosy](S1 (S (S (SBAR (IN While) (S (VP (VBG waiting) (PP (IN for) (NP (NN 911)))))) (, ,) (NP (PRP she)) (VP (VBD was) (VP (VBN attended) (PP (TO to)) (PP (IN by) (NP (NP (DT a) (NN physician)) (SBAR (WHNP (WP who)) (S (VP (VP (VBZ is) (NP (PRP$ her) (NN neighbor))) (CC and) (VP (VBZ he) (VP (VBN advised) (UCP (S (NP (PRP$ her)) (VP (TO to) (VP (VB take) (NP (DT the) (JJ third) (NN nitroglycerin))))) (CC and) (SBAR (IN that) (S (ADVP (RB apparently)) (VP (VBN relieved) (NP (PRP$ her) (NN pain)))))))))))))))) (. .)))By the time she presented here, she is currently pain-free and is feeling well.Bythetimeshepresentedhere,sheiscurrentlypain-free[orch][orch][orch][orch]andisfeelingwell.(S1 (S (S (PP (IN By) (NP (DT the) (NN time) (PRP she) (VP (VBN presented) (ADVP (RB here))))) (, ,) (NP (PRP she)) (VP (VP (VBZ is) (ADVP (RB currently)) (ADJP (JJ pain-free))) (CC and) (VP (VBZ is) (NP (NN feeling)) (ADVP (RB well))))) (. .)))PAST CARDIAC HISTORY: The patient has been having arm pain for several months.PASTCARDIACHISTORY:Thepatienthasbeenhavingarm[sosy][sosy][sosy][sosy]pain[sosy][sosy][sosy][sosy]forseveralmonths.(S1 (S (S (NP (JJ PAST) (JJ CARDIAC) (NN HISTORY)) (: :) (NP (DT The) (NN patient)) (VP (VBZ has) (VP (VBN been) (VP (VBG having) (NP (NP (NN arm) (NN pain)) (PP (IN for) (NP (JJ several) (NNS months)))))))) (. .)))She underwent an exercise stress echocardiogram within the last several months with me, which was equivocal, but then she had a nuclear stress test which showed inferobasilar ischemia.Sheunderwentanexercisestressechocardiogramwithinthelastseveralmonthswithme,whichwasequivocal,butthenshehadanuclearstresstestwhichshowedinferobasilarischemia[dsyn][dsyn][dsyn][dsyn].(S1 (S (S (S (NP (PRP She)) (VP (VBD underwent) (NP (DT an) (NN exercise) (NN stress) (NN echocardiogram)) (PP (IN within) (NP (NP (DT the) (JJ last) (JJ several) (NNS months)) (PP (IN with) (NP (NP (NN me)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (JJ equivocal))))))))))) (, ,) (CC but) (S (ADVP (RB then)) (NP (PRP she)) (VP (VBD had) (NP (NP (DT a) (JJ nuclear) (NN stress) (NN test)) (SBAR (WHNP (WDT which)) (S (VP (VBD showed) (NP (JJ inferobasilar) (NN ischemia))))))))) (. .)))I had originally advised her for a heart catheterization but she wanted medical therapy, so we put her on a beta-blocker.Ihadoriginallyadvisedherforaheartcatheterizationbutshewantedmedicaltherapy,soweputheronabeta-blocker[phsu][phsu][phsu][phsu].(S1 (S (S (S (NP (PRP I)) (VP (VBD had) (ADVP (RB originally)) (VP (VBN advised) (NP (PRP$ her)) (PP (IN for) (NP (DT a) (NN heart) (NN catheterization)))))) (CC but) (S (NP (PRP she)) (VP (VBD wanted) (NP (JJ medical) (NN therapy)) (, ,) (SBAR (IN so) (S (NP (PRP we)) (VP (VBP put) (NP (PRP$ her)) (PP (IN on) (NP (DT a) (NN beta-blocker))))))))) (. .)))However, her arm pain symptoms accelerated and she had some jaw pain, so she presented to the emergency room.However,herarm[sosy][sosy][sosy][sosy]pain[sosy][sosy][sosy][sosy][sosy][sosy][sosy][sosy]symptoms[sosy][sosy][sosy][sosy][sosy][sosy][sosy][sosy]acceleratedandshehadsomejaw[sosy][sosy][sosy][sosy]pain[sosy][sosy][sosy][sosy],soshepresentedtotheemergencyroom.(S1 (S (S (ADVP (RB However)) (, ,) (S (NP (PRP$ her) (NN arm) (NN pain) (NNS symptoms)) (VP (VBD accelerated))) (CC and) (S (NP (PRP she)) (VP (VBD had) (NP (DT some) (NN jaw) (NN pain)) (, ,) (SBAR (IN so) (S (NP (PRP she)) (VP (VBD presented) (PP (TO to) (NP (DT the) (NN emergency) (NN room))))))))) (. .)))On 08/16/08, she ended up having a cardiac catheterization and that showed normal left main 80% mid LAD lesion, circumflex normal, and RCA totally occluded in the mid portion and there were collaterals from the left to the right, as well as right to right to that area.On08/16/08,sheendeduphavingacardiaccatheterizationandthatshowednormalleftmain80%midLADlesion,circumflexnormal,andRCAtotallyoccludedinthemidportionandtherewerecollateralsfromthelefttotheright,aswellasrighttorighttothatarea.(S1 (S (PP (IN On) (NP (NN 08/16/08))) (, ,) (NP (PRP she)) (VP (VBD ended) (PP (IN up) (S (VP (VBG having) (NP (NP (DT a) (JJ cardiac) (NN catheterization)) (SBAR (CC and) (WHNP (WDT that)) (S (VP (VBD showed) (NP (NP (NP (JJ normal) (JJ left) (JJ main) (ADJP (CD 80) (NN %)) (JJ mid) (NN LAD)) (NP (NN lesion))) (, ,) (NP (NN circumflex) (JJ normal)) (, ,) (CC and) (NP (NN RCA))) (VP (VP (ADVP (RB totally)) (VBD occluded) (PP (IN in) (NP (DT the) (JJ mid) (NN portion)))) (CC and) (VP (ADVP (RB there)) (VBD were) (NP (NP (NNS collaterals)) (PP (IN from) (NP (DT the) (ADJP (ADJP (JJ left) (PP (TO to) (NP (DT the) (JJ right))) (, ,) (CONJP (RB as) (RB well) (IN as)) (ADJP (JJ right))) (TO to) (ADJP (JJ right) (PP (TO to) (NP (DT that) (NN area)))))))))))))))))) (. .)))The decision was made to transfer her as she may be having collateral insufficiency from the LAD stenosis to the RCA vessel.ThedecisionwasmadetotransferherasshemaybehavingcollateralinsufficiencyfromtheLADstenosistotheRCAvessel.(S1 (S (S (NP (DT The) (NN decision)) (VP (VBD was) (VP (VBN made) (S (VP (TO to) (VP (VB transfer) (NP (PRP$ her)) (SBAR (IN as) (S (NP (PRP she)) (VP (MD may) (VP (VB be) (VP (VBG having) (NP (NP (JJ collateral) (NN insufficiency)) (PP (IN from) (NP (DT the) (NN LAD) (NN stenosis))) (PP (TO to) (NP (DT the) (NN RCA) (NN vessel))))))))))))))) (. .)))She underwent that with drug-eluting stents on 08/16/08, with I believe three or four total placed, and was discharged on 08/17/08.Sheunderwentthatwithdrug-elutingstentson08/16/08,withIbelievethreeorfourtotalplaced,andwasdischargedon08/17/08.(S1 (S (NP (PRP She)) (VP (VBD underwent) (NP (NP (DT that)) (PP (IN with) (NP (NP (JJ drug-eluting) (NNS stents)) (PP (IN on) (NP (NN 08/16/08))) (, ,) (SBAR (SBAR (IN with) (S (NP (PRP I)) (VP (VBP believe) (ADJP (NP (QP (CD three) (CC or) (CD four)) (NN total)) (VBN placed))))) (, ,) (CC and) (S (VP (VBD was) (VP (VBN discharged) (PP (IN on) (NP (NN 08/17/08))))))))))) (. .)))She had some left arm discomfort on 08/18/08, but this was mild.Shehadsomeleftarm[sosy][sosy][sosy][sosy]discomfort[sosy][sosy][sosy][sosy][sosy][sosy][sosy][sosy][sosy][sosy][sosy][sosy]on08/18/08,butthiswasmild.(S1 (S (S (S (NP (PRP She)) (VP (VBD had) (NP (DT some) (JJ left) (NN arm) (NN discomfort)) (PP (IN on) (NP (NN 08/18/08))))) (, ,) (CC but) (S (NP (DT this)) (VP (VBD was) (ADJP (JJ mild))))) (. .)))Yesterday, she felt very fatigued, but no arm pain, and today, she had arm pain after walking and again it resolved now completely after three sublingual nitroglycerin.Yesterday,shefeltveryfatigued[sosy][sosy][sosy][sosy],butnoarm[sosy][sosy][sosy][sosy]pain[sosy][sosy][sosy][sosy],andtoday,shehadarm[sosy][sosy][sosy][sosy]pain[sosy][sosy][sosy][sosy][sosy][sosy][sosy][sosy]after[sosy][sosy][sosy][sosy]walking[sosy][sosy][sosy][sosy]and[sosy][sosy][sosy][sosy]againitresolvednowcompletelyafterthreesublingualnitroglycerin[orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu].(S1 (S (S (S (ADVP (RB Yesterday)) (, ,) (NP (PRP she)) (VP (VBD felt) (ADJP (RB very) (JJ fatigued)) (, ,) (CONJP (CC but) (RB no)) (NP (NN arm) (NN pain)))) (, ,) (CC and) (ADVP (RB today)) (, ,) (S (NP (PRP she)) (VP (VBD had) (NP (NN arm) (NN pain)) (PP (IN after) (NP (NN walking))))) (CC and) (S (ADVP (RB again)) (NP (PRP it)) (VP (VBN resolved) (ADVP (RB now) (RB completely)) (PP (IN after) (NP (CD three) (JJ sublingual) (NN nitroglycerin)))))) (. .)))This is her usual angina.Thisisherusual[sosy][sosy][sosy][sosy]angina[sosy][sosy][sosy][sosy].(S1 (S (S (NP (DT This)) (VP (VBZ is) (NP (PRP$ her) (JJ usual) (NN angina)))) (. .)))She is being admitted with unstable angina post stent.Sheisbeingadmittedwithunstable[dsyn][dsyn][dsyn][dsyn]angina[dsyn][dsyn][dsyn][dsyn]poststent.(S1 (S (S (NP (PRP She)) (VP (VBZ is) (VP (VBG being) (VP (VBN admitted) (PP (IN with) (NP (NP (JJ unstable) (NNS angina)) (PP (IN post) (NP (NN stent))))))))) (. .)))PAST MEDICAL HISTORY: Longstanding hypertension, CAD as above, hyperlipidemia, and overactive bladder.PASTMEDICALHISTORY:Longstandinghypertension[dsyn][dsyn][dsyn][dsyn],CADasabove,hyperlipidemia[dsyn][dsyn][dsyn][dsyn],andoveractive[dsyn][dsyn][dsyn][dsyn]bladder[dsyn][dsyn][dsyn][dsyn].(S1 (S (S (NP (JJ PAST) (JJ MEDICAL) (NN HISTORY)) (: :) (NP (NP (JJ Longstanding) (NN hypertension)) (, ,) (NP (NP (NN CAD)) (PP (IN as) (NP (JJ above)))) (, ,) (NP (NN hyperlipidemia)) (, ,) (CC and) (NP (JJ overactive) (NN bladder)))) (. .)))MEDICATIONS:MEDICATIONS:(S1 (S (NP (NP (NNS MEDICATIONS)) (: :))))1.1.(S1 (S (S (NP (CD 1))) (. .)))Detrol LA 2 mg once a day.Detrol[orch,phsu][orch,phsu][orch,phsu][orch,phsu]LA[orch,phsu][orch,phsu][orch,phsu][orch,phsu]2mgonceaday.(S1 (S (S (NP (NN Detrol) (NN LA) (CD 2) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))2.2.(S1 (S (NP (NP (CD 2)) (. .))))Prilosec for GERD 20 mg once a day.Prilosec[orch,phsu][orch,phsu][orch,phsu][orch,phsu]forGERD[dsyn][dsyn][dsyn][dsyn]20mgonceaday.(S1 (S (S (VP (VBN Prilosec) (PP (IN for) (NP (NP (NN GERD) (CD 20) (NN mg)) (PP (IN once) (NP (DT a) (NN day))))))) (. .)))3.3.(S1 (S (NP (NP (CD 3)) (. .))))Glucosamine 500/400 mg once a day for arthritis.Glucosamine500/400mgonceadayforarthritis[dsyn][dsyn][dsyn][dsyn].(S1 (S (S (NP (NP (NN Glucosamine) (CD 500/400) (NN mg)) (PP (IN once) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (NN arthritis))))))) (. .)))4.4.(S1 (S (S (NP (CD 4))) (. .)))Multivitamin p.o.Multivitaminp.o.(S1 (S (S (NP (NN Multivitamin)) (VP (VBZ p.o))) (. .)))daily.daily.(S1 (S (S (ADJP (JJ daily))) (. .)))5.5.(S1 (S (NP (NP (CD 5)) (. .))))Nitroglycerin sublingual as available to her.Nitroglycerinsublingualasavailabletoher.(S1 (S (S (NP (NN Nitroglycerin)) (VP (JJ sublingual) (PP (IN as) (ADJP (JJ available) (PP (TO to) (NP (PRP$ her))))))) (. .)))6.6.(S1 (S (NP (NP (CD 6)) (. .))))Toprol-XL 25 mg once a day which I started although she had been bradycardic, but she seems to be tolerating.Toprol-XL[orch,phsu][orch,phsu][orch,phsu][orch,phsu]25mgonceadaywhichIstartedalthoughshehadbeenbradycardic,butsheseemstobetolerating.(S1 (S (S (NP (NP (NN Toprol-XL) (CD 25) (NN mg)) (PP (IN once) (NP (NP (DT a) (NN day)) (SBAR (WHNP (WDT which)) (S (NP (PRP I))))))) (VP (VBD started) (SBAR (IN although) (S (S (NP (PRP she)) (VP (VBD had) (VP (VBN been) (ADJP (JJ bradycardic))))) (, ,) (CC but) (S (NP (PRP she)) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (ADJP (VBG tolerating))))))))))) (. .)))7.7.(S1 (S (NP (NP (CD 7)) (. .))))Aspirin 325 mg once a day.Aspirin325mgonceaday.(S1 (S (S (NP (NN Aspirin) (CD 325) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))8.8.(S1 (S (NP (NP (CD 8)) (. .))))Plavix 75 mg once a day.Plavix[orch,phsu][orch,phsu][orch,phsu][orch,phsu]75mgonceaday.(S1 (S (S (NP (NN Plavix) (CD 75) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))9.9.(S1 (S (NP (NP (CD 9)) (. .))))Diovan 160 mg once a day.Diovan[orch,phsu][orch,phsu][orch,phsu][orch,phsu]160mgonceaday.(S1 (S (S (NP (NN Diovan) (CD 160) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))10.10.(S1 (S (NP (NP (CD 10)) (. .))))Claritin 10 mg once a day for allergic rhinitis.Claritin[orch,phsu][orch,phsu][orch,phsu][orch,phsu]10mgonceadayforallergic[dsyn][dsyn][dsyn][dsyn]rhinitis[dsyn][dsyn][dsyn][dsyn].(S1 (S (S (NP (NP (NN Claritin) (CD 10) (NN mg)) (PP (IN once) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (JJ allergic) (NN rhinitis))))))) (. .)))11.11.(S1 (S (NP (NP (CD 11)) (. .))))Norvasc 5 mg once a day.Norvasc[orch,phsu][orch,phsu][orch,phsu][orch,phsu]5mgonceaday.(S1 (S (S (NP (NN Norvasc) (CD 5) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))12.12.(S1 (S (NP (NP (CD 12)) (. .))))Lipitor 5 mg once a day.Lipitor[orch,phsu][orch,phsu][orch,phsu][orch,phsu]5mgonceaday.(S1 (S (S (NP (NN Lipitor) (CD 5) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))13.13.(S1 (S (NP (NP (CD 13)) (. .))))Evista 60 mg once a day.Evista[orch,phsu][orch,phsu][orch,phsu][orch,phsu]60mgonceaday.(S1 (S (S (NP (NN Evista) (CD 60) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))ALLERGIES: ALLERGIES TO MEDICATIONS ARE NONE.ALLERGIES:ALLERGIESTOMEDICATIONSARENONE.(S1 (S (S (NP (NP (NNS ALLERGIES)) (: :) (NP (NP (NNS ALLERGIES)) (PP (TO TO) (NP (NNS MEDICATIONS))))) (VP (VBP ARE) (NP (NN NONE)))) (. .)))SHE DENIES ANY SHRIMP OR SEA FOOD ALLERGY.SHEDENIESANYSHRIMPORSEAFOODALLERGY.(S1 (S (S (NP (PRP SHE)) (VP (VBZ DENIES) (NP (DT ANY) (NN SHRIMP) (CC OR) (NN SEA) (NN FOOD) (NN ALLERGY)))) (. .)))FAMILY HISTORY: Her father died of an MI in his 50s and a brother had his first MI and bypass surgery at 54.FAMILYHISTORY[dsyn][dsyn][dsyn][dsyn]:[dsyn][dsyn][dsyn][dsyn]Her[dsyn][dsyn][dsyn][dsyn]fatherdiedofanMIinhis50sandabrotherhadhisfirstMIandbypasssurgeryat54.(S1 (S (S (NP (NP (NN FAMILY) (NN HISTORY)) (: :) (NP (NP (PRP$ Her) (NN father)) (VP (VBD died) (PP (IN of) (NP (NP (DT an) (NN MI)) (PP (IN in) (NP (NN his) (NN 50s))))))) (CC and) (NP (DT a) (NN brother))) (VP (VBD had) (NP (NP (NN his) (JJ first) (NN MI)) (CC and) (NP (VB bypass) (NN surgery))) (PP (IN at) (NP (CD 54))))) (. .)))SOCIAL HISTORY: She does not smoke cigarettes, abuse alcohol, no use of illicit drugs.SOCIALHISTORY:Shedoesnotsmokecigarettes,abusealcohol[orch][orch,phsu][orch][orch,phsu][orch][orch,phsu][orch][orch,phsu],nouseofillicitdrugs.(S1 (S (NP (NP (JJ SOCIAL) (NN HISTORY)) (: :) (S (NP (PRP She)) (VP (VBZ does) (RB not) (NP (NP (NN smoke) (NNS cigarettes)) (, ,) (NP (NN abuse) (NN alcohol)) (, ,) (NP (NP (DT no) (NN use)) (PP (IN of) (NP (JJ illicit) (NNS drugs))))))) (. .))))She is divorced and lives alone and is a retired laboratory technician from Cornell Diagnostic Laboratory.SheisdivorcedandlivesaloneandisaretiredlaboratorytechnicianfromCornellDiagnosticLaboratory.(S1 (S (S (NP (PRP She)) (VP (VP (VBZ is) (NP (NP (NN divorced)) (CC and) (NP (NP (NNS lives)) (ADVP (RB alone))))) (CC and) (VP (VBZ is) (NP (NP (DT a) (JJ retired) (NN laboratory) (NN technician)) (PP (IN from) (NP (NN Cornell) (JJ Diagnostic) (NN Laboratory))))))) (. .)))REVIEW OF SYSTEMS: She denies a history of stroke, cancer, vomiting up blood, coughing up blood, bright red blood per rectum, bleeding stomach ulcers, renal calculi, cholelithiasis, asthma, emphysema, pneumonia, tuberculosis, home oxygen use or sleep apnea, although she has been told in the past that she snores and there was some question of apnea in 05/08.REVIEWOFSYSTEMS:Shedeniesahistoryofstroke[dsyn][dsyn][dsyn][dsyn],cancer,vomiting[sosy][sosy][sosy][sosy]up[sosy][sosy][sosy][sosy]blood[sosy][sosy][sosy][sosy],[sosy][sosy][sosy][sosy]coughing[sosy][sosy][sosy][sosy]up[sosy][sosy][sosy][sosy]blood[sosy][sosy][sosy][sosy],brightredbloodperrectum,bleedingstomach[dsyn][dsyn][dsyn][dsyn]ulcers[dsyn][dsyn][dsyn][dsyn],renal[dsyn][dsyn][dsyn][dsyn]calculi[dsyn][dsyn][dsyn][dsyn],cholelithiasis[dsyn][dsyn][dsyn][dsyn],asthma[dsyn][dsyn][dsyn][dsyn],emphysema[dsyn][dsyn][dsyn][dsyn],pneumonia[dsyn][dsyn][dsyn][dsyn],tuberculosis[dsyn][dsyn][dsyn][dsyn],homeoxygenuseorsleep[dsyn][dsyn][dsyn][dsyn]apnea[dsyn][dsyn][dsyn][dsyn],althoughshehasbeentoldinthepastthatshesnores[sosy][sosy][sosy][sosy]andtherewassomequestionofapneain05/08.(S1 (S (NP (NP (NN REVIEW)) (PP (IN OF) (NP (NNS SYSTEMS)))) (: :) (S (NP (PRP She)) (VP (VBZ denies) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NN stroke)) (, ,) (NP (NN cancer)) (, ,) (NP (NP (NN vomiting)) (PP (IN up) (NP (NN blood))))))) (, ,) (S (VP (VBG coughing) (PP (IN up) (NP (NP (NN blood)) (, ,) (NP (NP (JJ bright) (JJ red) (NN blood)) (PP (IN per) (NP (NN rectum)))) (, ,) (NP (JJ bleeding) (NN stomach) (NNS ulcers)) (, ,) (NP (JJ renal) (NN calculi)) (, ,) (NP (NN cholelithiasis)) (, ,) (NP (NN asthma)) (, ,) (NP (NN emphysema)) (, ,) (NP (NN pneumonia)) (, ,) (NP (NN tuberculosis)) (, ,) (NP (NN home) (NN oxygen) (NN use)) (CC or) (NP (NN sleep) (NN apnea)))))) (, ,) (SBAR (IN although) (S (NP (PRP she)) (VP (VBZ has) (VP (VBN been) (VP (VBN told) (PP (IN in) (NP (DT the) (JJ past))) (SBAR (IN that) (S (NP (NP (NP (PRP she)) (NNS snores)) (CC and) (NP (EX there))) (VP (VBD was) (NP (NP (DT some) (NN question)) (PP (IN of) (NP (NN apnea))) (PP (IN in) (NP (NN 05/08)))))))))))))) (. .)))No morning headaches or fatigue.Nomorning[sosy][sosy][sosy][sosy]headaches[sosy][sosy][sosy][sosy]orfatigue[sosy][sosy][sosy][sosy].(S1 (S (S (NP (DT No) (NN morning) (NNS headaches)) (VP (CC or) (VP (VBP fatigue)))) (. .)))No psychiatric diagnosis.Nopsychiatricdiagnosis.(S1 (S (S (NP (DT No) (JJ psychiatric) (NN diagnosis))) (. .)))No psoriasis, no lupus.Nopsoriasis[dsyn][dsyn][dsyn][dsyn],nolupus[dsyn][dsyn][dsyn][dsyn][dsyn][dsyn][dsyn][dsyn][dsyn][dsyn][dsyn][dsyn].(S1 (S (S (NP (NN No) (NN psoriasis)) (, ,) (NP (DT no) (NN lupus))) (. .)))Remainder of the review of systems is negative x14 systems except as described above.Remainderofthereviewofsystemsisnegativex14systemsexceptasdescribedabove.(S1 (S (S (NP (NP (NN Remainder)) (PP (IN of) (NP (NP (DT the) (NN review)) (PP (IN of) (NP (NNS systems)))))) (VP (VBZ is) (NP (JJ negative) (NN x14) (NNS systems)) (PP (IN except) (SBAR (IN as) (S (VP (VBN described) (ADVP (RB above)))))))) (. .)))PHYSICAL EXAMINATION:PHYSICALEXAMINATION:(S1 (S (NP (NP (JJ PHYSICAL) (NN EXAMINATION)) (: :))))GENERAL: She is a pleasant elderly woman, currently in no acute distress.GENERAL:Sheisapleasantelderlywoman,currentlyinnoacutedistress.(S1 (S (S (NP (JJ GENERAL)) (: :) (S (NP (PRP She)) (VP (VBZ is) (NP (DT a) (JJ pleasant) (JJ elderly) (NN woman)) (, ,) (ADVP (RB currently)) (PP (IN in) (NP (DT no) (JJ acute) (NN distress)))))) (. .)))VITAL SIGNS: Height 4 feet 11 inches, weight 128 pounds, temperature 97.2 degrees Fahrenheit, blood pressure 142/70, pulse 47, respiratory rate 16, and O2 saturation 100%VITALSIGNS:Height4feet11inches,weight128pounds,temperature97.2degreesFahrenheit,bloodpressure142/70,pulse47,respiratoryrate16,andO2saturation100%(S1 (S (NP (NP (JJ VITAL) (NNS SIGNS)) (: :) (NP (NP (NN Height) (CD 4) (NN feet) (CD 11)) (NNS inches)) (, ,) (NP (NN weight) (CD 128) (NNS pounds)) (, ,) (NP (NN temperature) (CD 97.2) (NNS degrees) (NN Fahrenheit)) (, ,) (NP (NP (NN blood) (NN pressure) (CD 142/70)) (, ,) (NP (NN pulse) (CD 47)) (, ,) (NP (NN respiratory) (NN rate) (CD 16)) (, ,) (CC and) (NP (CD O2) (NN saturation) (CD 100) (NN %))))))HEENT: Cranium is normocephalic and atraumatic.HEENT:Craniumisnormocephalicandatraumatic.(S1 (S (S (NP (NP (NN HEENT)) (: :) (NP (NN Cranium))) (VP (VBZ is) (ADJP (ADJP (JJ normocephalic)) (CC and) (ADJP (JJ atraumatic))))) (. .)))She has moist mucosal membranes.Shehasmoistmucosalmembranes.(S1 (S (S (NP (PRP She)) (VP (VBZ has) (NP (JJ moist) (JJ mucosal) (NNS membranes)))) (. .)))NECK: Veins are not distended.NECK:Veinsarenotdistended.(S1 (S (NP (NP (NN NECK)) (: :) (S (NP (NNS Veins)) (VP (VBP are) (RB not) (ADJP (JJ distended)))) (. .))))There are no carotid bruits.Therearenocarotidbruits.(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (DT no) (NN carotid) (NNS bruits)))) (. .)))LUNGS: Clear to auscultation and percussion without wheezes.LUNGS:Cleartoauscultationandpercussionwithoutwheezes[sosy][sosy][sosy][sosy].(S1 (S (NP (NP (NNS LUNGS)) (: :) (NP (NP (JJ Clear)) (PP (TO to) (NP (NP (NP (NN auscultation)) (CC and) (NP (NN percussion))) (PP (IN without) (NP (NNS wheezes)))))) (. .))))HEART: S1 and S2, regular rate.HEART:S1andS2,regularrate.(S1 (S (S (NP (NN HEART)) (: :) (NP (NP (NP (NN S1)) (CC and) (NP (NN S2))) (, ,) (NP (JJ regular) (NN rate)))) (. .)))No significant murmurs, rubs or gallops.Nosignificantmurmurs,rubsorgallops.(S1 (S (S (NP (NP (DT No) (JJ significant) (NNS murmurs)) (, ,) (NP (NP (NNS rubs)) (CC or) (NP (NNS gallops))))) (. .)))PMI nondisplaced.PMInondisplaced.(S1 (S (S (NP (NN PMI)) (VP (VBD nondisplaced))) (. .)))ABDOMEN: Soft and nondistended.ABDOMEN:Soft[dsyn][dsyn][dsyn][dsyn]andnondistended.(S1 (S (NP (NP (NN ABDOMEN)) (: :) (NP (NP (ADJP (JJ Soft))) (CC and) (NP (ADJP (JJ nondistended)))) (. .))))Bowel sounds present.Bowelsoundspresent.(S1 (S (S (NP (NN Bowel) (NNS sounds)) (VP (VBP present))) (. .)))EXTREMITIES: Without significant clubbing, cyanosis or edema.EXTREMITIES:Withoutsignificantclubbing[sosy][sosy][sosy][sosy],cyanosis[sosy][sosy][sosy][sosy]oredema.(S1 (S (S (NP (NP (NNS EXTREMITIES) (: :)) (PP (IN Without) (NP (NP (JJ significant) (NN clubbing)) (, ,) (NP (NN cyanosis)) (CC or) (NP (NN edema)))))) (. .)))Pulses grossly intact.Pulsesgrosslyintact.(S1 (S (S (NP (NNS Pulses)) (VP (ADVP (RB grossly)) (JJ intact))) (. .)))Bilateral groins are inspected, status post as the right femoral artery was used for access for the diagnostic cardiac catheterization here and left femoral artery used for PCI and there is no evidence of hematoma or bruit and intact distal pulses.Bilateralgroinsareinspected,statuspostastherightfemoralarterywasusedforaccessforthediagnosticcardiaccatheterizationhereandleftfemoralarteryusedforPCIandthereisnoevidenceofhematomaorbruitandintactdistalpulses.(S1 (S (S (NP (JJ Bilateral) (NNS groins)) (VP (VBP are) (VP (VBN inspected) (, ,) (S (NP (NN status)) (ADJP (JJ post) (PP (IN as) (NP (NP (NP (NP (DT the) (JJ right) (JJ femoral) (NN artery)) (VP (VBD was) (VP (VBN used) (PP (IN for) (NP (NN access))) (PP (IN for) (NP (DT the) (JJ diagnostic) (JJ cardiac) (NN catheterization))) (ADVP (RB here))))) (CC and) (NP (JJ left) (JJ femoral) (NN artery))) (VP (VBN used) (PP (IN for) (NP (NN PCI))))))))))) (CC and) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NP (NN hematoma)) (CC or) (NP (NN bruit))) (CC and) (NP (JJ intact) (JJ distal) (NNS pulses))))))) (. .)))LABORATORY DATA: EKG reviewed which shows sinus bradycardia at the rate of 51 beats per minute and no acute disease.LABORATORYDATA:EKGreviewedwhichshowssinusbradycardiaattherateof51beatsperminuteandnoacute[dsyn][dsyn][dsyn][dsyn]disease[dsyn][dsyn][dsyn][dsyn].(S1 (S (NP (NP (NN LABORATORY) (NNS DATA)) (: :) (S (NP (NN EKG)) (VP (VBN reviewed) (SBAR (WHNP (WDT which)) (S (VP (VBZ shows) (NP (NN sinus) (NN bradycardia)) (PP (IN at) (NP (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (CD 51) (NNS beats))) (PP (IN per) (NP (NN minute)))) (CC and) (NP (DT no) (JJ acute) (NN disease))))))))) (. .))))Sodium 136, potassium 3.8, chloride 105, and bicarbonate 27.Sodium136,potassium3.8,chloride105,andbicarbonate[orch,phsu][orch,phsu][orch,phsu][orch,phsu]27.(S1 (S (S (NP (NP (NN Sodium) (CD 136)) (, ,) (NP (NN potassium) (CD 3.8)) (, ,) (NP (NN chloride) (CD 105)) (, ,) (CC and) (NP (NN bicarbonate) (CD 27)))) (. .)))BUN 16 and creatinine 0.9.BUN16andcreatinine0.9.(S1 (S (S (NP (NP (NN BUN) (CD 16)) (CC and) (NP (NN creatinine) (CD 0.9)))) (. .)))Glucose 110.Glucose110.(S1 (S (S (NP (NN Glucose)) (NP (CD 110))) (. .)))Magnesium 2.5.Magnesium2.5.(S1 (S (S (NP (NN Magnesium) (CD 2.5))) (. .)))ALT 107 and AST 65 and these were normal on 08/15/08.ALT107andAST65andthesewerenormalon08/15/08.(S1 (S (S (S (NP (NP (NN ALT) (CD 107)) (CC and) (NP (NN AST) (CD 65)))) (CC and) (S (NP (DT these)) (VP (VBD were) (ADJP (JJ normal)) (PP (IN on) (NP (NN 08/15/08)))))) (. .)))INR is 0.89, PTT 20.9, white blood cell count 8.2, hematocrit 31 and it was 35 on 08/15/08, and platelet count 257,000.INRis0.89,PTT20.9,whitebloodcellcount8.2,hematocrit31anditwas35on08/15/08,andplateletcount257,000.(S1 (S (S (S (NP (NN INR)) (VP (VBZ is) (NP (NP (CD 0.89)) (, ,) (NP (NP (NN PTT) (CD 20.9)) (, ,) (NP (JJ white) (NN blood) (NN cell) (NN count) (CD 8.2)) (, ,) (NP (NN hematocrit) (CD 31)))))) (CC and) (S (NP (PRP it)) (VP (VBD was) (NP (CD 35)) (PP (IN on) (NP (NP (NN 08/15/08)) (, ,) (CC and) (NP (NN platelet) (NN count) (CD 257,000))))))) (. .)))IMPRESSION AND PLAN: The patient is a 68-year-old woman with exertional angina, characterized with arm pain, who underwent recent left anterior descending percutaneous coronary intervention and has now had recurrence of that arm pain post stenting to the left anterior descending artery and it may be that she is continuing to have collateral insufficiency of the right coronary artery.IMPRESSIONANDPLAN[dsyn][dsyn][dsyn][dsyn]:Thepatientisa68-year-oldwomanwithexertional[sosy][sosy][sosy][sosy]angina[sosy][sosy][sosy][sosy],characterizedwitharm[sosy][sosy][sosy][sosy]pain[sosy][sosy][sosy][sosy],whounderwentrecentleftanteriordescendingpercutaneouscoronaryinterventionandhasnowhadrecurrenceofthatarm[sosy][sosy][sosy][sosy]pain[sosy][sosy][sosy][sosy]poststentingtotheleftanteriordescendingarteryanditmaybethatsheiscontinuingtohavecollateralinsufficiency[dsyn][dsyn][dsyn][dsyn]of[dsyn][dsyn][dsyn][dsyn]the[dsyn][dsyn][dsyn][dsyn]rightcoronary[dsyn][dsyn][dsyn][dsyn]artery[dsyn][dsyn][dsyn][dsyn].[dsyn][dsyn][dsyn][dsyn](S1 (S (NP (NP (NP (NN IMPRESSION)) (CC AND) (NP (NN PLAN))) (: :) (S (S (NP (DT The) (NN patient)) (VP (VP (VBZ is) (NP (NP (DT a) (JJ 68-year-old) (NN woman)) (PP (IN with) (NP (JJ exertional) (NNS angina))) (, ,) (VP (VBN characterized) (PP (IN with) (NP (NN arm) (NN pain)))) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (JJ recent) (JJ left) (JJ anterior) (NN descending) (NN percutaneous) (JJ coronary) (NN intervention))))))) (CC and) (VP (VBZ has) (ADVP (RB now)) (VP (VBD had) (NP (NP (NN recurrence)) (PP (IN of) (NP (DT that) (NN arm) (NN pain)))) (PP (IN post) (S (VP (VBG stenting) (PP (TO to) (NP (DT the) (JJ left) (JJ anterior) (NN descending) (NN artery)))))))))) (CC and) (S (NP (PRP it)) (VP (MD may) (VP (VB be) (SBAR (IN that) (S (NP (PRP she)) (VP (VBZ is) (VP (VBG continuing) (S (VP (TO to) (VP (VBP have) (NP (NP (JJ collateral) (NN insufficiency)) (PP (IN of) (NP (DT the) (JJ right) (JJ coronary) (NN artery))))))))))))))) (. .))))In any case, given this unstable presentation requiring three sublingual nitroglycerin before she was even pain free, I am going to admit her to the hospital and there is currently no evidence requiring acute reperfusion therapy.Inanycase,giventhisunstablepresentationrequiringthreesublingualnitroglycerin[orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu][orch,phsu]beforeshewasevenpainfree,Iamgoingtoadmithertothehospitalandthereiscurrentlynoevidencerequiringacutereperfusiontherapy.(S1 (S (S (PP (IN In) (NP (DT any) (NN case))) (, ,) (S (PP (IN given) (NP (NP (DT this) (JJ unstable) (NN presentation)) (VP (VBG requiring) (NP (NP (CD three) (JJ sublingual) (NN nitroglycerin)) (SBAR (IN before) (S (NP (PRP she)) (VP (VBD was) (ADVP (RB even)) (ADJP (NN pain) (JJ free))))))))) (, ,) (NP (CD I) (NN am)) (VP (VBG going) (S (VP (TO to) (VP (VB admit) (NP (PRP$ her)) (PP (TO to) (NP (DT the) (NN hospital)))))))) (CC and) (NP (EX there)) (VP (VBZ is) (ADVP (RB currently)) (NP (NP (DT no) (NN evidence)) (VP (VBG requiring) (NP (JJ acute) (NN reperfusion) (NN therapy)))))) (. .)))We will continue her beta-blocker and I cannot increase the dose because she is bradycardic already.Wewillcontinueherbeta-blockerandIcannotincreasethedosebecausesheisbradycardicalready.(S1 (S (NP (PRP We)) (VP (MD will) (VP (VBP continue) (S (NP (PRP$ her) (NP (NP (NN beta-blocker)) (CC and) (NP (NN I)))) (VP (MD can) (RB not) (VP (VB increase) (NP (DT the) (NN dose) (SBAR (IN because) (S (NP (PRP she)) (VP (VBZ is) (ADJP (JJ bradycardic)))))) (ADVP (RB already))))))) (. .)))Aspirin, Plavix, valsartan, Lipitor, and Norvasc.Aspirin[orch,phsu][orch,phsu][orch,phsu][orch,phsu],Plavix[orch,phsu][orch,phsu][orch,phsu][orch,phsu],valsartan[orch,phsu][orch,phsu][orch,phsu][orch,phsu],Lipitor[orch,phsu][orch,phsu][orch,phsu][orch,phsu],andNorvasc[orch,phsu][orch,phsu][orch,phsu][orch,phsu].(S1 (S (NP (NP (NP (NN Aspirin)) (, ,) (NP (NN Plavix)) (, ,) (NP (NN valsartan)) (, ,) (NP (NN Lipitor)) (, ,) (CC and) (NP (NN Norvasc))) (. .))))I am going to add Imdur and watch headaches as she apparently had some on nitro paste before, and we will rule out MI, although there is a little suspicion.IamgoingtoaddImdur[orch,phsu][orch,phsu][orch,phsu][orch,phsu]andwatchheadaches[sosy][sosy][sosy][sosy]assheapparentlyhadsomeonnitropastebefore,andwewillruleoutMI,althoughthereisalittlesuspicion.(S1 (S (S (S (NP (CD I) (NN am)) (VP (VBG going) (S (VP (TO to) (VP (VBP add) (NP (ADJP (ADJP (JJ Imdur)) (CC and) (ADJP (JJ watch))) (NNS headaches) (SBAR (IN as) (S (NP (PRP she)) (ADVP (RB apparently)) (VP (VBD had) (NP (DT some)) (PP (IN on) (NP (NP (NN nitro) (NN paste)) (PP (IN before))))))))))))) (, ,) (CC and) (S (NP (PRP we)) (VP (MD will) (VP (NN rule) (PP (IN out) (NP (NN MI))) (, ,) (SBAR (IN although) (S (NP (EX there)) (VP (VBZ is) (NP (DT a) (JJ little) (NN suspicion))))))))) (. .)))I suppose it is possible that she has non-cardiac arm pain, but that seems less likely as it has been nitrate responsive and seems exertionally related and the other possibility may be that we end up needing to put in a pacemaker, so we can maximize beta-blocker use for anti-anginal effect.Isupposeitispossiblethatshehasnon-cardiacarm[sosy][sosy][sosy][sosy]pain[sosy][sosy][sosy][sosy][sosy][sosy][sosy][sosy],[sosy][sosy][sosy][sosy]butthatseemslesslikelyasithasbeennitrateresponsiveandseemsexertionallyrelatedandtheotherpossibilitymaybethatweendupneedingtoputinapacemaker,sowecanmaximizebeta-blockeruseforanti-anginaleffect.(S1 (S (S (NP (PRP I)) (VP (VBP suppose) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (SBAR (IN that) (S (NP (PRP she)) (VP (VBZ has) (NP (JJ non-cardiac) (NN arm) (NN pain))))) (, ,) (CC but) (SBAR (IN that) (S (VP (VBZ seems) (ADJP (RBR less) (JJ likely)) (SBAR (IN as) (S (S (NP (PRP it)) (VP (VP (VBZ has) (VP (VBN been) (ADJP (NN nitrate) (JJ responsive)))) (CC and) (VP (VBZ seems) (ADJP (RB exertionally) (JJ related))))) (CC and) (S (NP (DT the) (JJ other) (NN possibility)) (VP (MD may) (VP (VB be) (SBAR (IN that) (S (NP (PRP we)) (VP (NN end) (RP up) (S (VP (VBG needing) (S (VP (TO to) (VP (VBP put) (PP (IN in) (NP (NP (DT a) (NN pacemaker)) (, ,) (SBAR (IN so) (S (NP (PRP we)) (VP (MD can) (VP (VB maximize) (NP (NN beta-blocker) (NN use)) (PP (IN for) (NP (JJ anti-anginal) (NN effect)))))))))))))))))))))))))))))) (. .)))My concern is that there is persistent right coronary artery ischemia, not helped by left anterior descending percutaneous coronary intervention, which was severely stenotic and she does have normal LV function.Myconcernisthatthereispersistentrightcoronaryarteryischemia[dsyn][dsyn][dsyn][dsyn],nothelpedbyleftanteriordescendingpercutaneouscoronaryintervention,whichwasseverelystenoticandshedoeshavenormalLVfunction.(S1 (S (S (NP (NN My) (NN concern)) (VP (VBZ is) (SBAR (IN that) (S (S (NP (EX there)) (VP (VBZ is) (NP (NP (NP (JJ persistent) (JJ right) (JJ coronary) (NN artery)) (NN ischemia)) (, ,) (VP (ADVP (RB not)) (VBD helped) (PP (IN by) (NP (JJ left) (JJ anterior) (NN descending) (NP (JJ percutaneous) (JJ coronary) (NN intervention))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADVP (RB severely)) (ADJP (JJ stenotic)))))))) (CC and) (S (NP (PRP she)) (VP (VBZ does) (VP (VB have) (NP (JJ normal) (NN LV) (NN function))))))))) (. .)))She will continue the glucosamine for her arthritis, Claritin for allergies, and Detrol LA for urinary incontinence.Shewillcontinuetheglucosamineforherarthritis[dsyn][dsyn][dsyn][dsyn],Claritin[orch,phsu][orch,phsu][orch,phsu][orch,phsu]forallergies,andDetrol[orch,phsu][orch,phsu][orch,phsu][orch,phsu]LA[orch,phsu][orch,phsu][orch,phsu][orch,phsu]forurinaryincontinence.(S1 (S (S (NP (PRP She)) (VP (MD will) (VP (VBP continue) (NP (NP (NP (DT the) (NN glucosamine)) (PP (IN for) (NP (PRP$ her) (NN arthritis)))) (, ,) (NP (NP (NN Claritin)) (PP (IN for) (NP (NNS allergies)))) (, ,) (CC and) (NP (NN Detrol) (NN LA))) (PP (IN for) (NP (JJ urinary) (NN incontinence)))))) (. .)))Total patient care time in the emergency department 75 minutes.Totalpatientcaretimeintheemergencydepartment75minutes.(S1 (S (S (NP (NP (JJ Total) (NN patient) (NN care) (NN time)) (PP (IN in) (NP (DT the) (NN emergency) (NN department)))) (NP (CD 75) (NNS minutes))) (. .)))All this was discussed in detail with the patient and her daughter who expressed understanding and agreement.Allthiswasdiscussedindetailwiththepatientandherdaughterwhoexpressedunderstandingandagreement.(S1 (S (S (NP (PDT All) (DT this)) (VP (VBD was) (VP (VBN discussed) (PP (IN in) (NP (NN detail))) (PP (IN with) (NP (NP (DT the) (NP (NN patient)) (CC and) (NP (PRP$ her) (NN daughter))) (SBAR (WHNP (WP who)) (S (VP (VBD expressed) (NP (NP (NN understanding)) (CC and) (NP (NN agreement))))))))))) (. .)))The patient desires full resuscitation status.Thepatientdesiresfullresuscitationstatus.(S1 (S (S (NP (DT The) (NN patient) (NNS desires)) (NP (JJ full) (NN resuscitation) (NN status))) (. .))) \ No newline at end of file +HISTORY OF PRESENT ILLNESS: The patient is a 68 year old woman whom I have been following, who has had angina.HISTORYOFPRESENTILLNESS:Thepatientisa68yearoldwomanwhomIhavebeenfollowing,whohashadangina[sosy].(S1 (S (S (NP (NP (NN HISTORY)) (PP (IN OF) (NP (JJ PRESENT) (NN ILLNESS)))) (: :) (S (NP (DT The) (NN patient)) (VP (VBZ is) (NP (NP (DT a) (ADJP (CD 68) (NN year) (JJ old)) (NN woman)) (SBAR (WHNP (WP whom)) (S (NP (PRP I)) (VP (VBP have) (VP (VBN been) (NP (NP (NN following)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBZ has) (VP (VBD had) (NP (NN angina))))))))))))))) (. .)))In any case today, she called me because she had a recurrent left arm pain after her stent, three days ago, and this persisted after two sublingual nitroglycerin when I spoke to her.Inanycasetoday,shecalledmebecauseshehadarecurrentleft[sosy]arm[sosy]pain[sosy]afterherstent,threedaysago,andthispersistedaftertwosublingualnitroglycerin[orch,phsu][orch,phsu]whenIspoketoher.(S1 (S (PP (IN In) (NP (NP (DT any) (NN case)) (ADVP (RB today)))) (, ,) (NP (PRP she)) (VP (VBN called) (NP (NN me)) (SBAR (IN because) (S (S (NP (PRP she)) (VP (VBD had) (NP (DT a) (JJ recurrent) (JJ left) (NN arm) (NN pain)) (PP (IN after) (NP (PRP$ her) (NN stent))) (, ,) (ADVP (NP (CD three) (NNS days)) (RB ago)))) (, ,) (CC and) (S (NP (DT this)) (VP (VBD persisted) (PP (IN after) (NP (CD two) (JJ sublingual) (NN nitroglycerin))) (SBAR (WHADVP (WRB when)) (S (NP (PRP I)) (VP (VBP spoke) (PP (TO to) (NP (PRP$ her))))))))))) (. .)))I advised her to call 911, which she did.Iadvisedhertocall911,whichshedid.(S1 (S (S (NP (PRP I)) (VP (VBN advised) (NP (PRP$ her) (PP (TO to) (NP (NN call) (CD 911))) (, ,) (SBAR (WHNP (WDT which)) (S (NP (PRP she)) (VP (VBD did))))))) (. .)))While waiting for 911, she was attended to by a physician who is her neighbor and he advised her to take the third nitroglycerin and that apparently relieved her pain.Whilewaitingfor911,shewasattendedtobyaphysicianwhoisherneighborandheadvisedhertotakethethirdnitroglycerin[orch,phsu][orch,phsu]andthatapparentlyrelievedherpain[sosy].[sosy](S1 (S (S (SBAR (IN While) (S (VP (VBG waiting) (PP (IN for) (NP (NN 911)))))) (, ,) (NP (PRP she)) (VP (VBD was) (VP (VBN attended) (PP (TO to)) (PP (IN by) (NP (NP (DT a) (NN physician)) (SBAR (WHNP (WP who)) (S (VP (VP (VBZ is) (NP (PRP$ her) (NN neighbor))) (CC and) (VP (VBZ he) (VP (VBN advised) (UCP (S (NP (PRP$ her)) (VP (TO to) (VP (VB take) (NP (DT the) (JJ third) (NN nitroglycerin))))) (CC and) (SBAR (IN that) (S (ADVP (RB apparently)) (VP (VBN relieved) (NP (PRP$ her) (NN pain)))))))))))))))) (. .)))By the time she presented here, she is currently pain free and is feeling well.Bythetimeshepresentedhere,sheiscurrentlypain[orch]freeandisfeelingwell.(S1 (S (S (PP (IN By) (NP (DT the) (NN time) (PRP she) (VP (VBN presented) (ADVP (RB here))))) (, ,) (NP (PRP she)) (VP (VP (VBZ is) (ADVP (RB currently)) (ADJP (NN pain) (JJ free))) (CC and) (VP (VBZ is) (NP (NN feeling)) (ADVP (RB well))))) (. .)))PAST CARDIAC HISTORY: The patient has been having arm pain for several months.PASTCARDIACHISTORY:Thepatienthasbeenhavingarm[sosy]pain[sosy]forseveralmonths.(S1 (S (S (NP (JJ PAST) (JJ CARDIAC) (NN HISTORY)) (: :) (NP (DT The) (NN patient)) (VP (VBZ has) (VP (VBN been) (VP (VBG having) (NP (NP (NN arm) (NN pain)) (PP (IN for) (NP (JJ several) (NNS months)))))))) (. .)))She underwent an exercise stress echocardiogram within the last several months with me, which was equivocal, but then she had a nuclear stress test which showed inferobasilar ischemia.Sheunderwentanexercisestressechocardiogramwithinthelastseveralmonthswithme,whichwasequivocal,butthenshehadanuclearstresstestwhichshowedinferobasilarischemia[dsyn].(S1 (S (S (S (NP (PRP She)) (VP (VBD underwent) (NP (DT an) (NN exercise) (NN stress) (NN echocardiogram)) (PP (IN within) (NP (NP (DT the) (JJ last) (JJ several) (NNS months)) (PP (IN with) (NP (NP (NN me)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (JJ equivocal))))))))))) (, ,) (CC but) (S (ADVP (RB then)) (NP (PRP she)) (VP (VBD had) (NP (NP (DT a) (JJ nuclear) (NN stress) (NN test)) (SBAR (WHNP (WDT which)) (S (VP (VBD showed) (NP (JJ inferobasilar) (NN ischemia))))))))) (. .)))I had originally advised her for a heart catheterization but she wanted medical therapy, so we put her on a beta blocker.Ihadoriginallyadvisedherforaheartcatheterizationbutshewantedmedicaltherapy,soweputheronabeta[phsu]blocker.(S1 (S (S (S (NP (NN I)) (VP (VBD had) (ADVP (RB originally)) (VP (VBN advised) (NP (PRP$ her)) (PP (IN for) (NP (DT a) (NN heart) (NN catheterization)))))) (CC but) (S (NP (PRP she)) (VP (VBD wanted) (NP (JJ medical) (NN therapy)) (, ,) (SBAR (IN so) (S (NP (PRP we)) (VP (VBP put) (NP (PRP$ her)) (PP (IN on) (NP (DT a) (NN beta) (NN blocker))))))))) (. .)))However, her arm pain symptoms accelerated and she had some jaw pain, so she presented to the emergency room.However,herarm[sosy]pain[sosy][sosy]symptoms[sosy][sosy]acceleratedandshehadsomejaw[sosy]pain[sosy],soshepresentedtotheemergencyroom.(S1 (S (S (ADVP (RB However)) (, ,) (S (NP (PRP$ her) (NN arm) (NN pain) (NNS symptoms)) (VP (VBD accelerated))) (CC and) (S (NP (PRP she)) (VP (VBD had) (NP (DT some) (NN jaw) (NN pain)) (, ,) (SBAR (IN so) (S (NP (PRP she)) (VP (VBD presented) (PP (TO to) (NP (DT the) (NN emergency) (NN room))))))))) (. .)))On 08/16/08, she ended up having a cardiac catheterization and that showed normal left main 80% mid LAD lesion, circumflex normal, and RCA totally occluded in the mid portion and there were collaterals from the left to the right, as well as right to right to that area.On08/16/08,sheendeduphavingacardiaccatheterizationandthatshowednormalleftmain80%midLADlesion,circumflexnormal,andRCAtotallyoccludedinthemidportionandtherewerecollateralsfromthelefttotheright,aswellasrighttorighttothatarea.(S1 (S (PP (IN On) (NP (NN 08/16/08))) (, ,) (NP (PRP she)) (VP (VBD ended) (PP (IN up) (S (VP (VBG having) (NP (NP (DT a) (JJ cardiac) (NN catheterization)) (SBAR (CC and) (WHNP (WDT that)) (S (VP (VBD showed) (NP (NP (NP (JJ normal) (JJ left) (JJ main) (ADJP (CD 80) (NN %)) (JJ mid) (NN LAD)) (NP (NN lesion))) (, ,) (NP (NN circumflex) (JJ normal)) (, ,) (CC and) (NP (NN RCA))) (VP (VP (ADVP (RB totally)) (VBD occluded) (PP (IN in) (NP (DT the) (JJ mid) (NN portion)))) (CC and) (VP (ADVP (RB there)) (VBD were) (NP (NP (NNS collaterals)) (PP (IN from) (NP (DT the) (ADJP (ADJP (JJ left) (PP (TO to) (NP (DT the) (JJ right))) (, ,) (CONJP (RB as) (RB well) (IN as)) (ADJP (JJ right))) (TO to) (ADJP (JJ right) (PP (TO to) (NP (DT that) (NN area)))))))))))))))))) (. .)))The decision was made to transfer her as she may be having collateral insufficiency from the LAD stenosis to the RCA vessel.ThedecisionwasmadetotransferherasshemaybehavingcollateralinsufficiencyfromtheLADstenosistotheRCAvessel.(S1 (S (S (NP (DT The) (NN decision)) (VP (VBD was) (VP (VBN made) (S (VP (TO to) (VP (VB transfer) (NP (PRP$ her)) (SBAR (IN as) (S (NP (PRP she)) (VP (MD may) (VP (VB be) (VP (VBG having) (NP (NP (JJ collateral) (NN insufficiency)) (PP (IN from) (NP (DT the) (NN LAD) (NN stenosis))) (PP (TO to) (NP (DT the) (NN RCA) (NN vessel))))))))))))))) (. .)))She underwent that with drug eluting stents on 08/16/08, with I believe three or four total placed, and was discharged on 08/17/08.Sheunderwentthatwithdrugelutingstentson08/16/08,withIbelievethreeorfourtotalplaced,andwasdischargedon08/17/08.(S1 (S (NP (PRP She)) (VP (VBD underwent) (NP (NP (DT that)) (PP (IN with) (NP (NN drug) (NN eluting) (NNS stents)))) (PP (IN on) (NP (NN 08/16/08))) (, ,) (SBAR (IN with) (S (NP (PRP I)) (VP (VBP believe) (S (NP (QP (CD three) (CC or) (CD four)) (NN total)) (VP (VP (VBD placed)) (, ,) (CC and) (VP (VBD was) (VP (VBN discharged) (PP (IN on) (NP (NN 08/17/08))))))))))) (. .)))She had some left arm discomfort on 08/18/08, but this was mild.Shehadsomeleftarm[sosy]discomfort[sosy][sosy][sosy]on08/18/08,butthiswasmild.(S1 (S (S (S (NP (PRP She)) (VP (VBD had) (NP (DT some) (JJ left) (NN arm) (NN discomfort)) (PP (IN on) (NP (NN 08/18/08))))) (, ,) (CC but) (S (NP (DT this)) (VP (VBD was) (ADJP (JJ mild))))) (. .)))Yesterday, she felt very fatigued, but no arm pain, and today, she had arm pain after walking and again it resolved now completely after three sublingual nitroglycerin.Yesterday,shefeltveryfatigued[sosy],butnoarm[sosy]pain[sosy],andtoday,shehadarm[sosy]pain[sosy][sosy]after[sosy]walking[sosy]and[sosy]againitresolvednowcompletelyafterthreesublingualnitroglycerin[orch,phsu][orch,phsu].(S1 (S (S (S (ADVP (RB Yesterday)) (, ,) (NP (PRP she)) (VP (VBD felt) (ADJP (RB very) (JJ fatigued)) (, ,) (CONJP (CC but) (RB no)) (NP (NN arm) (NN pain)))) (, ,) (CC and) (ADVP (RB today)) (, ,) (S (NP (PRP she)) (VP (VBD had) (NP (NN arm) (NN pain)) (PP (IN after) (NP (NN walking))))) (CC and) (S (ADVP (RB again)) (NP (PRP it)) (VP (VBN resolved) (ADVP (RB now) (RB completely)) (PP (IN after) (NP (CD three) (JJ sublingual) (NN nitroglycerin)))))) (. .)))This is her usual angina.Thisisherusual[sosy]angina[sosy].(S1 (S (S (NP (DT This)) (VP (VBZ is) (NP (PRP$ her) (JJ usual) (NN angina)))) (. .)))She is being admitted with unstable angina post stent.Sheisbeingadmittedwithunstable[dsyn]angina[dsyn]poststent.(S1 (S (S (NP (PRP She)) (VP (VBZ is) (VP (VBG being) (VP (VBN admitted) (PP (IN with) (NP (NP (JJ unstable) (NNS angina)) (PP (IN post) (NP (NN stent))))))))) (. .)))PAST MEDICAL HISTORY: Longstanding hypertension, CAD as above, hyperlipidemia, and overactive bladder.PASTMEDICALHISTORY:Longstandinghypertension[dsyn],CADasabove,hyperlipidemia[dsyn],andoveractive[dsyn]bladder[dsyn].(S1 (S (S (NP (JJ PAST) (JJ MEDICAL) (NN HISTORY)) (: :) (NP (NP (JJ Longstanding) (NN hypertension)) (, ,) (NP (NP (NN CAD)) (PP (IN as) (NP (JJ above)))) (, ,) (NP (NN hyperlipidemia)) (, ,) (CC and) (NP (JJ overactive) (NN bladder)))) (. .)))MEDICATIONS:MEDICATIONS:(S1 (S (NP (NP (NNS MEDICATIONS)) (: :))))1.1.(S1 (S (S (NP (CD 1))) (. .)))Detrol LA 2 mg once a day.Detrol[orch,phsu]LA[orch,phsu]2mgonceaday.(S1 (S (S (NP (NN Detrol) (NN LA) (CD 2) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))2.2.(S1 (S (NP (NP (CD 2)) (. .))))Prilosec for GERD 20 mg once a day.Prilosec[orch,phsu]forGERD[dsyn]20mgonceaday.(S1 (S (S (VP (VBN Prilosec) (PP (IN for) (NP (NP (NN GERD) (CD 20) (NN mg)) (PP (IN once) (NP (DT a) (NN day))))))) (. .)))3.3.(S1 (S (NP (NP (CD 3)) (. .))))Glucosamine 500/400 mg once a day for arthritis.Glucosamine500/400mgonceadayforarthritis[dsyn].(S1 (S (S (NP (NP (NN Glucosamine) (CD 500/400) (NN mg)) (PP (IN once) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (NN arthritis))))))) (. .)))4.4.(S1 (S (S (NP (CD 4))) (. .)))Multivitamin p.o.Multivitaminp.o.(S1 (S (S (NP (NN Multivitamin)) (VP (VBZ p.o))) (. .)))daily.daily.(S1 (S (S (ADJP (JJ daily))) (. .)))5.5.(S1 (S (NP (NP (CD 5)) (. .))))Nitroglycerin sublingual as available to her.Nitroglycerinsublingualasavailabletoher.(S1 (S (S (NP (NN Nitroglycerin)) (VP (JJ sublingual) (PP (IN as) (ADJP (JJ available) (PP (TO to) (NP (PRP$ her))))))) (. .)))6.6.(S1 (S (NP (NP (CD 6)) (. .))))Toprol XL 25 mg once a day which I started although she had been bradycardic, but she seems to be tolerating.Toprol[orch,phsu]XL25mgonceadaywhichIstartedalthoughshehadbeenbradycardic,butsheseemstobetolerating.(S1 (S (S (NP (NP (NN Toprol) (NN XL) (CD 25) (NN mg)) (PP (IN once) (NP (NP (DT a) (NN day)) (SBAR (WHNP (WDT which)) (S (NP (PRP I))))))) (VP (VBD started) (SBAR (IN although) (S (S (NP (PRP she)) (VP (VBD had) (VP (VBN been) (ADJP (JJ bradycardic))))) (, ,) (CC but) (S (NP (PRP she)) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (ADJP (VBG tolerating))))))))))) (. .)))7.7.(S1 (S (NP (NP (CD 7)) (. .))))Aspirin 325 mg once a day.Aspirin325mgonceaday.(S1 (S (S (NP (NN Aspirin) (CD 325) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))8.8.(S1 (S (NP (NP (CD 8)) (. .))))Plavix 75 mg once a day.Plavix[orch,phsu]75mgonceaday.(S1 (S (S (NP (NN Plavix) (CD 75) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))9.9.(S1 (S (NP (NP (CD 9)) (. .))))Diovan 160 mg once a day.Diovan[orch,phsu]160mgonceaday.(S1 (S (S (NP (NN Diovan) (CD 160) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))10.10.(S1 (S (NP (NP (CD 10)) (. .))))Claritin 10 mg once a day for allergic rhinitis.Claritin[orch,phsu]10mgonceadayforallergic[dsyn]rhinitis[dsyn].(S1 (S (S (NP (NP (NN Claritin) (CD 10) (NN mg)) (PP (IN once) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (JJ allergic) (NN rhinitis))))))) (. .)))11.11.(S1 (S (NP (NP (CD 11)) (. .))))Norvasc 5 mg once a day.Norvasc[orch,phsu]5mgonceaday.(S1 (S (S (NP (NN Norvasc) (CD 5) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))12.12.(S1 (S (NP (NP (CD 12)) (. .))))Lipitor 5 mg once a day.Lipitor[orch,phsu]5mgonceaday.(S1 (S (S (NP (NN Lipitor) (CD 5) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))13.13.(S1 (S (NP (NP (CD 13)) (. .))))Evista 60 mg once a day.Evista[orch,phsu]60mgonceaday.(S1 (S (S (NP (NN Evista) (CD 60) (NN mg)) (VP (ADVP (RB once)) (NP (DT a) (NN day)))) (. .)))ALLERGIES: ALLERGIES TO MEDICATIONS ARE NONE.ALLERGIES:ALLERGIESTOMEDICATIONSARENONE.(S1 (S (S (NP (NP (NNS ALLERGIES)) (: :) (NP (NP (NNS ALLERGIES)) (PP (TO TO) (NP (NNS MEDICATIONS))))) (VP (VBP ARE) (NP (NN NONE)))) (. .)))SHE DENIES ANY SHRIMP OR SEA FOOD ALLERGY.SHEDENIESANYSHRIMPORSEAFOODALLERGY.(S1 (S (S (NP (PRP SHE)) (VP (VBZ DENIES) (NP (DT ANY) (NN SHRIMP) (CC OR) (NN SEA) (NN FOOD) (NN ALLERGY)))) (. .)))FAMILY HISTORY: Her father died of an MI in his 50s and a brother had his first MI and bypass surgery at 54.FAMILYHISTORY[dsyn]:[dsyn]Her[dsyn]fatherdiedofanMIinhis50sandabrotherhadhisfirstMIandbypasssurgeryat54.(S1 (S (S (NP (NP (NN FAMILY) (NN HISTORY)) (: :) (NP (NP (PRP$ Her) (NN father)) (VP (VBD died) (PP (IN of) (NP (NP (DT an) (NN MI)) (PP (IN in) (NP (NN his) (NN 50s))))))) (CC and) (NP (DT a) (NN brother))) (VP (VBD had) (NP (NP (NN his) (JJ first) (NN MI)) (CC and) (NP (VB bypass) (NN surgery))) (PP (IN at) (NP (CD 54))))) (. .)))SOCIAL HISTORY: She does not smoke cigarettes, abuse alcohol, no use of illicit drugs.SOCIALHISTORY:Shedoesnotsmokecigarettes,abusealcohol[orch][orch,phsu],nouseofillicitdrugs.(S1 (S (NP (NP (JJ SOCIAL) (NN HISTORY)) (: :) (S (NP (PRP She)) (VP (VBZ does) (RB not) (NP (NP (NN smoke) (NNS cigarettes)) (, ,) (NP (NN abuse) (NN alcohol)) (, ,) (NP (NP (DT no) (NN use)) (PP (IN of) (NP (JJ illicit) (NNS drugs))))))) (. .))))She is divorced and lives alone and is a retired laboratory technician from Cornell Diagnostic Laboratory.SheisdivorcedandlivesaloneandisaretiredlaboratorytechnicianfromCornellDiagnosticLaboratory.(S1 (S (S (NP (PRP She)) (VP (VP (VBZ is) (NP (NP (NN divorced)) (CC and) (NP (NP (NNS lives)) (ADVP (RB alone))))) (CC and) (VP (VBZ is) (NP (NP (DT a) (JJ retired) (NN laboratory) (NN technician)) (PP (IN from) (NP (NN Cornell) (JJ Diagnostic) (NN Laboratory))))))) (. .)))REVIEW OF SYSTEMS: She denies a history of stroke, cancer, vomiting up blood, coughing up blood, bright red blood per rectum, bleeding stomach ulcers, renal calculi, cholelithiasis, asthma, emphysema, pneumonia, tuberculosis, home oxygen use or sleep apnea, although she has been told in the past that she snores and there was some question of apnea in 05/08.REVIEWOFSYSTEMS:Shedeniesahistoryofstroke[dsyn],cancer,vomiting[sosy]up[sosy]blood[sosy],[sosy]coughing[sosy]up[sosy]blood[sosy],brightredbloodperrectum,bleedingstomach[dsyn]ulcers[dsyn],renal[dsyn]calculi[dsyn],cholelithiasis[dsyn],asthma[dsyn],emphysema[dsyn],pneumonia[dsyn],tuberculosis[dsyn],homeoxygenuseorsleep[dsyn]apnea[dsyn],althoughshehasbeentoldinthepastthatshesnores[sosy]andtherewassomequestionofapneain05/08.(S1 (S (NP (NP (NN REVIEW)) (PP (IN OF) (NP (NNS SYSTEMS)))) (: :) (S (NP (PRP She)) (VP (VBZ denies) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NN stroke)) (, ,) (NP (NN cancer)) (, ,) (NP (NP (NN vomiting)) (PP (IN up) (NP (NN blood))))))) (, ,) (S (VP (VBG coughing) (PP (IN up) (NP (NP (NN blood)) (, ,) (NP (NP (JJ bright) (JJ red) (NN blood)) (PP (IN per) (NP (NN rectum)))) (, ,) (NP (JJ bleeding) (NN stomach) (NNS ulcers)) (, ,) (NP (JJ renal) (NN calculi)) (, ,) (NP (NN cholelithiasis)) (, ,) (NP (NN asthma)) (, ,) (NP (NN emphysema)) (, ,) (NP (NN pneumonia)) (, ,) (NP (NN tuberculosis)) (, ,) (NP (NN home) (NN oxygen) (NN use)) (CC or) (NP (NN sleep) (NN apnea)))))) (, ,) (SBAR (IN although) (S (NP (PRP she)) (VP (VBZ has) (VP (VBN been) (VP (VBN told) (PP (IN in) (NP (DT the) (JJ past))) (SBAR (IN that) (S (NP (NP (NP (PRP she)) (NNS snores)) (CC and) (NP (EX there))) (VP (VBD was) (NP (NP (DT some) (NN question)) (PP (IN of) (NP (NN apnea))) (PP (IN in) (NP (NN 05/08)))))))))))))) (. .)))No morning headaches or fatigue.Nomorning[sosy]headaches[sosy]orfatigue[sosy].(S1 (S (S (NP (DT No) (NN morning) (NNS headaches)) (VP (CC or) (VP (VBP fatigue)))) (. .)))No psychiatric diagnosis.Nopsychiatricdiagnosis.(S1 (S (S (NP (DT No) (JJ psychiatric) (NN diagnosis))) (. .)))No psoriasis, no lupus.Nopsoriasis[dsyn],nolupus[dsyn][dsyn][dsyn].(S1 (S (S (NP (NN No) (NN psoriasis)) (, ,) (NP (DT no) (NN lupus))) (. .)))Remainder of the review of systems is negative x14 systems except as described above.Remainderofthereviewofsystemsisnegativex14systemsexceptasdescribedabove.(S1 (S (S (NP (NP (NN Remainder)) (PP (IN of) (NP (NP (DT the) (NN review)) (PP (IN of) (NP (NNS systems)))))) (VP (VBZ is) (NP (JJ negative) (NN x14) (NNS systems)) (PP (IN except) (SBAR (IN as) (S (VP (VBN described) (ADVP (RB above)))))))) (. .)))PHYSICAL EXAMINATION:PHYSICALEXAMINATION:(S1 (S (NP (NP (JJ PHYSICAL) (NN EXAMINATION)) (: :))))GENERAL: She is a pleasant elderly woman, currently in no acute distress.GENERAL:Sheisapleasantelderlywoman,currentlyinnoacutedistress.(S1 (S (S (NP (JJ GENERAL)) (: :) (S (NP (PRP She)) (VP (VBZ is) (NP (DT a) (JJ pleasant) (JJ elderly) (NN woman)) (, ,) (ADVP (RB currently)) (PP (IN in) (NP (DT no) (JJ acute) (NN distress)))))) (. .)))VITAL SIGNS: Height 4 feet 11 inches, weight 128 pounds, temperature 97.2 degrees Fahrenheit, blood pressure 142/70, pulse 47, respiratory rate 16, and O2 saturation 100%VITALSIGNS:Height4feet11inches,weight128pounds,temperature97.2degreesFahrenheit,bloodpressure142/70,pulse47,respiratoryrate16,andO2saturation100%(S1 (S (NP (NP (JJ VITAL) (NNS SIGNS)) (: :) (NP (NP (NN Height) (CD 4) (NN feet) (CD 11)) (NNS inches)) (, ,) (NP (NN weight) (CD 128) (NNS pounds)) (, ,) (NP (NN temperature) (CD 97.2) (NNS degrees) (NN Fahrenheit)) (, ,) (NP (NP (NN blood) (NN pressure) (CD 142/70)) (, ,) (NP (NN pulse) (CD 47)) (, ,) (NP (NN respiratory) (NN rate) (CD 16)) (, ,) (CC and) (NP (CD O2) (NN saturation) (CD 100) (NN %))))))HEENT: Cranium is normocephalic and atraumatic.HEENT:Craniumisnormocephalicandatraumatic.(S1 (S (S (NP (NP (NN HEENT)) (: :) (NP (NN Cranium))) (VP (VBZ is) (ADJP (ADJP (JJ normocephalic)) (CC and) (ADJP (JJ atraumatic))))) (. .)))She has moist mucosal membranes.Shehasmoistmucosalmembranes.(S1 (S (S (NP (PRP She)) (VP (VBZ has) (NP (JJ moist) (JJ mucosal) (NNS membranes)))) (. .)))NECK: Veins are not distended.NECK:Veinsarenotdistended.(S1 (S (NP (NP (NN NECK)) (: :) (S (NP (NNS Veins)) (VP (VBP are) (RB not) (ADJP (JJ distended)))) (. .))))There are no carotid bruits.Therearenocarotidbruits.(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (DT no) (NN carotid) (NNS bruits)))) (. .)))LUNGS: Clear to auscultation and percussion without wheezes.LUNGS:Cleartoauscultationandpercussionwithoutwheezes[sosy].(S1 (S (NP (NP (NNS LUNGS)) (: :) (NP (NP (JJ Clear)) (PP (TO to) (NP (NP (NP (NN auscultation)) (CC and) (NP (NN percussion))) (PP (IN without) (NP (NNS wheezes)))))) (. .))))HEART: S1 and S2, regular rate.HEART:S1andS2,regularrate.(S1 (S (S (NP (NN HEART)) (: :) (NP (NP (NP (NN S1)) (CC and) (NP (NN S2))) (, ,) (NP (JJ regular) (NN rate)))) (. .)))No significant murmurs, rubs or gallops.Nosignificantmurmurs,rubsorgallops.(S1 (S (S (NP (NP (DT No) (JJ significant) (NNS murmurs)) (, ,) (NP (NP (NNS rubs)) (CC or) (NP (NNS gallops))))) (. .)))PMI nondisplaced.PMInondisplaced.(S1 (S (S (NP (NN PMI)) (VP (VBD nondisplaced))) (. .)))ABDOMEN: Soft and nondistended.ABDOMEN:Soft[dsyn]andnondistended.(S1 (S (NP (NP (NN ABDOMEN)) (: :) (NP (NP (ADJP (JJ Soft))) (CC and) (NP (ADJP (JJ nondistended)))) (. .))))Bowel sounds present.Bowelsoundspresent.(S1 (S (S (NP (NN Bowel) (NNS sounds)) (VP (VBP present))) (. .)))EXTREMITIES: Without significant clubbing, cyanosis or edema.EXTREMITIES:Withoutsignificantclubbing[sosy],cyanosis[sosy]oredema.(S1 (S (S (NP (NP (NNS EXTREMITIES) (: :)) (PP (IN Without) (NP (NP (JJ significant) (NN clubbing)) (, ,) (NP (NN cyanosis)) (CC or) (NP (NN edema)))))) (. .)))Pulses grossly intact.Pulsesgrosslyintact.(S1 (S (S (NP (NNS Pulses)) (VP (ADVP (RB grossly)) (JJ intact))) (. .)))Bilateral groins are inspected, status post as the right femoral artery was used for access for the diagnostic cardiac catheterization here and left femoral artery used for PCI and there is no evidence of hematoma or bruit and intact distal pulses.Bilateralgroinsareinspected,statuspostastherightfemoralarterywasusedforaccessforthediagnosticcardiaccatheterizationhereandleftfemoralarteryusedforPCIandthereisnoevidenceofhematomaorbruitandintactdistalpulses.(S1 (S (S (NP (JJ Bilateral) (NNS groins)) (VP (VBP are) (VP (VBN inspected) (, ,) (S (NP (NN status)) (ADJP (JJ post) (PP (IN as) (NP (NP (NP (NP (DT the) (JJ right) (JJ femoral) (NN artery)) (VP (VBD was) (VP (VBN used) (PP (IN for) (NP (NN access))) (PP (IN for) (NP (DT the) (JJ diagnostic) (JJ cardiac) (NN catheterization))) (ADVP (RB here))))) (CC and) (NP (JJ left) (JJ femoral) (NN artery))) (VP (VBN used) (PP (IN for) (NP (NN PCI))))))))))) (CC and) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NP (NN hematoma)) (CC or) (NP (NN bruit))) (CC and) (NP (JJ intact) (JJ distal) (NNS pulses))))))) (. .)))LABORATORY DATA: EKG reviewed which shows sinus bradycardia at the rate of 51 beats per minute and no acute disease.LABORATORYDATA:EKGreviewedwhichshowssinusbradycardiaattherateof51beatsperminuteandnoacute[dsyn]disease[dsyn].(S1 (S (NP (NP (NN LABORATORY) (NNS DATA)) (: :) (S (NP (NN EKG)) (VP (VBN reviewed) (SBAR (WHNP (WDT which)) (S (VP (VBZ shows) (NP (NN sinus) (NN bradycardia)) (PP (IN at) (NP (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (CD 51) (NNS beats))) (PP (IN per) (NP (NN minute)))) (CC and) (NP (DT no) (JJ acute) (NN disease))))))))) (. .))))Sodium 136, potassium 3.8, chloride 105, and bicarbonate 27.Sodium136,potassium3.8,chloride105,andbicarbonate[orch,phsu]27.(S1 (S (S (NP (NP (NN Sodium) (CD 136)) (, ,) (NP (NN potassium) (CD 3.8)) (, ,) (NP (NN chloride) (CD 105)) (, ,) (CC and) (NP (NN bicarbonate) (CD 27)))) (. .)))BUN 16 and creatinine 0.9.BUN16andcreatinine0.9.(S1 (S (S (NP (NP (NN BUN) (CD 16)) (CC and) (NP (NN creatinine) (CD 0.9)))) (. .)))Glucose 110.Glucose110.(S1 (S (S (NP (NN Glucose)) (NP (CD 110))) (. .)))Magnesium 2.5.Magnesium2.5.(S1 (S (S (NP (NN Magnesium) (CD 2.5))) (. .)))ALT 107 and AST 65 and these were normal on 08/15/08.ALT107andAST65andthesewerenormalon08/15/08.(S1 (S (S (S (NP (NP (NN ALT) (CD 107)) (CC and) (NP (NN AST) (CD 65)))) (CC and) (S (NP (DT these)) (VP (VBD were) (ADJP (JJ normal)) (PP (IN on) (NP (NN 08/15/08)))))) (. .)))INR is 0.89, PTT 20.9, white blood cell count 8.2, hematocrit 31 and it was 35 on 08/15/08, and platelet count 257,000.INRis0.89,PTT20.9,whitebloodcellcount8.2,hematocrit31anditwas35on08/15/08,andplateletcount257,000.(S1 (S (S (S (NP (NN INR)) (VP (VBZ is) (NP (NP (CD 0.89)) (, ,) (NP (NP (NN PTT) (CD 20.9)) (, ,) (NP (JJ white) (NN blood) (NN cell) (NN count) (CD 8.2)) (, ,) (NP (NN hematocrit) (CD 31)))))) (CC and) (S (NP (PRP it)) (VP (VBD was) (NP (CD 35)) (PP (IN on) (NP (NP (NN 08/15/08)) (, ,) (CC and) (NP (NN platelet) (NN count) (CD 257,000))))))) (. .)))IMPRESSION AND PLAN: The patient is a 68 year old woman with exertional angina, characterized with arm pain, who underwent recent left anterior descending percutaneous coronary intervention and has now had recurrence of that arm pain post stenting to the left anterior descending artery and it may be that she is continuing to have collateral insufficiency of the right coronary artery.IMPRESSIONANDPLAN[dsyn]:Thepatientisa68yearoldwomanwithexertional[sosy]angina[sosy],characterizedwitharm[sosy]pain[sosy],whounderwentrecentleftanteriordescendingpercutaneouscoronaryinterventionandhasnowhadrecurrenceofthatarm[sosy]pain[sosy]poststentingtotheleftanteriordescendingarteryanditmaybethatsheiscontinuingtohavecollateralinsufficiency[dsyn]of[dsyn]the[dsyn]rightcoronary[dsyn]artery[dsyn].[dsyn](S1 (S (NP (NP (NP (NN IMPRESSION)) (CC AND) (NP (NN PLAN))) (: :) (S (S (NP (DT The) (NN patient)) (VP (VP (VBZ is) (NP (NP (DT a) (ADJP (CD 68) (NN year) (JJ old)) (NN woman)) (PP (IN with) (NP (JJ exertional) (NNS angina))) (, ,) (VP (VBN characterized) (PP (IN with) (NP (NN arm) (NN pain)))) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (JJ recent) (JJ left) (JJ anterior) (NN descending) (NN percutaneous) (JJ coronary) (NN intervention))))))) (CC and) (VP (VBZ has) (ADVP (RB now)) (VP (VBD had) (NP (NP (NN recurrence)) (PP (IN of) (NP (DT that) (NN arm) (NN pain)))) (PP (IN post) (S (VP (VBG stenting) (PP (TO to) (NP (DT the) (JJ left) (JJ anterior) (NN descending) (NN artery)))))))))) (CC and) (S (NP (PRP it)) (VP (MD may) (VP (VB be) (SBAR (IN that) (S (NP (PRP she)) (VP (VBZ is) (VP (VBG continuing) (S (VP (TO to) (VP (VBP have) (NP (NP (JJ collateral) (NN insufficiency)) (PP (IN of) (NP (DT the) (JJ right) (JJ coronary) (NN artery))))))))))))))) (. .))))In any case, given this unstable presentation requiring three sublingual nitroglycerin before she was even pain free, I am going to admit her to the hospital and there is currently no evidence requiring acute reperfusion therapy.Inanycase,giventhisunstablepresentationrequiringthreesublingualnitroglycerin[orch,phsu][orch,phsu]beforeshewasevenpainfree,Iamgoingtoadmithertothehospitalandthereiscurrentlynoevidencerequiringacutereperfusiontherapy.(S1 (S (S (PP (IN In) (NP (DT any) (NN case))) (, ,) (S (PP (IN given) (NP (NP (DT this) (JJ unstable) (NN presentation)) (VP (VBG requiring) (NP (NP (CD three) (JJ sublingual) (NN nitroglycerin)) (SBAR (IN before) (S (NP (PRP she)) (VP (VBD was) (ADVP (RB even)) (ADJP (NN pain) (JJ free))))))))) (, ,) (NP (CD I) (NN am)) (VP (VBG going) (S (VP (TO to) (VP (VB admit) (NP (PRP$ her)) (PP (TO to) (NP (DT the) (NN hospital)))))))) (CC and) (NP (EX there)) (VP (VBZ is) (ADVP (RB currently)) (NP (NP (DT no) (NN evidence)) (VP (VBG requiring) (NP (JJ acute) (NN reperfusion) (NN therapy)))))) (. .)))We will continue her beta blocker and I cannot increase the dose because she is bradycardic already.WewillcontinueherbetablockerandIcannotincreasethedosebecausesheisbradycardicalready.(S1 (S (S (NP (PRP We)) (VP (MD will) (VP (VBP continue) (S (NP (NP (PRP$ her) (NN beta) (NN blocker)) (CC and) (NP (CD I))) (VP (MD can) (RB not) (VP (VB increase) (NP (DT the) (NN dose) (SBAR (IN because) (S (NP (PRP she)) (VP (VBZ is) (ADJP (JJ bradycardic)))))) (ADVP (RB already)))))))) (. .)))Aspirin, Plavix, valsartan, Lipitor, and Norvasc.Aspirin[orch,phsu],Plavix[orch,phsu],valsartan[orch,phsu],Lipitor[orch,phsu],andNorvasc[orch,phsu].(S1 (S (NP (NP (NP (NN Aspirin)) (, ,) (NP (NN Plavix)) (, ,) (NP (NN valsartan)) (, ,) (NP (NN Lipitor)) (, ,) (CC and) (NP (NN Norvasc))) (. .))))I am going to add Imdur and watch headaches as she apparently had some on nitro paste before, and we will rule out MI, although there is a little suspicion.IamgoingtoaddImdur[orch,phsu]andwatchheadaches[sosy]assheapparentlyhadsomeonnitropastebefore,andwewillruleoutMI,althoughthereisalittlesuspicion.(S1 (S (S (S (NP (CD I) (NN am)) (VP (VBG going) (S (VP (TO to) (VP (VBP add) (NP (ADJP (ADJP (JJ Imdur)) (CC and) (ADJP (JJ watch))) (NNS headaches) (SBAR (IN as) (S (NP (PRP she)) (ADVP (RB apparently)) (VP (VBD had) (NP (DT some)) (PP (IN on) (NP (NP (NN nitro) (NN paste)) (PP (IN before))))))))))))) (, ,) (CC and) (S (NP (PRP we)) (VP (MD will) (VP (NN rule) (PP (IN out) (NP (NN MI))) (, ,) (SBAR (IN although) (S (NP (EX there)) (VP (VBZ is) (NP (DT a) (JJ little) (NN suspicion))))))))) (. .)))I suppose it is possible that she has non cardiac arm pain, but that seems less likely as it has been nitrate responsive and seems exertionally related and the other possibility may be that we end up needing to put in a pacemaker, so we can maximize beta blocker use for anti anginal effect.Isupposeitispossiblethatshehasnoncardiac[sosy]arm[sosy][sosy]pain[sosy][sosy],[sosy]butthatseemslesslikelyasithasbeennitrateresponsiveandseemsexertionallyrelatedandtheotherpossibilitymaybethatweendupneedingtoputinapacemaker,sowecanmaximizebetablockeruseforantianginaleffect.(S1 (S (S (NP (PRP I)) (VP (VBP suppose) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (SBAR (IN that) (S (NP (PRP she)) (VP (VBZ has) (NP (JJ non) (JJ cardiac) (NN arm) (NN pain))))) (, ,) (CC but) (SBAR (IN that) (S (VP (VBZ seems) (ADJP (RBR less) (JJ likely)) (SBAR (IN as) (S (S (NP (PRP it)) (VP (VP (VBZ has) (VP (VBN been) (ADJP (NN nitrate) (JJ responsive)))) (CC and) (VP (VBZ seems) (ADJP (RB exertionally) (JJ related))))) (CC and) (S (NP (DT the) (JJ other) (NN possibility)) (VP (MD may) (VP (VB be) (SBAR (IN that) (S (NP (PRP we)) (VP (NN end) (PP (IN up) (S (VP (VBG needing) (S (VP (TO to) (VP (VBP put) (PP (IN in) (NP (NP (DT a) (NN pacemaker)) (, ,) (SBAR (IN so) (S (NP (PRP we)) (VP (MD can) (VP (VB maximize) (NP (NP (NN beta) (NN blocker) (NN use)) (PP (IN for) (NP (JJ anti) (JJ anginal) (NN effect)))))))))))))))))))))))))))))))) (. .)))My concern is that there is persistent right coronary artery ischemia, not helped by left anterior descending percutaneous coronary intervention, which was severely stenotic and she does have normal LV function.Myconcernisthatthereispersistentrightcoronaryarteryischemia[dsyn],nothelpedbyleftanteriordescendingpercutaneouscoronaryintervention,whichwasseverelystenoticandshedoeshavenormalLVfunction.(S1 (S (S (NP (NN My) (NN concern)) (VP (VBZ is) (SBAR (IN that) (S (S (NP (EX there)) (VP (VBZ is) (NP (NP (NP (JJ persistent) (JJ right) (JJ coronary) (NN artery)) (NN ischemia)) (, ,) (VP (ADVP (RB not)) (VBD helped) (PP (IN by) (NP (JJ left) (JJ anterior) (NN descending) (NP (JJ percutaneous) (JJ coronary) (NN intervention))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADVP (RB severely)) (ADJP (JJ stenotic)))))))) (CC and) (S (NP (PRP she)) (VP (VBZ does) (VP (VB have) (NP (JJ normal) (NN LV) (NN function))))))))) (. .)))She will continue the glucosamine for her arthritis, Claritin for allergies, and Detrol LA for urinary incontinence.Shewillcontinuetheglucosamineforherarthritis[dsyn],Claritin[orch,phsu]forallergies,andDetrol[orch,phsu]LA[orch,phsu]forurinaryincontinence.(S1 (S (S (NP (PRP She)) (VP (MD will) (VP (VBP continue) (NP (NP (NP (DT the) (NN glucosamine)) (PP (IN for) (NP (PRP$ her) (NN arthritis)))) (, ,) (NP (NP (NN Claritin)) (PP (IN for) (NP (NNS allergies)))) (, ,) (CC and) (NP (NN Detrol) (NN LA))) (PP (IN for) (NP (JJ urinary) (NN incontinence)))))) (. .)))Total patient care time in the emergency department 75 minutes.Totalpatientcaretimeintheemergencydepartment75minutes.(S1 (S (S (NP (NP (JJ Total) (NN patient) (NN care) (NN time)) (PP (IN in) (NP (DT the) (NN emergency) (NN department)))) (NP (CD 75) (NNS minutes))) (. .)))All this was discussed in detail with the patient and her daughter who expressed understanding and agreement.Allthiswasdiscussedindetailwiththepatientandherdaughterwhoexpressedunderstandingandagreement.(S1 (S (S (NP (PDT All) (DT this)) (VP (VBD was) (VP (VBN discussed) (PP (IN in) (NP (NN detail))) (PP (IN with) (NP (NP (DT the) (NP (NN patient)) (CC and) (NP (PRP$ her) (NN daughter))) (SBAR (WHNP (WP who)) (S (VP (VBD expressed) (NP (NP (NN understanding)) (CC and) (NP (NN agreement))))))))))) (. .)))The patient desires full resuscitation status.Thepatientdesiresfullresuscitationstatus.(S1 (S (S (NP (DT The) (NN patient) (NNS desires)) (NP (JJ full) (NN resuscitation) (NN status))) (. .))) \ No newline at end of file diff --git a/Postprocessing/Intermediate4/gen043_Intermediate.xml b/Postprocessing/Intermediate4/gen043_Intermediate.xml index 49d46c3..ac7d27b 100755 --- a/Postprocessing/Intermediate4/gen043_Intermediate.xml +++ b/Postprocessing/Intermediate4/gen043_Intermediate.xml @@ -1 +1 @@ -FDA contacted a female patient of age 32 and weight 135lbs for follow-up after she contacted Drug Information to disclose information regarding an adverse event related to domperidone.FDAcontactedafemalepatientofage32andweight135lbsforfollow-upaftershecontactedDrugInformationtodiscloseinformationregardinganadverseeventrelatedtodomperidone[orch,phsu][orch,phsu][orch,phsu][orch,phsu].(S1 (S (S (NP (NN FDA)) (VP (VBD contacted) (NP (NP (NP (DT a) (JJ female) (NN patient)) (PP (IN of) (NP (NN age) (CD 32)))) (CC and) (NP (NP (NN weight) (NNS 135lbs)) (PP (IN for) (NP (NN follow-up))))) (SBAR (IN after) (S (NP (PRP she)) (VP (VBD contacted) (NP (NN Drug) (NN Information)) (S (VP (TO to) (VP (VBP disclose) (NP (NP (NN information)) (VP (VBG regarding) (NP (NP (DT an) (JJ adverse) (NN event)) (ADJP (JJ related) (PP (TO to) (NP (NN domperidone))))))))))))))) (. .)))Domperidone 30mg 3-4 times per day was prescribed in August 2014 for lactation.Domperidone[orch,phsu][orch,phsu][orch,phsu][orch,phsu]30mg3-4timesperdaywasprescribedinAugust2014forlactation.(S1 (S (S (NP (NP (NN Domperidone)) (PP (IN 30mg) (NP (NP (JJ 3-4) (NNS times)) (PP (IN per) (NP (NN day)))))) (VP (VBD was) (VP (VBN prescribed) (PP (IN in) (NP (NP (NNP August) (CD 2014)) (PP (IN for) (NP (NN lactation)))))))) (. .)))About 3 weeks-1 month later (mid-January 2015), patient developed palpations ("butterflies in my chest") and felt "very tired."About3weeks-1monthlater(mid-January2015),patientdevelopedpalpations("butterfliesinmychest")andfelt"verytired.[sosy][sosy][sosy][sosy]"(S1 (S (S (ADJP (ADJP (NP (QP (RB About) (CD 3)) (NN weeks-1) (NN month)) (JJR later)) (PRN (-LRB- -LRB-) (ADJP (JJ mid-January) (NP (CD 2015))) (-RRB- -RRB-)))) (, ,) (S (NP (NN patient)) (VP (VP (VBD developed) (NP (NP (NNS palpations)) (PRN (-LRB- -LRB-) (NP (NP (JJ ") (NNS butterflies)) (PP (IN in) (NP (NN my) (NN chest) (NNS ")))) (-RRB- -RRB-)))) (CC and) (VP (VBD felt) (NP (CD ") (ADJP (RB very) (VBN tired.)) (NNS ")))))))She didn't think much of symptoms and attributed them to being tired and having a new baby, so she continued domperidone and tried to get more sleep.Shedidn'tthinkmuchofsymptomsandattributedthemtobeingtiredandhavinganewbaby,soshecontinueddomperidoneandtriedtogetmoresleep.(S1 (S (S (NP (PRP She)) (ADVP (RB didn't)) (VP (VBP think) (ADVP (RB much) (PP (IN of) (NP (NNS symptoms)))) (VP (CC and) (VP (VBN attributed) (NP (PRP them)) (S (VP (TO to) (VP (VP (VBG being) (NP (JJ tired))) (CC and) (VP (VBG having) (NP (DT a) (JJ new) (NN baby)))))) (, ,) (SBAR (IN so) (S (NP (PRP she)) (VP (VBD continued) (NP (NN domperidone)))))) (CC and) (VP (VBN tried) (S (VP (TO to) (VP (VB get) (ADJP (RBR more) (JJ sleep))))))))) (. .)))Symptoms of malaise, palpitation, "chest pain", syncope-like feelings continued, so patient decided to research domperidone online.Symptomsofmalaise,palpitation,"chestpain",syncope-likefeelingscontinued,sopatientdecidedtoresearchdomperidoneonline.(S1 (S (S (S (NP (NP (NNS Symptoms)) (PP (IN of) (NP (NP (NN malaise)) (, ,) (NP (NN palpitation)) (, ,) (NP (NN ") (NN chest) (NN pain) (CD ")) (, ,) (NP (JJ syncope-like) (NNS feelings))))) (VP (VBD continued))) (, ,) (IN so) (S (NP (NN patient)) (VP (VBD decided) (PP (TO to) (NP (NN research) (NN domperidone) (NN online)))))) (. .)))After finding out that QT prolongation and sudden death are possibly associated with domperidone (and that the symptoms she was having could be the result of QT prolongation), and that it is not approved in the US, she stopped taking the medication and contacted her OB/GYN office.AfterfindingoutthatQTprolongationandsuddendeatharepossiblyassociatedwithdomperidone(andthatthesymptomsshewashavingcouldbetheresultofQTprolongation),andthatitisnotapprovedintheUS,shestoppedtakingthemedicationandcontactedherOB/GYNoffice.(S1 (S (S (PP (IN After) (S (VP (VBG finding) (PRT (RP out)) (SBAR (SBAR (IN that) (S (NP (NP (NN QT) (NN prolongation)) (CC and) (NP (NN sudden) (NN death))) (VP (VBP are) (ADVP (RB possibly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN domperidone)) (PRN (-LRB- -LRB-) (CC and) (PP (IN that) (NP (NP (DT the) (NNS symptoms)) (S (NP (PRP she)) (VP (VBD was) (VP (VBG having) (VP (MD could) (VP (VB be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NN QT) (NN prolongation))))))))))) (-RRB- -RRB-)))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ approved) (PP (IN in) (NP (DT the) (NP (PRP US)))))))))))) (, ,) (NP (PRP she)) (VP (VP (VBD stopped) (VP (VBG taking) (NP (DT the) (NN medication)))) (CC and) (VP (VBD contacted) (NP (PRP$ her) (NN OB/GYN) (NN office))))) (. .)))The office told her that she was incorrect and that domperidone is allowed to be prescribed in the US and that lactation was just an off-label use.TheofficetoldherthatshewasincorrectandthatdomperidoneisallowedtobeprescribedintheUSandthatlactationwasjustanoff-labeluse.(S1 (S (S (NP (DT The) (NN office)) (VP (VBN told) (NP (PRP$ her)) (SBAR (IN that) (S (NP (PRP she)) (VP (VBD was) (NP (NN incorrect) (SBAR (CC and) (SBAR (IN that) (S (NP (NN domperidone)) (VP (VBZ is) (VP (VBN allowed) (S (VP (TO to) (VP (VB be) (VP (VBN prescribed) (PP (IN in) (NP (DT the) (NP (PRP US)))))))))))) (CC and) (SBAR (IN that) (S (NP (NN lactation)) (VP (VBD was) (ADVP (RB just)) (NP (DT an) (JJ off-label) (NN use)))))))))))) (. .)))Symptoms resolved after domperidone was stopped. Symptomsresolvedafterdomperidonewasstopped.(S1 (S (S (NP (NP (NNS Symptoms)) (VP (VBN resolved) (PP (IN after) (NP (NN domperidone))))) (VP (VBD was) (VP (VBN stopped)))) (. .))) \ No newline at end of file +FDA contacted a female patient of age 32 and weight 135lbs for follow up after she contacted Drug Information to disclose information regarding an adverse event related to domperidone.FDAcontactedafemalepatientofage32andweight135lbsforfollowupaftershecontactedDrugInformationtodiscloseinformationregardinganadverseeventrelatedtodomperidone[orch,phsu].(S1 (S (NP (NN FDA)) (VP (VBD contacted) (NP (NP (NP (DT a) (JJ female) (NN patient)) (PP (IN of) (NP (NN age) (CD 32)))) (CC and) (NP (NP (NN weight) (NNS 135lbs)) (PP (IN for) (S (VP (VBP follow) (ADVP (RB up)) (SBAR (IN after) (S (NP (PRP she)) (VP (VBD contacted) (NP (NN Drug) (NN Information)) (S (VP (TO to) (VP (VBP disclose) (NP (NP (NN information)) (VP (VBG regarding) (NP (NP (DT an) (JJ adverse) (NN event)) (ADJP (JJ related) (PP (TO to) (NP (NN domperidone))))))))))))))))))) (. .)))Domperidone 30mg 3 4 times per day was prescribed in August 2014 for lactation.Domperidone[orch,phsu]30mg34timesperdaywasprescribedinAugust2014forlactation.(S1 (S (S (NP (NP (NN Domperidone) (NN 30mg) (CD 3)) (NP (NP (CD 4) (NNS times)) (PP (IN per) (NP (NN day))))) (VP (VBD was) (VP (VBN prescribed) (PP (IN in) (NP (NP (NNP August) (CD 2014)) (PP (IN for) (NP (NN lactation)))))))) (. .)))About 3 weeks 1 month later (mid January 2015), patient developed palpations ("butterflies in my chest") and felt "very tired."About3weeks1monthlater(midJanuary2015),patientdevelopedpalpations(``butterfliesinmychest'')andfelt``verytired.''(S1 (S (S (PP (IN About) (NP (NP (NP (CD 3) (NNS weeks)) (ADVP (NP (CD 1) (NN month)) (RB later))) (PRN (-LRB- -LRB-) (NP (CD mid) (NNP January) (CD 2015)) (-RRB- -RRB-)))) (, ,) (NP (NN patient)) (VP (VP (VBD developed) (NP (NP (NNS palpations)) (PRN (-LRB- -LRB-) (NP (NP (`` ``) (NNS butterflies)) (PP (IN in) (NP (NN my) (NN chest) (NNS '')))) (-RRB- -RRB-)))) (CC and) (VP (VBD felt) (ADJP (`` ``) (RB very) (JJ tired)))) (. .)) (NP (NN ''))))She didn't think much of symptoms and attributed them to being tired and having a new baby, so she continued domperidone and tried to get more sleep.Shedidn'tthinkmuchofsymptomsandattributedthemtobeingtiredandhavinganewbaby,soshecontinueddomperidoneandtriedtogetmoresleep.(S1 (S (S (NP (PRP She)) (VP (VP (VBD did) (RB n't) (VP (VBP think) (ADVP (RB much)) (PP (IN of) (NP (NNS symptoms))))) (CC and) (VP (VBN attributed) (NP (PRP them)) (S (VP (TO to) (VP (VP (VBG being) (NP (JJ tired))) (CC and) (VP (VBG having) (NP (DT a) (JJ new) (NN baby))))))))) (, ,) (IN so) (S (NP (PRP she)) (VP (VP (VBD continued) (NP (NN domperidone))) (CC and) (VP (VBD tried) (S (VP (TO to) (VP (VB get) (ADVP (RBR more) (RB sleep)))))))) (. .)))Symptoms of malaise, palpitation, "chest pain", syncope like feelings continued, so patient decided to research domperidone online.Symptomsofmalaise,palpitation,``chestpain'',syncopelikefeelingscontinued,sopatientdecidedtoresearchdomperidoneonline.(S1 (S (S (NP (NP (NNS Symptoms)) (PP (IN of) (NP (NP (NN malaise)) (, ,) (NP (NN palpitation)) (, ,) (NP (`` ``) (NN chest) (NN pain) (NNS '')) (, ,) (NP (NN syncope)))) (PP (IN like) (NP (NNS feelings)))) (VP (VBD continued) (, ,) (SBAR (IN so) (S (NP (NN patient)) (VP (VBD decided) (PP (TO to) (NP (NN research) (NN domperidone) (NN online)))))))) (. .)))After finding out that QT prolongation and sudden death are possibly associated with domperidone (and that the symptoms she was having could be the result of QT prolongation), and that it is not approved in the US, she stopped taking the medication and contacted her OB/GYN office.AfterfindingoutthatQTprolongationandsuddendeatharepossiblyassociatedwithdomperidone(andthatthesymptomsshewashavingcouldbetheresultofQTprolongation),andthatitisnotapprovedintheUS,shestoppedtakingthemedicationandcontactedherOB/GYNoffice.(S1 (S (S (PP (IN After) (S (VP (VBG finding) (PRT (RP out)) (SBAR (SBAR (IN that) (S (NP (NP (NN QT) (NN prolongation)) (CC and) (NP (NN sudden) (NN death))) (VP (VBP are) (ADVP (RB possibly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN domperidone)) (PRN (-LRB- -LRB-) (CC and) (PP (IN that) (NP (NP (DT the) (NNS symptoms)) (S (NP (PRP she)) (VP (VBD was) (VP (VBG having) (VP (MD could) (VP (VB be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NN QT) (NN prolongation))))))))))) (-RRB- -RRB-)))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ approved) (PP (IN in) (NP (DT the) (NP (PRP US)))))))))))) (, ,) (NP (PRP she)) (VP (VP (VBD stopped) (VP (VBG taking) (NP (DT the) (NN medication)))) (CC and) (VP (VBD contacted) (NP (PRP$ her) (NN OB/GYN) (NN office))))) (. .)))The office told her that she was incorrect and that domperidone is allowed to be prescribed in the US and that lactation was just an off label use.TheofficetoldherthatshewasincorrectandthatdomperidoneisallowedtobeprescribedintheUSandthatlactationwasjustanofflabeluse.(S1 (S (S (NP (DT The) (NN office)) (VP (VBN told) (NP (PRP$ her)) (SBAR (IN that) (S (NP (PRP she)) (VP (VBD was) (ADJP (JJ incorrect)) (SBAR (CC and) (SBAR (IN that) (S (NP (NN domperidone)) (VP (VBZ is) (VP (VBN allowed) (S (VP (TO to) (VP (VB be) (VP (VBN prescribed) (PP (IN in) (NP (DT the) (NP (PRP US)))))))))))) (CC and) (SBAR (IN that) (S (NP (NN lactation)) (VP (VBD was) (ADVP (RB just) (DT an) (RP off)) (VP (VB label) (NP (NN use)))))))))))) (. .)))Symptoms resolved after domperidone was stopped. Symptomsresolvedafterdomperidonewasstopped.(S1 (S (S (NP (NP (NNS Symptoms)) (VP (VBN resolved) (PP (IN after) (NP (NN domperidone))))) (VP (VBD was) (VP (VBN stopped)))) (. .))) \ No newline at end of file diff --git a/Postprocessing/Intermediate4/gen046_Intermediate.xml b/Postprocessing/Intermediate4/gen046_Intermediate.xml index 23d51e9..a9144f2 100755 --- a/Postprocessing/Intermediate4/gen046_Intermediate.xml +++ b/Postprocessing/Intermediate4/gen046_Intermediate.xml @@ -1 +1 @@ -A spontaneous report was received from a Health canada via Health professional concerning a Female patient.AspontaneousreportwasreceivedfromaHealthcanadaviaHealthprofessionalconcerningaFemalepatient.The patient was of 34 years old and weighted 130.2 pounds as of 2 14 2013.Thepatientwasof34yearsoldandweighted130.2poundsasof2142013.Concomitant medications included paracetamol and ramipril.Concomitantmedicationsincludedparacetamolandramipril.Patients relevant history and concurrent disease were not available.Patientsrelevanthistoryandconcurrentdiseasewerenotavailable.It was reported that a patient had arthritis (preferred term: arthritis) and her condition aggravated (preferred term: condition aggravated).Itwasreportedthatapatienthadarthritis(preferredterm:arthritis)andherconditionaggravated(preferredterm:conditionaggravated).Patient also had coronary artery occlusion (preferred term: coronary artery occlusion).Action taken with all suspect drugs were unknown.The outcome of the event of arthritis, condition aggravated and coronary artery occlusion were unknown.The reporter has assessed the events of arthritis, condition aggravated and coronary artery occlusion to be serious with seriousness criteria of important medical event.Patientalsohadcoronaryarteryocclusion(preferredterm:coronaryarteryocclusion).Actiontakenwithallsuspectdrugswereunknown.Theoutcomeoftheeventofarthritis,conditionaggravatedandcoronaryarteryocclusionwereunknown.Thereporterhasassessedtheeventsofarthritis,conditionaggravatedandcoronaryarteryocclusiontobeseriouswithseriousnesscriteriaofimportantmedicalevent. \ No newline at end of file +A spontaneous report was received from a Health canada via Health professional concerning a Female patient.AspontaneousreportwasreceivedfromaHealthcanadaviaHealthprofessionalconcerningaFemalepatient.(S1 (S (S (NP (DT A) (JJ spontaneous) (NN report)) (VP (VBD was) (VP (VBN received) (PP (IN from) (NP (NP (DT a) (NN Health) (NN canada) (IN via) (NN Health) (NN professional)) (VP (VBG concerning) (NP (DT a) (JJ Female) (NN patient)))))))) (. .)))The patient was of 34 years old and weighted 130.2 pounds as of 2 14 2013.Thepatientwas[dsyn]of34yearsoldandweighted130.2poundsasof2142013.(S1 (S (S (NP (DT The) (NN patient)) (VP (VP (VBD was) (ADJP (NP (QP (IN of) (CD 34)) (NNS years)) (JJ old))) (CC and) (VP (VBD weighted) (NP (CD 130.2) (NNS pounds)) (PP (IN as) (NP (QP (IN of) (CD 2) (CD 14)) (NN 2013)))))) (. .)))Concomitant medications included paracetamol and ramipril.Concomitantmedications[phsu]includedparacetamol[orch,phsu]andramipril[orch,phsu].(S1 (S (S (NP (JJ Concomitant) (NNS medications)) (VP (VBD included) (NP (NP (NN paracetamol)) (CC and) (NP (NN ramipril))))) (. .)))Patients relevant history and concurrent disease were not available.Patientsrelevanthistoryandconcurrentdisease[dsyn]werenotavailable.(S1 (S (S (NP (NNS Patients) (NP (NP (JJ relevant) (NN history)) (CC and) (NP (JJ concurrent) (NN disease)))) (VP (VBD were) (RB not) (ADJP (JJ available)))) (. .)))It was reported that a patient had arthritis (preferred term: arthritis) and her condition aggravated (preferred term: condition aggravated).Itwasreportedthatapatienthadarthritis[dsyn](preferredterm:arthritis[dsyn])andhercondition[dsyn]aggravated(preferredterm:condition[dsyn]aggravated).(S1 (S (S (NP (PRP It)) (VP (VBD was) (VP (VBN reported) (SBAR (IN that) (S (S (NP (DT a) (NN patient)) (VP (VBD had) (NP (NN arthritis)) (PRN (-LRB- -LRB-) (NP (JJ preferred) (NN term) (: :) (NN arthritis)) (-RRB- -RRB-)))) (CC and) (S (NP (PRP$ her) (NN condition)) (VP (VBN aggravated) (PRN (-LRB- -LRB-) (NP (NP (JJ preferred) (NN term)) (: :) (NP (NP (NN condition)) (VP (VBN aggravated)))) (-RRB- -RRB-))))))))) (. .)))Patient also had coronary artery occlusion (preferred term: coronary artery occlusion).Action taken with all suspect drugs were unknown.The outcome of the event of arthritis, condition aggravated and coronary artery occlusion were unknown.The reporter has assessed the events of arthritis, condition aggravated and coronary artery occlusion to be serious with seriousness criteria of important medical event.Patientalsohadcoronary[dsyn]artery[dsyn]occlusion[dsyn](preferredterm:coronary[dsyn]artery[dsyn]occlusion[dsyn]).Actiontakenwithallsuspectdrugs[phsu]wereunknown.Theoutcomeoftheeventofarthritis[dsyn],condition[dsyn]aggravatedandcoronary[dsyn]artery[dsyn]occlusion[dsyn]wereunknown.Thereporterhasassessedtheeventsofarthritis[dsyn],condition[dsyn]aggravatedandcoronary[dsyn]artery[dsyn]occlusion[dsyn]tobeseriouswithseriousnesscriteriaofimportantmedicalevent.(S1 (S (S (NP (NN Patient)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJ coronary) (NN artery) (NN occlusion)) (PRN (-LRB- -LRB-) (NP (NP (JJ preferred) (NN term)) (: :) (NP (JJ coronary) (NN artery) (NN occlusion))) (-RRB- -RRB-))))) (S (NP (NP (NN .Action)) (VP (VBN taken) (PP (IN with) (NP (DT all) (NN suspect) (NNS drugs))))) (VP (VBD were) (NP (NP (NN unknown.The) (NN outcome)) (PP (IN of) (NP (NP (DT the) (NN event)) (PP (IN of) (NP (NP (NN arthritis)) (, ,) (NP (NP (NN condition)) (VP (VBN aggravated)))))))))) (CC and) (S (NP (JJ coronary) (NN artery) (NN occlusion)) (VP (VBD were) (VP (VBG unknown.The) (S (NP (NN reporter)) (VP (VBZ has) (VP (VBN assessed) (NP (NP (DT the) (NNS events)) (PP (IN of) (NP (NP (NP (NN arthritis)) (, ,) (NP (NP (NN condition)) (VP (VBN aggravated)))) (CC and) (NP (JJ coronary) (NN artery) (NN occlusion))))) (S (VP (TO to) (VP (VB be) (ADJP (JJ serious) (PP (IN with) (NP (NP (NNS seriousness) (NNS criteria)) (PP (IN of) (NP (JJ important) (JJ medical) (NN event))))))))))))))) (. .))) \ No newline at end of file diff --git a/Resources/Concept.py b/Resources/Concept.py new file mode 100644 index 0000000..6f07a45 --- /dev/null +++ b/Resources/Concept.py @@ -0,0 +1,86 @@ + + +# Licensed under the Apache License, Version 2.0 (the "License"); +# you may not use this file except in compliance with the License. +# You may obtain a copy of the License at +# +# http://www.apache.org/licenses/LICENSE-2.0 +# +# Unless required by applicable law or agreed to in writing, software +# distributed under the License is distributed on an "AS IS" BASIS, +# WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. +# See the License for the specific language governing permissions and +# limitations under the License. + +from collections import namedtuple + +FIELD_NAMES_MMI = ('index', 'mm', 'score', 'preferred_name', 'cui', 'semtypes', + 'trigger', 'location', 'pos_info', 'tree_codes') + +FIELD_NAMES_AA = ('index', 'aa', 'short_form', 'long_form', 'num_tokens_short_form', + 'num_chars_short_form', 'num_tokens_long_form', + 'num_chars_long_form')#, 'pos_info') + +FIELD_NAMES_UA = ('index', 'ua', 'short_form', 'long_form', 'num_tokens_short_form', + 'num_chars_short_form', 'num_tokens_long_form', + 'num_chars_long_form', 'pos_info') + +class ConceptMMI(namedtuple('Concept', FIELD_NAMES_MMI)): + def __repr__(self): + items = [(field, getattr(self, field, None)) for field in FIELD_NAMES_MMI] + fields = ['%s=%r' % (k, v) for k, v in items if v is not None] + return '%s(%s)' % (self.__class__.__name__, ', '.join(fields)) + + def as_mmi(self): + return '|'.join([get(field) for field in FIELD_NAMES_MMI]) + + @classmethod + def from_mmi(this_class, line): + fields = line.split('|') + return this_class(**dict(zip(FIELD_NAMES_MMI, fields))) + +class ConceptAA(namedtuple('Concept', FIELD_NAMES_AA)): + def __repr__(self): + items = [(field, getattr(self, field, None)) for field in FIELD_NAMES_AA] + fields = ['%s=%r' % (k, v) for k, v in items if v is not None] + return '%s(%s)' % (self.__class__.__name__, ', '.join(fields)) + + def as_mmi(self): + return '|'.join([get(field) for field in FIELD_NAMES_AA]) + + @classmethod + def from_mmi(this_class, line): + fields = line.split('|') + return this_class(**dict(zip(FIELD_NAMES_AA, fields))) + +class ConceptUA(namedtuple('Concept', FIELD_NAMES_UA)): + def __repr__(self): + items = [(field, getattr(self, field, None)) for field in FIELD_NAMES_UA] + fields = ['%s=%r' % (k, v) for k, v in items if v is not None] + return '%s(%s)' % (self.__class__.__name__, ', '.join(fields)) + + def as_mmi(self): + return '|'.join([get(field) for field in FIELD_NAMES_UA]) + + @classmethod + def from_mmi(this_class, line): + fields = line.split('|') + return this_class(**dict(zip(FIELD_NAMES_UA, fields))) + +class Corpus(list): + @classmethod + def load(this_class, stream): + stream = iter(stream) + corpus = this_class() + for line in stream: + fields = line.split('|') + if fields[1] == 'MMI': + corpus.append(ConceptMMI.from_mmi(line)) + elif fields[1] == 'AA': + corpus.append(ConceptAA.from_mmi(line)) + else: + corpus.append(ConceptUA.from_mmi(line)) + + return corpus + + diff --git a/Test_Suite/Eval_Env/semifinal/fda001_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda001_SEX_Semifinal.xml index 56e40ec..deb0924 100755 --- a/Test_Suite/Eval_Env/semifinal/fda001_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda001_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/fda007_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda007_AGE_SET_Semifinal.xml index 032e0ec..e56e54d 100644 --- a/Test_Suite/Eval_Env/semifinal/fda007_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda007_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 54YR + 54YR54YR diff --git a/Test_Suite/Eval_Env/semifinal/fda008_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda008_AGE_SET_Semifinal.xml index 82e8942..59a1e1c 100755 --- a/Test_Suite/Eval_Env/semifinal/fda008_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda008_AGE_SET_Semifinal.xml @@ -1,10 +1,10 @@ - + - 5YR + 5YR5YR diff --git a/Test_Suite/Eval_Env/semifinal/fda008_EVENT_DT_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda008_EVENT_DT_Semifinal.xml index 1723b7b..1ae6c0d 100644 --- a/Test_Suite/Eval_Env/semifinal/fda008_EVENT_DT_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda008_EVENT_DT_Semifinal.xml @@ -1,4 +1,4 @@ - + @@ -42,4 +42,4 @@ This section is for freeform comments from the annotator regarding any particular test case. -unspecified dateunspecified date16-Apr-2015 \ No newline at end of file +unspecified dateunspecified date16-Apr-2015 \ No newline at end of file diff --git a/Test_Suite/Eval_Env/semifinal/fda008_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda008_SEX_Semifinal.xml index 5015419..e6784bc 100755 --- a/Test_Suite/Eval_Env/semifinal/fda008_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda008_SEX_Semifinal.xml @@ -1,4 +1,4 @@ - + @@ -10,7 +10,7 @@ - F + F diff --git a/Test_Suite/Eval_Env/semifinal/fda008_WT_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda008_WT_SET_Semifinal.xml index cf3feab..2818817 100755 --- a/Test_Suite/Eval_Env/semifinal/fda008_WT_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda008_WT_SET_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/fda009_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda009_AGE_SET_Semifinal.xml index 7bdd295..9a37750 100755 --- a/Test_Suite/Eval_Env/semifinal/fda009_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda009_AGE_SET_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/fda009_EVENT_DT_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda009_EVENT_DT_Semifinal.xml index e143976..2d3a0cb 100644 --- a/Test_Suite/Eval_Env/semifinal/fda009_EVENT_DT_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda009_EVENT_DT_Semifinal.xml @@ -1,4 +1,4 @@ - + @@ -42,4 +42,4 @@ This section is for freeform comments from the annotator regarding any particular test case. -unknown dateunknown date \ No newline at end of file +unknown dateunknown date \ No newline at end of file diff --git a/Test_Suite/Eval_Env/semifinal/fda009_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda009_SEX_Semifinal.xml index d98a597..b65cde4 100755 --- a/Test_Suite/Eval_Env/semifinal/fda009_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda009_SEX_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/fda009_WT_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda009_WT_SET_Semifinal.xml index 7bdd295..9a37750 100755 --- a/Test_Suite/Eval_Env/semifinal/fda009_WT_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda009_WT_SET_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/fda010_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda010_AGE_SET_Semifinal.xml index 6c00667..c8fce66 100644 --- a/Test_Suite/Eval_Env/semifinal/fda010_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda010_AGE_SET_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/fda010_EVENT_DT_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda010_EVENT_DT_Semifinal.xml index f60e242..05d2bf4 100644 --- a/Test_Suite/Eval_Env/semifinal/fda010_EVENT_DT_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda010_EVENT_DT_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/fda010_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda010_SEX_Semifinal.xml index 2914554..f53d097 100755 --- a/Test_Suite/Eval_Env/semifinal/fda010_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda010_SEX_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/fda010_WT_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/fda010_WT_SET_Semifinal.xml index c90a490..dba454c 100755 --- a/Test_Suite/Eval_Env/semifinal/fda010_WT_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/fda010_WT_SET_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/gen011_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen011_AGE_SET_Semifinal.xml index 53d95b1..e4bd522 100644 --- a/Test_Suite/Eval_Env/semifinal/gen011_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen011_AGE_SET_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/gen011_EVENT_DT_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen011_EVENT_DT_Semifinal.xml index f005b98..677bf8c 100644 --- a/Test_Suite/Eval_Env/semifinal/gen011_EVENT_DT_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen011_EVENT_DT_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/gen011_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen011_SEX_Semifinal.xml index d39146b..672c838 100755 --- a/Test_Suite/Eval_Env/semifinal/gen011_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen011_SEX_Semifinal.xml @@ -1,4 +1,4 @@ - + @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen011_WT_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen011_WT_SET_Semifinal.xml index d39146b..78a3fab 100755 --- a/Test_Suite/Eval_Env/semifinal/gen011_WT_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen011_WT_SET_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/gen012_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen012_SEX_Semifinal.xml index c6f3a11..f0bed20 100755 --- a/Test_Suite/Eval_Env/semifinal/gen012_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen012_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen013_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen013_AGE_SET_Semifinal.xml index d63ac1c..61f27b7 100755 --- a/Test_Suite/Eval_Env/semifinal/gen013_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen013_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 47YR + 47YR47YR diff --git a/Test_Suite/Eval_Env/semifinal/gen013_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen013_SEX_Semifinal.xml index f2eb015..7019a1e 100755 --- a/Test_Suite/Eval_Env/semifinal/gen013_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen013_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - M + F diff --git a/Test_Suite/Eval_Env/semifinal/gen014_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen014_AGE_SET_Semifinal.xml index e60c89d..5173c5a 100755 --- a/Test_Suite/Eval_Env/semifinal/gen014_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen014_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 65YR + 65YR65YR diff --git a/Test_Suite/Eval_Env/semifinal/gen014_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen014_SEX_Semifinal.xml index 4aad6a2..a4ec87e 100755 --- a/Test_Suite/Eval_Env/semifinal/gen014_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen014_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - M + F diff --git a/Test_Suite/Eval_Env/semifinal/gen015_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen015_AGE_SET_Semifinal.xml index e92d8c5..ef38171 100755 --- a/Test_Suite/Eval_Env/semifinal/gen015_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen015_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 65YR + 65YR65YR diff --git a/Test_Suite/Eval_Env/semifinal/gen015_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen015_SEX_Semifinal.xml index acbd94d..833663c 100755 --- a/Test_Suite/Eval_Env/semifinal/gen015_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen015_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen016_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen016_AGE_SET_Semifinal.xml index 79aca2c..4e923b2 100755 --- a/Test_Suite/Eval_Env/semifinal/gen016_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen016_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 56YR + 56YR56YR diff --git a/Test_Suite/Eval_Env/semifinal/gen016_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen016_SEX_Semifinal.xml index 852fce8..4285887 100755 --- a/Test_Suite/Eval_Env/semifinal/gen016_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen016_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen019_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen019_AGE_SET_Semifinal.xml index e73b076..d8253f5 100755 --- a/Test_Suite/Eval_Env/semifinal/gen019_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen019_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 27YR + 27YR27YR diff --git a/Test_Suite/Eval_Env/semifinal/gen021_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen021_AGE_SET_Semifinal.xml index 84a7bbd..c79b1c1 100755 --- a/Test_Suite/Eval_Env/semifinal/gen021_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen021_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 75YR + 75YR75YR diff --git a/Test_Suite/Eval_Env/semifinal/gen023_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen023_AGE_SET_Semifinal.xml index e8ca1d7..76ce86c 100755 --- a/Test_Suite/Eval_Env/semifinal/gen023_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen023_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 95YR + 95YR95YR diff --git a/Test_Suite/Eval_Env/semifinal/gen025_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen025_AGE_SET_Semifinal.xml index 3d4fe9d..508360e 100755 --- a/Test_Suite/Eval_Env/semifinal/gen025_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen025_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 67YR + 67YR67YR diff --git a/Test_Suite/Eval_Env/semifinal/gen025_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen025_SEX_Semifinal.xml index 2bb7b66..5d46804 100755 --- a/Test_Suite/Eval_Env/semifinal/gen025_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen025_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen026_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen026_AGE_SET_Semifinal.xml index cfa3f72..c086506 100755 --- a/Test_Suite/Eval_Env/semifinal/gen026_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen026_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - + 60YR diff --git a/Test_Suite/Eval_Env/semifinal/gen028_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen028_AGE_SET_Semifinal.xml index 56c18bc..44e7d5b 100755 --- a/Test_Suite/Eval_Env/semifinal/gen028_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen028_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 8YR + 8YR67YR diff --git a/Test_Suite/Eval_Env/semifinal/gen028_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen028_SEX_Semifinal.xml index f7ea300..0fa130a 100755 --- a/Test_Suite/Eval_Env/semifinal/gen028_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen028_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen029_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen029_AGE_SET_Semifinal.xml index 8950f5f..34b7015 100755 --- a/Test_Suite/Eval_Env/semifinal/gen029_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen029_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - + twoYR diff --git a/Test_Suite/Eval_Env/semifinal/gen029_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen029_SEX_Semifinal.xml index 8950f5f..c51d8d0 100755 --- a/Test_Suite/Eval_Env/semifinal/gen029_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen029_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + M diff --git a/Test_Suite/Eval_Env/semifinal/gen030_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen030_AGE_SET_Semifinal.xml index d73222c..fe49d3b 100755 --- a/Test_Suite/Eval_Env/semifinal/gen030_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen030_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 70YR + 70YR70YR diff --git a/Test_Suite/Eval_Env/semifinal/gen030_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen030_SEX_Semifinal.xml index 8b497e3..d2406a2 100755 --- a/Test_Suite/Eval_Env/semifinal/gen030_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen030_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - M + F diff --git a/Test_Suite/Eval_Env/semifinal/gen031_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen031_AGE_SET_Semifinal.xml index b08ebbf..07ecd12 100755 --- a/Test_Suite/Eval_Env/semifinal/gen031_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen031_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 23YR + 23YR23YR diff --git a/Test_Suite/Eval_Env/semifinal/gen032_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen032_AGE_SET_Semifinal.xml index dbd9744..197ee39 100755 --- a/Test_Suite/Eval_Env/semifinal/gen032_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen032_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 30YR + 30YR30YR diff --git a/Test_Suite/Eval_Env/semifinal/gen032_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen032_SEX_Semifinal.xml index 51e63ec..70fb3ef 100755 --- a/Test_Suite/Eval_Env/semifinal/gen032_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen032_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen032_WT_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen032_WT_SET_Semifinal.xml index 46085cb..44648f2 100755 --- a/Test_Suite/Eval_Env/semifinal/gen032_WT_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen032_WT_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 172LBS + 18LBS diff --git a/Test_Suite/Eval_Env/semifinal/gen033_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen033_AGE_SET_Semifinal.xml index cf5e092..9675d11 100755 --- a/Test_Suite/Eval_Env/semifinal/gen033_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen033_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 89YR + 89YR89YR diff --git a/Test_Suite/Eval_Env/semifinal/gen033_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen033_SEX_Semifinal.xml index 3598d55..963c2de 100755 --- a/Test_Suite/Eval_Env/semifinal/gen033_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen033_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - M + F diff --git a/Test_Suite/Eval_Env/semifinal/gen034_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen034_AGE_SET_Semifinal.xml index 46b83e5..8a2765d 100755 --- a/Test_Suite/Eval_Env/semifinal/gen034_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen034_AGE_SET_Semifinal.xml @@ -1,10 +1,10 @@ - + - 68YR + 68YR68YR diff --git a/Test_Suite/Eval_Env/semifinal/gen034_EVENT_DT_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen034_EVENT_DT_Semifinal.xml index 78aec17..fe561bf 100755 --- a/Test_Suite/Eval_Env/semifinal/gen034_EVENT_DT_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen034_EVENT_DT_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/gen034_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen034_SEX_Semifinal.xml index c0be0c1..d8efc48 100755 --- a/Test_Suite/Eval_Env/semifinal/gen034_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen034_SEX_Semifinal.xml @@ -1,4 +1,4 @@ - + @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen034_WT_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen034_WT_SET_Semifinal.xml index 105016c..0640fcb 100755 --- a/Test_Suite/Eval_Env/semifinal/gen034_WT_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen034_WT_SET_Semifinal.xml @@ -1,10 +1,10 @@ - + - + 128LBS diff --git a/Test_Suite/Eval_Env/semifinal/gen035_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen035_AGE_SET_Semifinal.xml index 4c3888a..e8179de 100755 --- a/Test_Suite/Eval_Env/semifinal/gen035_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen035_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 83YR + 83YR83YR diff --git a/Test_Suite/Eval_Env/semifinal/gen035_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen035_SEX_Semifinal.xml index 215b7e0..fa55808 100755 --- a/Test_Suite/Eval_Env/semifinal/gen035_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen035_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen036_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen036_SEX_Semifinal.xml index 732e113..72216ca 100755 --- a/Test_Suite/Eval_Env/semifinal/gen036_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen036_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen037_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen037_AGE_SET_Semifinal.xml index 08ed397..b4f231d 100755 --- a/Test_Suite/Eval_Env/semifinal/gen037_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen037_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 55YR + 55YR55YR diff --git a/Test_Suite/Eval_Env/semifinal/gen037_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen037_SEX_Semifinal.xml index 1736593..8239fee 100755 --- a/Test_Suite/Eval_Env/semifinal/gen037_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen037_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen038_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen038_AGE_SET_Semifinal.xml index 90ffdb3..dda9de2 100755 --- a/Test_Suite/Eval_Env/semifinal/gen038_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen038_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 76YR + 76YR76YR diff --git a/Test_Suite/Eval_Env/semifinal/gen039_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen039_AGE_SET_Semifinal.xml index 98f9d1f..81a0201 100755 --- a/Test_Suite/Eval_Env/semifinal/gen039_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen039_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 55YR + 55YR55YR diff --git a/Test_Suite/Eval_Env/semifinal/gen039_WT_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen039_WT_SET_Semifinal.xml index 4a5564b..a558d77 100755 --- a/Test_Suite/Eval_Env/semifinal/gen039_WT_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen039_WT_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 20LBS + 25LBS diff --git a/Test_Suite/Eval_Env/semifinal/gen040_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen040_AGE_SET_Semifinal.xml index 88d7a59..da7e1f1 100755 --- a/Test_Suite/Eval_Env/semifinal/gen040_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen040_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 80YR + 80YR80YR diff --git a/Test_Suite/Eval_Env/semifinal/gen041_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen041_AGE_SET_Semifinal.xml index 6ea9edf..9503891 100755 --- a/Test_Suite/Eval_Env/semifinal/gen041_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen041_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 44YR + 44YR44YR diff --git a/Test_Suite/Eval_Env/semifinal/gen041_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen041_SEX_Semifinal.xml index ec694f6..2e628ad 100755 --- a/Test_Suite/Eval_Env/semifinal/gen041_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen041_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - M + F diff --git a/Test_Suite/Eval_Env/semifinal/gen042_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen042_AGE_SET_Semifinal.xml index ee7c495..4a88a59 100755 --- a/Test_Suite/Eval_Env/semifinal/gen042_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen042_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 61YR + 61YR61YR diff --git a/Test_Suite/Eval_Env/semifinal/gen042_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen042_SEX_Semifinal.xml index 7154421..f3a06b3 100755 --- a/Test_Suite/Eval_Env/semifinal/gen042_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen042_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - M + F diff --git a/Test_Suite/Eval_Env/semifinal/gen043_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen043_AGE_SET_Semifinal.xml index ff68f24..5b7d48d 100755 --- a/Test_Suite/Eval_Env/semifinal/gen043_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen043_AGE_SET_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/gen043_EVENT_DT_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen043_EVENT_DT_Semifinal.xml index 07bd366..572aa0d 100644 --- a/Test_Suite/Eval_Env/semifinal/gen043_EVENT_DT_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen043_EVENT_DT_Semifinal.xml @@ -1,4 +1,4 @@ - + @@ -42,4 +42,4 @@ This section is for freeform comments from the annotator regarding any particular test case. -August 2014August 2014 \ No newline at end of file +August 2014August 2014 \ No newline at end of file diff --git a/Test_Suite/Eval_Env/semifinal/gen043_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen043_SEX_Semifinal.xml index 52b4dd4..af4c32c 100755 --- a/Test_Suite/Eval_Env/semifinal/gen043_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen043_SEX_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/gen043_WT_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen043_WT_SET_Semifinal.xml index 3a5942a..8ffd60b 100755 --- a/Test_Suite/Eval_Env/semifinal/gen043_WT_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen043_WT_SET_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/gen044_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen044_SEX_Semifinal.xml index 0f2da0f..e3df632 100755 --- a/Test_Suite/Eval_Env/semifinal/gen044_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen044_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen046_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen046_AGE_SET_Semifinal.xml index 4676e13..6a46086 100755 --- a/Test_Suite/Eval_Env/semifinal/gen046_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen046_AGE_SET_Semifinal.xml @@ -1,10 +1,10 @@ - + - 34YR + 34YR34YR diff --git a/Test_Suite/Eval_Env/semifinal/gen046_EVENT_DT_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen046_EVENT_DT_Semifinal.xml index 7409432..2540c22 100644 --- a/Test_Suite/Eval_Env/semifinal/gen046_EVENT_DT_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen046_EVENT_DT_Semifinal.xml @@ -1,4 +1,4 @@ - + @@ -42,4 +42,4 @@ This section is for freeform comments from the annotator regarding any particular test case. -2-14-20132-14-2013 \ No newline at end of file +2-14-20132-14-2013 \ No newline at end of file diff --git a/Test_Suite/Eval_Env/semifinal/gen046_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen046_SEX_Semifinal.xml index 3df41f7..f14d0fc 100755 --- a/Test_Suite/Eval_Env/semifinal/gen046_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen046_SEX_Semifinal.xml @@ -1,4 +1,4 @@ - + diff --git a/Test_Suite/Eval_Env/semifinal/gen046_WT_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen046_WT_SET_Semifinal.xml index 3e5468f..0d805ef 100755 --- a/Test_Suite/Eval_Env/semifinal/gen046_WT_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen046_WT_SET_Semifinal.xml @@ -1,10 +1,10 @@ - + - + 130.2LBS diff --git a/Test_Suite/Eval_Env/semifinal/gen047_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen047_AGE_SET_Semifinal.xml index b3539c1..0ecf337 100755 --- a/Test_Suite/Eval_Env/semifinal/gen047_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen047_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 71YR + 71YR71YR diff --git a/Test_Suite/Eval_Env/semifinal/gen048_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen048_AGE_SET_Semifinal.xml index f5166e4..2b0f00d 100755 --- a/Test_Suite/Eval_Env/semifinal/gen048_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen048_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 58YR + 58YR58YR diff --git a/Test_Suite/Eval_Env/semifinal/gen048_SEX_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen048_SEX_Semifinal.xml index 44eb348..38165a0 100755 --- a/Test_Suite/Eval_Env/semifinal/gen048_SEX_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen048_SEX_Semifinal.xml @@ -10,7 +10,7 @@ - + F diff --git a/Test_Suite/Eval_Env/semifinal/gen049_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen049_AGE_SET_Semifinal.xml index de31655..dffcad9 100755 --- a/Test_Suite/Eval_Env/semifinal/gen049_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen049_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 55YR + 55YR55YR diff --git a/Test_Suite/Eval_Env/semifinal/gen049_WT_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen049_WT_SET_Semifinal.xml index 6319377..92c151c 100755 --- a/Test_Suite/Eval_Env/semifinal/gen049_WT_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen049_WT_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 192LBS + 25LBS diff --git a/Test_Suite/Eval_Env/semifinal/gen050_AGE_SET_Semifinal.xml b/Test_Suite/Eval_Env/semifinal/gen050_AGE_SET_Semifinal.xml index d17a6e4..2e4b708 100755 --- a/Test_Suite/Eval_Env/semifinal/gen050_AGE_SET_Semifinal.xml +++ b/Test_Suite/Eval_Env/semifinal/gen050_AGE_SET_Semifinal.xml @@ -4,7 +4,7 @@ - 80YR + 80YR80YR diff --git a/Test_Suite/Test_Cases/fda010.txt b/Test_Suite/Test_Cases/fda010.txt index c78e029..cbcdf14 100644 --- a/Test_Suite/Test_Cases/fda010.txt +++ b/Test_Suite/Test_Cases/fda010.txt @@ -1,4 +1,4 @@ -This spontaneous report from a patient concerns a 71-year-old Caucasian female from the United States: Local ID: 1-1878275180. +This spontaneous report from a patient concerns a 71-year-old Caucasian Female from the United States: Local ID: 1-1878275180. The patient's weight was 160 pounds and height was 67.5 inches. Concurrent conditions included abdominal bloating, abdominal gas, abdominal pain, allergy to trees, belching (abdominal), diabetic paresis (coded as diabetic gastroparesis), no alcohol use, no smoking, and type 2 diabetes. Other medical history included no history of drug abuse/illicit drug use. The patient had previously experienced allergy when taking mycins (not otherwise specified or NOS) (antibacterials for systemic use) and sulfa (sulfacetamide sodium). The patient was treated with canagliflozin (tablet, oral, batch unknown) 300 mg once a day, initiated on 06-AUG-2014, for type 2 diabetes and domperidone (unspecified, batch unknown) dose and frequency unspecified, initiated on an unspecified date, for diabetic gastroparesis. Concomitant medications were not reported. The patient was not initially prescribed 100 mg dose of canagliflozin. On 06-AUG-2014, the patient experienced "worsening of pre-existing abdominal belching" (coded as increased belching), "worsening of pre-existing abdominal pain" (coded as worsening of abdominal pain), "worsening of pre-existing abdominal gassiness" (coded as very gaseous), and "worsening of pre-existing abdominal bloating" (coded as worsening of bloating). In AUG-2014, the patient contacted her physician about the events and was prescribed an increased dosage of domperidone. The patient reported the increased dose of domperidone had not relieved her worsening symptoms. On 13-AUG-2014, the patient experienced not feeling well today. No laboratory findings were provided. The dose of domperidone was increased and the dose of canagliflozin was not changed. The patient had not recovered from increased belching, worsening of abdominal pain, very gaseous, worsening of bloating, and not feeling well today. diff --git a/output_file.xml b/output_file.xml index e5e9b91..806ac78 100644 --- a/output_file.xml +++ b/output_file.xml @@ -1 +1 @@ -This spontaneous report from a patient concerns a 71 year old Caucasian female from the United States: Local ID: 1 1878275180.Thisspontaneousreportfromapatientconcernsa71yearoldCaucasianfemalefromtheUnitedStates:LocalID:11878275180.(S1 (S (S (NP (NP (DT This) (JJ spontaneous) (NN report)) (PP (IN from) (NP (DT a) (NN patient)))) (VP (VBZ concerns) (NP (NP (DT a) (ADJP (CD 71) (NN year) (JJ old)) (NN Caucasian) (NN female)) (PP (IN from) (NP (NP (DT the) (JJ United) (NNS States)) (: :) (NP (JJ Local) (NN ID) (: :) (CD 1) (NN 1878275180))))))) (. .)))The patient's weight was 160 pounds and height was 67.5 inches.Thepatient'sweightwas160poundsandheightwas67.5inches.(S1 (S (S (S (NP (NP (DT The) (NN patient) (POS 's)) (NN weight)) (VP (VBD was) (NP (CD 160) (NNS pounds)))) (CC and) (S (NP (NN height)) (VP (VBD was) (NP (CD 67.5) (NNS inches))))) (. .)))Concurrent conditions included abdominal bloating, abdominal gas, abdominal pain, allergy to trees, belching (abdominal), diabetic paresis (coded as diabetic gastroparesis), no alcohol use, no smoking, and type 2 diabetes.Concurrentconditionsincludedabdominalbloating,abdominalgas,abdominalpain,allergytotrees,belching(abdominal),diabeticparesis(codedasdiabeticgastroparesis),noalcoholuse,nosmoking,andtype2diabetes.(S1 (S (S (NP (JJ Concurrent) (NNS conditions)) (VP (VBD included) (NP (NP (JJ abdominal) (NN bloating)) (, ,) (NP (JJ abdominal) (NN gas)) (, ,) (NP (JJ abdominal) (NN pain)) (, ,) (NP (NP (NN allergy)) (PP (TO to) (NP (NNS trees)))) (, ,) (NP (NP (NN belching)) (PRN (-LRB- -LRB-) (NP (JJ abdominal)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ diabetic) (NN paresis)) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (JJ diabetic) (NN gastroparesis)))) (-RRB- -RRB-))) (, ,) (NP (DT no) (NN alcohol) (NN use)) (, ,) (NP (NN no) (NN smoking)) (, ,) (CC and) (NP (NN type) (CD 2) (NNS diabetes))))) (. .)))Other medical history included no history of drug abuse/illicit drug use.Othermedicalhistoryincludednohistoryofdrugabuse/illicitdruguse.(S1 (S (S (NP (JJ Other) (JJ medical) (NN history)) (VP (VBD included) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (NN drug) (NN abuse/illicit) (NN drug) (NN use)))))) (. .)))The patient had previously experienced allergy when taking mycins (not otherwise specified or NOS) (antibacterials for systemic use) and sulfa (sulfacetamide sodium).Thepatienthadpreviouslyexperiencedallergywhentakingmycins(nototherwisespecifiedorNOS)(antibacterialsforsystemicuse)andsulfa(sulfacetamidesodium).(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (ADVP (RB previously)) (VP (VBN experienced) (NP (NN allergy))) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (NP (NP (NP (NNS mycins)) (PRN (-LRB- -LRB-) (NP (ADJP (ADVP (RB not) (RB otherwise)) (VBN specified)) (NN or) (NN NOS)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NNS antibacterials)) (PP (IN for) (NP (JJ systemic) (NN use)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN sulfa)) (PRN (-LRB- -LRB-) (NP (NN sulfacetamide) (NN sodium)) (-RRB- -RRB-))))))))) (. .)))The patient was treated with canagliflozin (tablet, oral, batch unknown) 300 mg once a day, initiated on 06 AUG 2014, for type 2 diabetes and domperidone (unspecified, batch unknown) dose and frequency unspecified, initiated on an unspecified date, for diabetic gastroparesis.Thepatientwastreatedwithcanagliflozin(tablet,oral,batchunknown)300mgonceaday,initiatedon06AUG2014,fortype2diabetesanddomperidone(unspecified,batchunknown)doseandfrequencyunspecified,initiatedonanunspecifieddate,fordiabeticgastroparesis.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NP (NN canagliflozin)) (PRN (-LRB- -LRB-) (NP (NN tablet)) (, ,) (NP (NP (JJ oral)) (, ,) (NP (JJ batch) (JJ unknown))) (-RRB- -RRB-))) (NP (NP (CD 300) (NN mg)) (PP (IN once) (NP (NP (DT a) (NN day)) (, ,) (VP (VBN initiated) (PP (IN on) (NP (NN 06) (NN AUG) (NN 2014)))) (, ,))) (PP (IN for) (NP (NN type) (CD 2) (NNS diabetes))))) (CC and) (NP (NP (NN domperidone)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ unspecified)) (, ,) (ADJP (NN batch) (JJ unknown))) (-RRB- -RRB-)) (NP (NN dose) (CC and) (NN frequency) (NN unspecified)) (, ,) (VP (VBN initiated) (PP (IN on) (NP (DT an) (JJ unspecified) (NN date)))) (, ,)))) (PP (IN for) (NP (JJ diabetic) (NN gastroparesis)))))) (. .)))Concomitant medications were not reported.Concomitantmedicationswerenotreported.(S1 (S (S (NP (JJ Concomitant) (NNS medications)) (VP (VBD were) (RB not) (VP (VBN reported)))) (. .)))The patient was not initially prescribed 100 mg dose of canagliflozin.Thepatientwasnotinitiallyprescribed100mgdoseofcanagliflozin.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD was) (RB not) (ADVP (RB initially)) (VP (VBN prescribed) (NP (NP (ADJP (CD 100) (NN mg)) (NN dose)) (PP (IN of) (NP (NN canagliflozin))))))) (. .)))On 06 AUG 2014, the patient experienced "worsening of pre existing abdominal belching" (coded as increased belching), "worsening of pre existing abdominal pain" (coded as worsening of abdominal pain), "worsening of pre existing abdominal gassiness" (coded as very gaseous), and "worsening of pre existing abdominal bloating" (coded as worsening of bloating).On06AUG2014,thepatientexperienced``worseningofpreexistingabdominalbelching''(codedasincreasedbelching),``worseningofpreexistingabdominalpain''(codedasworseningofabdominalpain),``worseningofpreexistingabdominalgassiness''(codedasverygaseous),and``worseningofpreexistingabdominalbloating''(codedasworseningofbloating).(S1 (S (S (PP (IN On) (NP (NN 06) (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VBN experienced) (NP (NP (NP (`` ``) (ADJP (ADJP (JJ worsening) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN belching) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (VBN increased) (NN belching)))) (-RRB- -RRB-))))) (, ,) (`` ``) (ADJP (JJ worsening) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN pain) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (NP (NN worsening)) (PP (IN of) (NP (JJ abdominal) (NN pain)))))) (-RRB- -RRB-))))) (, ,)) (`` ``) (NN worsening)) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN gassiness) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (ADJP (RB very) (JJ gaseous)))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (`` ``) (NN worsening)) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN bloating) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (NP (NN worsening)) (PP (IN of) (NP (NN bloating)))))) (-RRB- -RRB-)))))))) (. .)))In AUG 2014, the patient contacted her physician about the events and was prescribed an increased dosage of domperidone.InAUG2014,thepatientcontactedherphysicianabouttheeventsandwasprescribedanincreaseddosageofdomperidone.(S1 (S (S (PP (IN In) (NP (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBD contacted) (NP (PRP$ her) (NN physician)) (PP (IN about) (NP (DT the) (NNS events)))) (CC and) (VP (VBD was) (VP (VBN prescribed) (NP (NP (DT an) (VBN increased) (NN dosage)) (PP (IN of) (NP (NN domperidone)))))))) (. .)))The patient reported the increased dose of domperidone had not relieved her worsening symptoms.Thepatientreportedtheincreaseddoseofdomperidonehadnotrelievedherworseningsymptoms.(S1 (S (S (NP (NP (DT The) (NN patient)) (VP (VBD reported) (NP (NP (DT the) (VBN increased) (NN dose)) (PP (IN of) (NP (NN domperidone)))))) (VP (VBD had) (RB not) (VP (VBN relieved) (NP (PRP$ her) (JJ worsening) (NNS symptoms))))) (. .)))On 13 AUG 2014, the patient experienced not feeling well today.On13AUG2014,thepatientexperiencednotfeelingwelltoday.(S1 (S (S (PP (IN On) (NP (CD 13) (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VBN experienced) (NP (RB not) (NN feeling)) (PP (RB well) (ADVP (RB today))))) (. .)))No laboratory findings were provided.Nolaboratoryfindingswereprovided.(S1 (S (S (NP (NN No) (NN laboratory) (NNS findings)) (VP (VBD were) (VP (VBN provided)))) (. .)))The dose of domperidone was increased and the dose of canagliflozin was not changed.Thedoseofdomperidonewasincreasedandthedoseofcanagliflozinwasnotchanged.(S1 (S (S (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NN domperidone)))) (VP (VBD was) (VP (VBN increased)))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN canagliflozin)))) (VP (VBD was) (RB not) (VP (VBN changed))))) (. .)))The patient had not recovered from increased belching, worsening of abdominal pain, very gaseous, worsening of bloating, and not feeling well today. Thepatienthadnotrecoveredfromincreasedbelching,worseningofabdominalpain,verygaseous,worseningofbloating,andnotfeelingwelltoday.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (RB not) (VP (VBN recovered) (PP (IN from) (NP (VBN increased) (UCP (ADJP (JJ belching)) (, ,) (NP (NP (NN worsening)) (PP (IN of) (NP (JJ abdominal) (NN pain)))) (, ,) (ADJP (RB very) (JJ gaseous)) (, ,) (ADJP (JJ worsening) (PP (IN of) (NP (NN bloating)))) (, ,) (CC and) (ADJP (RB not) (JJ feeling))) (NN well) (NN today)))))) (. .)))This report was identified by the call center as a product quality complaint: PQMS reference number 10000228235.Thisreportwasidentifiedbythecallcenterasaproductqualitycomplaint:PQMSreferencenumber10000228235.(S1 (S (S (NP (DT This) (NN report)) (VP (VBD was) (VP (VBN identified) (PP (IN by) (NP (DT the) (NN call) (NN center))) (PP (IN as) (NP (NP (DT a) (NN product) (NN quality) (NN complaint)) (: :) (NP (NN PQMS) (NN reference) (NN number) (CD 10000228235))))))) (. .)))This report was not serious.Thisreportwasnotserious.(S1 (S (S (NP (DT This) (NN report)) (VP (VBD was) (RB not) (ADJP (JJ serious)))) (. .))) \ No newline at end of file +This spontaneous report from a patient concerns a 71 year old Caucasian from the United States: Local ID: 1 1878275180.Thisspontaneousreportfromapatientconcernsa71yearoldCaucasianfromtheUnitedStates:LocalID:11878275180.(S1 (S (S (NP (NP (DT This) (JJ spontaneous) (NN report)) (PP (IN from) (NP (DT a) (NN patient)))) (VP (VBZ concerns) (NP (NP (DT a) (ADJP (CD 71) (NN year) (JJ old)) (NN Caucasian)) (PP (IN from) (NP (NP (DT the) (JJ United) (NNS States)) (: :) (NP (JJ Local) (NN ID) (: :) (CD 1) (NN 1878275180))))))) (. .)))Her weight was 160 pounds and height was 67.5 inches.Herweightwas160poundsandheightwas67.5inches.(S1 (S (S (S (NP (PRP$ Her) (NN weight)) (VP (VBD was) (NP (CD 160) (NNS pounds)))) (CC and) (S (NP (NN height)) (VP (VBD was) (NP (CD 67.5) (NNS inches))))) (. .)))Concurrent conditions included abdominal bloating, abdominal gas, abdominal pain, allergy to trees, belching (abdominal), diabetic paresis (coded as diabetic gastroparesis), no alcohol use, no smoking, and type 2 diabetes.Concurrentconditions[dsyn]includedabdominal[sosy]bloating,abdominalgas[sosy],abdominal[sosy]pain[sosy],allergy[dsyn]totrees,belching[sosy](abdominal),diabeticparesis[sosy](codedasdiabetic[dsyn]gastroparesis[dsyn]),noalcoholuse,nosmoking,andtype[dsyn]2[dsyn]diabetes[dsyn].(S1 (S (S (NP (JJ Concurrent) (NNS conditions)) (VP (VBD included) (NP (NP (JJ abdominal) (NN bloating)) (, ,) (NP (JJ abdominal) (NN gas)) (, ,) (NP (JJ abdominal) (NN pain)) (, ,) (NP (NP (NN allergy)) (PP (TO to) (NP (NNS trees)))) (, ,) (NP (NP (NN belching)) (PRN (-LRB- -LRB-) (NP (JJ abdominal)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ diabetic) (NN paresis)) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (JJ diabetic) (NN gastroparesis)))) (-RRB- -RRB-))) (, ,) (NP (DT no) (NN alcohol) (NN use)) (, ,) (NP (NN no) (NN smoking)) (, ,) (CC and) (NP (NN type) (CD 2) (NNS diabetes))))) (. .)))Other medical history included no history of drug abuse/illicit drug use.Othermedicalhistoryincludednohistoryofdrugabuse/illicitdruguse.(S1 (S (S (NP (JJ Other) (JJ medical) (NN history)) (VP (VBD included) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (NN drug) (NN abuse/illicit) (NN drug) (NN use)))))) (. .)))The patient had previously experienced allergy when taking mycins (not otherwise specified or NOS) (antibacterials for systemic use) and sulfa (sulfacetamide sodium).Thepatienthadpreviouslyexperiencedallergy[dsyn]whentakingmycins(nototherwisespecifiedorNOS)(antibacterialsforsystemicuse)andsulfa[phsu](sulfacetamide[orch,phsu]sodium[orch,phsu]).(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (ADVP (RB previously)) (VP (VBN experienced) (NP (NN allergy))) (SBAR (WHADVP (WRB when)) (S (VP (VBG taking) (NP (NP (NP (NP (NNS mycins)) (PRN (-LRB- -LRB-) (NP (ADJP (ADVP (RB not) (RB otherwise)) (VBN specified)) (NN or) (NN NOS)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NNS antibacterials)) (PP (IN for) (NP (JJ systemic) (NN use)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN sulfa)) (PRN (-LRB- -LRB-) (NP (NN sulfacetamide) (NN sodium)) (-RRB- -RRB-))))))))) (. .)))The patient was treated with canagliflozin (tablet, oral, batch unknown) 300 mg once a day, initiated on 06 AUG 2014, for type 2 diabetes and domperidone (unspecified, batch unknown) dose and frequency unspecified, initiated on an unspecified date, for diabetic gastroparesis.Thepatientwastreatedwithcanagliflozin(tablet,oral,batchunknown)300mgonceaday,initiatedon06AUG2014,fortype[dsyn]2[dsyn]diabetes[dsyn]anddomperidone[orch,phsu](unspecified,batchunknown)doseandfrequencyunspecified,initiatedonanunspecifieddate,fordiabetic[dsyn]gastroparesis[dsyn].(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NP (NN canagliflozin)) (PRN (-LRB- -LRB-) (NP (NN tablet)) (, ,) (NP (NP (JJ oral)) (, ,) (NP (JJ batch) (JJ unknown))) (-RRB- -RRB-))) (NP (NP (CD 300) (NN mg)) (PP (IN once) (NP (NP (DT a) (NN day)) (, ,) (VP (VBN initiated) (PP (IN on) (NP (NN 06) (NN AUG) (NN 2014)))) (, ,))) (PP (IN for) (NP (NN type) (CD 2) (NNS diabetes))))) (CC and) (NP (NP (NN domperidone)) (PRN (-LRB- -LRB-) (ADJP (ADJP (JJ unspecified)) (, ,) (ADJP (NN batch) (JJ unknown))) (-RRB- -RRB-)) (NP (NN dose) (CC and) (NN frequency) (NN unspecified)) (, ,) (VP (VBN initiated) (PP (IN on) (NP (DT an) (JJ unspecified) (NN date)))) (, ,)))) (PP (IN for) (NP (JJ diabetic) (NN gastroparesis)))))) (. .)))Concomitant medications were not reported.Concomitantmedications[phsu]werenotreported.(S1 (S (S (NP (JJ Concomitant) (NNS medications)) (VP (VBD were) (RB not) (VP (VBN reported)))) (. .)))The patient was not initially prescribed 100 mg dose of canagliflozin.Thepatientwasnotinitiallyprescribed100mgdoseofcanagliflozin.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD was) (RB not) (ADVP (RB initially)) (VP (VBN prescribed) (NP (NP (ADJP (CD 100) (NN mg)) (NN dose)) (PP (IN of) (NP (NN canagliflozin))))))) (. .)))On 06 AUG 2014, the patient experienced "worsening of pre existing abdominal belching" (coded as increased belching), "worsening of pre existing abdominal pain" (coded as worsening of abdominal pain), "worsening of pre existing abdominal gassiness" (coded as very gaseous), and "worsening of pre existing abdominal bloating" (coded as worsening of bloating).On06AUG2014,thepatientexperienced``worseningofpreexistingabdominalbelching''(codedasincreasedbelching),``worseningofpreexistingabdominalpain''(codedasworseningofabdominalpain),``worseningofpreexistingabdominalgassiness''(codedasverygaseous),and``worseningofpreexistingabdominalbloating''(codedasworseningofbloating).(S1 (S (S (PP (IN On) (NP (NN 06) (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VBN experienced) (NP (NP (NP (`` ``) (ADJP (ADJP (JJ worsening) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN belching) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (VBN increased) (NN belching)))) (-RRB- -RRB-))))) (, ,) (`` ``) (ADJP (JJ worsening) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN pain) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (NP (NN worsening)) (PP (IN of) (NP (JJ abdominal) (NN pain)))))) (-RRB- -RRB-))))) (, ,)) (`` ``) (NN worsening)) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN gassiness) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (ADJP (RB very) (JJ gaseous)))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (`` ``) (NN worsening)) (PP (IN of) (NP (NP (JJ pre) (JJ existing) (JJ abdominal) (NN bloating) (NNS '')) (PRN (-LRB- -LRB-) (VP (VBN coded) (PP (IN as) (NP (NP (NN worsening)) (PP (IN of) (NP (NN bloating)))))) (-RRB- -RRB-)))))))) (. .)))In AUG 2014, the patient contacted her physician about the events and was prescribed an increased dosage of domperidone.InAUG2014,thepatientcontactedherphysicianabouttheeventsandwasprescribedanincreaseddosageofdomperidone.(S1 (S (S (PP (IN In) (NP (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBD contacted) (NP (PRP$ her) (NN physician)) (PP (IN about) (NP (DT the) (NNS events)))) (CC and) (VP (VBD was) (VP (VBN prescribed) (NP (NP (DT an) (VBN increased) (NN dosage)) (PP (IN of) (NP (NN domperidone)))))))) (. .)))The patient reported the increased dose of domperidone had not relieved her worsening symptoms.Thepatientreportedtheincreaseddoseofdomperidonehadnotrelievedherworseningsymptoms.(S1 (S (S (NP (NP (DT The) (NN patient)) (VP (VBD reported) (NP (NP (DT the) (VBN increased) (NN dose)) (PP (IN of) (NP (NN domperidone)))))) (VP (VBD had) (RB not) (VP (VBN relieved) (NP (PRP$ her) (JJ worsening) (NNS symptoms))))) (. .)))On 13 AUG 2014, the patient experienced not feeling well today.On13AUG2014,thepatientexperiencednotfeelingwelltoday.(S1 (S (S (PP (IN On) (NP (CD 13) (NN AUG) (NN 2014))) (, ,) (NP (DT the) (NN patient)) (VP (VBN experienced) (NP (RB not) (NN feeling)) (PP (RB well) (ADVP (RB today))))) (. .)))No laboratory findings were provided.Nolaboratoryfindingswereprovided.(S1 (S (S (NP (NN No) (NN laboratory) (NNS findings)) (VP (VBD were) (VP (VBN provided)))) (. .)))The dose of domperidone was increased and the dose of canagliflozin was not changed.Thedoseofdomperidonewasincreasedandthedoseofcanagliflozinwasnotchanged.(S1 (S (S (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NN domperidone)))) (VP (VBD was) (VP (VBN increased)))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN canagliflozin)))) (VP (VBD was) (RB not) (VP (VBN changed))))) (. .)))The patient had not recovered from increased belching, worsening of abdominal pain, very gaseous, worsening of bloating, and not feeling well today. Thepatienthadnotrecoveredfromincreasedbelching,worseningofabdominalpain,verygaseous,worseningofbloating,andnotfeelingwelltoday.(S1 (S (S (NP (DT The) (NN patient)) (VP (VBD had) (RB not) (VP (VBN recovered) (PP (IN from) (NP (VBN increased) (UCP (ADJP (JJ belching)) (, ,) (NP (NP (NN worsening)) (PP (IN of) (NP (JJ abdominal) (NN pain)))) (, ,) (ADJP (RB very) (JJ gaseous)) (, ,) (ADJP (JJ worsening) (PP (IN of) (NP (NN bloating)))) (, ,) (CC and) (ADJP (RB not) (JJ feeling))) (NN well) (NN today)))))) (. .)))This report was identified by the call center as a product quality complaint: PQMS reference number 10000228235.Thisreportwasidentifiedbythecallcenterasaproductqualitycomplaint:PQMSreferencenumber10000228235.(S1 (S (S (NP (DT This) (NN report)) (VP (VBD was) (VP (VBN identified) (PP (IN by) (NP (DT the) (NN call) (NN center))) (PP (IN as) (NP (NP (DT a) (NN product) (NN quality) (NN complaint)) (: :) (NP (NN PQMS) (NN reference) (NN number) (CD 10000228235))))))) (. .)))This report was not serious.Thisreportwasnotserious.(S1 (S (S (NP (DT This) (NN report)) (VP (VBD was) (RB not) (ADJP (JJ serious)))) (. .))) \ No newline at end of file